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1. Introduction 
1.1. The human immune system 
The human immune system is classified into two branches: the innate (non-specific) and the 
adaptive (specific) immune system. Innate immunity (also called natural or native immunity) 
provides the early line of defense against microbes. In addition to physical barriers and the 
complement system (Sarma and Ward 2011) different immune cell populations are important 
components of the innate immune response as phagocytic cells (neutrophils, macrophages), 
dendritic cells (DC) and natural (NK) cells.  
The immune cell populations can be categorized into either the myeloid or the lymphoid 
lineage. Besides macrophages, monocytes, DCs and granulocytes belong to the myeloid cells. 
Granulocytes consist of eosinophils, basophils and neutrophils, which secret vesicles, containing 
enzymes such as lysozymes and other molecules lethal to pathogens. Macrophages and DCs 
take up antigens, process them and present them to immune cells from the adaptive immune 
system. These so called professional antigen presenting cells (APCs) serve as an important link 
between the innate and the adaptive immune system.  
Unlike the innate immune system, the adaptive immune system is highly specific to a 
particular pathogen and develops during a person’s lifetime. Moreover, immunological memory 
is created after an initial response to a specific pathogen and leads to an enhanced and faster 
immune response in case of a reinfection. The adaptive immune system consists of 
lymphocytes, B and T cells, and their secreted products such as antibodies or cytokines. These 
two cell types as well as NK cells belong to the lymphoid lineage.  
T cells and NK cells play a major role in the defense against virally infected cells. Both 
secrete cytokines and chemokines driving and modulating the immune response (Caligiuri 
2008). In the context of the anti-tumor immune response T cells are of special importance as 
they are able to directly kill tumor cells beside cytokine secretion.  
 
 
1.2. T cell differentiation and maturation 
T cells play a central role in cell mediated immune responses. Derived from hematopoietic 
stem cells in the bone marrow, progenitor T cells migrate to the thymus for maturation. Within 
the thymus developing T cells, referred to as thymocytes, undergo several selection processes. 
  Introduction 
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By positive selection the cells acquire the capability to recognize foreign antigens. A negative 
selection process ensures T cells to maintain self-tolerance by eliminating progenitors with 
receptors binding to self-antigens. After maturation T cells express the T cell receptor (TCR) and 
either the cluster of differentiation (CD) 4 or CD8 co-receptor on the cell surface. The TCR binds 
to peptides presented by major histocompatibility complex (MHC) molecules (Moss et al. 1992). 
MHCs interacting with T cell receptors are divided into two major forms, class I (MHC I) and 
class II (MHC II) molecules. 
Class II molecules are expressed by professional APCs (Doyle and Strominger 1987). APCs 
ingest exogenous antigens in the periphery, process them into peptides and present them as 
epitopes via MHC II molecules on their surface. Suchlike activated APCs migrate to lymphatic 
organs, where the epitopes are recognized by specific CD4 T cells. Within the CD4 T cell 
compartment, four major populations can be distinguished: The T helper (Th) cell lineages Th1, 
Th2, Th17 and the regulatory T (Treg) cells (Zhu and Paul 2008). Helper T cells secrete 
cytokines and chemokines that activate and/or recruit other immune cell types. Th1 and Th2 
cells are known as effector CD4 T cells. Th1 cells are triggered by interleukin (IL)-12 and secrete 
predominantly the cytokines IL-2 and interferon (IFN) γ (Zhu and Paul 2008). IL-2 stimulates 
survival, proliferation and differentiation of activated T cells. IFNγ, discussed more into detail in 
chapter 1.3.2, is critical for macrophage activation and upregulation of MHC II molecules. Th2 
cells are stimulated by IL-2 and IL-4 and are characterized by a secretion of a broad range of 
cytokines as, among others, IL-4, IL-5 and IL-10 (Zhu and Paul 2008). IL-4 is a stimulatory factor 
for Th2 differentiation and serves as a positive feedback amplifier. Moreover it promotes, similar 
to IL-5, proliferation of B and T cells. IL-10 is an anti-inflammatory, immunosuppressive cytokine, 
as it downregulates MHC II expression for instance. Th17 cell differentiation is induced by tumor 
growth factor (TGF)-ß and IL-6, IL-21 and IL-23. This pro-inflammatory population produces     
IL-17 and IL-21 (Zhu and Paul 2008). IL-17 promotes secretion of chemokines recruiting other 
immune cells to sites of inflammation. IL-21 acts as a stimulatory factor in a positive feedback 
loop. Tregs characterized by expression of CD25 and forkhead box protein 3 (FoxP3) are 
important immunosuppressive cells releasing IL-10 and TGF-β (Zhu and Paul 2008). Within this 
group naturally occurring, generated in the thymus or at peripheral sites, and in cell culture  
TGF-ß induced Tregs can be distinguished (Shevach and Thornton 2014). TGF-ß is essential for 
the differentiation of naïve CD4 T cells to Tregs and maintains homeostasis of this population.  
MHC I molecules interacting with CD8 as a co-receptor (Salter et al. 1990) are expressed by 
platelets and nearly all nucleated cells. Molecules presented by MHC class I are cytosolic 
proteins degraded in the proteasome and transported to the cell surface. Foreign or mutated 
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peptides are presented by MHC I molecules to other cells. Therefore CD8 T cells have an 
important role in the anti-tumor immunity by recognizing mutated cells (Hadrup et al. 2013). Due 
to this fact, this work is focused on CD8 T cells which will be further highlighted in the following 
chapters. 
 
 
1.3. Human CD8 T cells 
1.3.1. Differentiation of human CD8 T cells  
Human CD8 T cells can be grouped into various subsets based on their antigen experience, 
function and molecular phenotype (Figure 1). Major subsets circulating in the blood are classified 
into naïve (NV) T cells and antigen-experienced populations such as central memory (CM) and 
effector memory (EM) T cells. These subsets are distinguished on the basis of differential 
expression of surface molecules, including splice variants of CD45, the lymph-node homing 
receptors CCR7 (C-C chemokine receptor 7) and CD62L (L-selectin) (Sallusto et al. 1999). 
CD45, a protein tyrosine phosphatase exclusively expressed on cells of the hematopoietic 
lineage, is the most abundant leukocyte cell surface marker and plays a key role in TCR signal 
transduction (Tonks et al. 1988; Trowbridge and Thomas 1994). Different isoforms of CD45 are 
generated by alternative splicing and are expressed in cell type specific patterns on functional 
subsets of lymphocytes. CD45RA is found on naïve T cells as well as on a group of effector cells 
(EMRA T cells). After binding to the respective antigen, central and effector memory T cells lose 
expression of CD45RA and gain expression of CD45RO.  
CCR7 and CD62L are lymphocyte homing receptors expressed on naïve and CM cells in 
order to track them to secondary lymphoid organs (Picker et al. 1993). In line, lack of those 
receptors on effector memory and effector T cells triggers migration of these subsets in 
peripheral regions of the body where they are recruited by chemokines into inflammatory sites. 
However, all three T cell subsets are present in peripheral and lymphoid tissues. 
  Introduction 
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Figure 1: Model of the differentiation process of CD8 T cell subsets in humans and their relationship with 
functional attributes. According to Appay et al. 2008, Larbi and Tamas 2014 and Mahnke et al. 2013. CD8 subsets 
of circulating CD8 T cells are mainly defined according to differential expression of CCR7, CD62L, CD45RO and 
CD45RA. These markers change when T cells differentiate from one subset to another. Upon T cell differentiation 
CD8 T cells downregulate the expression of CD27 (IL-7 receptor) and CD28 (co-stimulatory receptor) and upregulate 
the expression of KLRG1 (killer cell lectin-like receptor-1), PD1 (programmed cell death protein 1) and CD57 (function 
unknown, marker for senescence). Moreover CD8 T cells lose their proliferation capacity, but acquire specific effector 
functions. NV: naïve T cells; SCM: stem cell memory T cells; CM: central memory T cells; EM: effector memory 
T cells; EFF: effector T cells. 
 
 
The lineage relationship and specific phenotype of CD8 T cell subsets is still a subject of 
controversy in the field (Mahnke et al. 2013). After antigen exposure in the lymph nodes naïve 
T cells undergo proliferative expansion, differentiate into antigen experienced T cell subsets and 
end up as terminally differentiated effector T cells (Figure 1). CM T cells are long-lived memory 
cells capable to differentiate into shorter-lived EM upon antigen stimulation (Sallusto et al. 2004). 
Other studies propose the other way around, claiming that EM convert to CM (Wherry et al. 
2003). The EM and EFF subsets seem to display a more exhausted phenotype indicated by 
reduced proliferative capacity and the expression of proposed senescence/ exhaustion markers 
such as CD57, killer cell lectin-like receptor-1 (KLRG1) and programmed cell death protein 1 
  Introduction 
                                                                                                                                                           
5 
 
(PD1) (Larbi and Tamas 2014). Moreover, the loss of the co-receptors CD27 and/ or CD28 is 
regarded as a characteristic for exhausted T cells. 
Lately, a population of memory T cells has been defined, which has enhanced stem cell-like 
qualities compared to conventional CM T cells and an enhanced capacity for self-renewal. This 
cell type was designated memory stem T cells (SCM) (Gattinoni et al. 2011). 
While CD4 Tregs are an accepted population, studies on human CD8 Tregs are rather sparse 
(Kapp and Bucy 2008). Patients with a leishmanial infection showed CD8 with an 
immunosuppressing phenotype (Holaday et al. 1993). A minor population of FoxP3 expressing 
CD8 T cells was detected in rheumatoid arthritis displaying superior regulatory abilities and 
inhibiting Th17 response (Ellis et al. 2014). A CD8, LAG-3, CD25, FoxP3, CCL4 expressing Treg 
subset may play a role in immunoregulation in humans through the secretion of CC chemokine 
ligand 4 (CCL4), which can inhibit T cell activation (Joosten et al. 2007). 
 
 
1.3.2. CD8 T cells as key players in the immune response 
CD8 T cells, also named cytotoxic T lymphocytes (CTL), are very important for the immune 
defense against intracellular pathogens such as viruses as well as for tumor immune 
surveillance. For a proper T cell stimulation various signals are required including antigen 
recognition by the TCR and secondary activating stimuli. The TCR complex is composed of two 
highly variable chains, the α- and the β-chain interacting with the antigens, the CD3 molecule 
and two ζ-chains mediating signal transduction. The CD8 co-receptor also binds to MHC I 
leading to a stabilization of the whole complex. Another required co-receptor, CD28, receives a 
co-stimulatory signal by binding to B7-1 (CD80) and B7-2 (CD86) on APCs. Besides cell to cell 
interaction leading to stimulation, cytokines support and enhance T cell stimulation and 
activation. The most important cytokine is IL-2. IL-2 is produced mainly by CD4 T cells and acts 
in an auto- and paracrine fashion. 
After activation CD8 T cells secrete cytokines, primarily IFNγ and tumor necrosis factor (TNF), 
which have anti-tumor, immunoregulatory and anti-viral effects. IFNγ activates the Janus kinase-
signal transducer and activator of transcription (JAK-STAT) signaling pathway in macrophages 
(Schroder et al. 2004). The JAK-STAT pathway targets gene promoters in the nucleus triggering 
anti-viral and adaptive immune responses (Aaronson and Horvath 2002). One well described 
effect of IFNγ is the inhibition of cell growth, even of tumor cells (Jonasch and Haluska 2001). 
This effect could be linked to the capability of IFNγ to upregulate the expression of MHC class I 
and II molecules (Propper et al. 2003; Schroder et al. 2004), which could result in a better 
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recognition by other immune cells. Moreover IFNγ orchestrates the recruitment of specific 
immune cells to sites of inflammation by upregulation of adhesion molecules and chemokines 
(Boehm et al. 1997). Besides its impact on cells of the adaptive immune system, IFNγ also 
triggers the innate immune response. Macrophages activated by IFNγ display increased 
pinocytosis and phagocytosis as well as enhanced microbial killing ability (Schroder et al. 
2004).TNF triggers five different types of signals including nuclear factor κB (NF-κB) activation, 
extracellular signal-regulated kinase (ERK), p38 mitogen-activated protein kinase (p38MAPK) 
and c-Jun N-terminal kinase (JNK) (Aggarwal et al. 2012). TNF binds also to the TNF-related 
apoptosis-inducing ligand (TRAIL). This pathway induces apoptosis in tumor cells but not in 
normal cells (Wiley et al. 1995).  
Moreover, CD8 T cells are capable to directly lyse cells by release of cytotoxic proteins 
(Peters 1991). The pore-forming protein perforin is released to facilitate granzyme influx into the 
target cell. Granzymes are serine proteases and cause cell death in any type of target cell. 
Granzyme B is the most powerful pro-apoptotic member and induces apoptosis by both caspase 
mediated and caspase independent pathways (Trapani 2001). 
Another important mechanism how CD8 T cells kill target cells, is the binding of Fas (CD95) 
on their targets by the Fas ligand (FasL, CD95L) (Waring and Müllbacher 1999). This binding 
induces cell death mediated by caspase activation (Waring and Müllbacher 1999). 
Due to their specificity and cytotoxic capability CD8 T cells comprise a powerful branch of the 
adaptive immune response. Regarding the ‘tumor-specific adaptive immune response’ tumor 
infiltrating CD8 cells have been shown to be of major importance in different types of solid 
tumors, including renal, ovarian, colorectal and lung cancer (Nakano et al. 2001; Sato et al. 
2005; Galon et al. 2006; Kawai et al. 2008). A meta-analysis of expression signatures of 18.000 
human tumors has confirmed that infiltration and activation of CD8 T cells is linked to improved 
patient outcome in different cancer types (Gentles et al. 2015). However, they also frequently fail 
to induce a sufficient anti-tumor immune response. Despite the lack of antigens and the 
expression of inhibitory surface markers, so called checkpoint molecules as cytotoxic 
T lymphocyte associated protein 4 (CTLA-4) or PD-1, which will be more elucidated later on, one 
reason might be their high metabolic demands upon activation and interplay with the specific 
metabolic tumor microenvironment. 
 
 
 
 
  Introduction 
                                                                                                                                                           
7 
 
1.3.3. Metabolism of T cells – a link between metabolism and effector functions?  
In the resting state T lymphocytes cover their basal energy demand primarily through 
mitochondrial oxidation of glucose and glutamine (Bental and Deutsch 1993; Jones and 
Thompson 2007). Stimulation of T cells leads to a change from a resting towards an activated 
state. T cell activation requires metabolic reprogramming supporting their highly proliferative and 
biosynthetic phenotype (Frauwirth et al. 2002). During T cell activation and differentiation key 
metabolic processes such as glycolysis, mitochondrial respiration and fatty acid oxidation are 
recognized as crucial pathways (MacIver et al. 2013).  
The metabolic reprogramming upon T cell activation is regulated on both the transcriptional 
and posttranscriptional level. Several studies have implicated the involvement of different 
signaling cascades such as 5' AMP-activated protein kinase (AMPK), AKT and mechanistic 
target of rapamycin (mTOR) in regulating T cell metabolism (Frauwirth et al. 2002; Pearce et al. 
2009; Carr et al. 2010; Xu et al. 2012; Finlay and Cantrell 2011). Notably, those pathways are 
also known to be upregulated in cancer cells. Moreover, Wang and colleagues were able to 
show that metabolic genes involved in glucose and glutamine metabolism as well as 
mitochondrial biogenesis are regulated by the oncogene c-myc in murine T cells (Wang et al. 
2011). Deletion of myc significantly impaired glycolytic flux and inhibited the upregulation of 
glutamine oxidation in active T cells. Myc, but not hypoxia-inducible factor 1-alpha (HIF1α) was 
required for activation-induced T cell metabolic reprogramming.  
Pathways that control T cell function and cellular metabolism are linked and changes in cell 
metabolism can suppress or even enhance lymphocyte function (MacIver et al. 2013). As most 
of the publications are focused on murine T cells, it is of major importance to elucidate the role of 
metabolic pathways for CD8 T cell activation and function. 
 
 
1.3.3.1. Glucose metabolism is strongly increased in activated T cells 
Highly proliferating cells show an accelerated glucose metabolism, degrading most of the 
glucose into lactate, named aerobic glycolysis, first described in tumor cells by Otto Warburg 
(Warburg 1956). In contrast, non-proliferating cells metabolize glucose to pyruvate via glycolysis 
in the cytoplasm, which is subsequently oxidized to carbon dioxide (CO2) by oxidative 
phosphorylation (OXPHOS) in the mitochondria. A yield of 36 mol adenosine triphosphate (ATP) 
is gained by 1 mol of glucose by OXPHOS, whereas only 2 mol ATP are produced by glycolysis. 
Nevertheless, the accelerated glycolytic flux rate and the rapid turnover of glucose allow cells to 
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produce sufficient amounts of ATP and at the same time to use the intermediates of the 
tricarboxylic acid cycle (TCA) for the biosynthesis of molecules (Fox et al. 2005; Vander Heiden 
et al. 2009). Already during the 1960’s it has been shown that proliferating lymphocytes show an 
increased glucose metabolism (Cooper et al. 1963) and this phenomenon has regained attention 
during the last years. 
After stimulation the expression of glycolysis associated genes is upregulated in human T cell 
populations. The expression of glycolytic enzymes and transporters such as the lactate 
dehydrogenase A (LDHA), the hexokinases (HK), the glucose transporter 1 (GLUT1) or the 
monocarboxylate transporter 1 (MCT1), responsible for lactate secretion is increased (Frauwirth 
et al. 2002; Macintyre et al. 2014; Renner et al. 2015). Accordingly, T cells show enhanced 
glucose uptake and lactate secretion in the course of stimulation. The increase in glucose 
metabolism has been reported in activated murine and human T cells. However, its impact on 
T cell function is still controversially discussed. 
A strong link between glycolysis and effector functions as IFNγ production has been 
investigated in the murine system (Jacobs et al. 2008; Cham and Gajewski 2005; Macintyre et 
al. 2014). It has been reported that glycerinaldehyde 3-phosphate dehydrogenase (GAPDH) 
interferes with the translation of IFNγ in murine Th1 cells (Chang et al. 2013). Murine CD4 
T cells lacking LDHA, an enzyme converting pyruvate to lactate, secret less IFNγ indicating that 
glycolysis promotes T cell effector functions (Peng et al. 2016). Therefore glycolytic enzymes 
could function as metabolic checkpoints by linking T cell effector functions to glucose availability. 
However, another study showed that mitochondrial respiration is able to compensate for the lack 
of glucose to maintain IFNγ production in murine T cells (Salerno et al. 2016). Although cytokine 
production might require a glycolytic switch (Chang et al. 2013), glucose availability does not 
alter the rate of IFNγ production in murine T cells upon activation (Salerno et al. 2016). 
Moreover, other effector functions such as IL-2 production or cytolytic activity appear not to 
depend on glucose in the murine system (Cham and Gajewski 2005; Sukumar et al. 2013). 
In human T cells IFNγ, TNF and IL-2 secretion is if at all moderately affected by low glucose 
levels (Renner et al. 2015). Cytokine secretion seems to be preserved even under very low 
glucose conditions (0.4 mM) (Renner et al. 2015) suggesting minor importance of glycolysis for 
T cell function. In another study glucose deprivation caused only tentatively reduced secretions 
of IL‐2, TNF, IFNγ and IL‐4 in human CD4 T cells (Tripmacher et al. 2008). Nevertheless, rapid 
IFNγ production was shown to be linked to increased glycolytic flux in human memory T cells 
(Gubser et al. 2013). However, the link between metabolism and human T cell effector functions 
is still a matter of debate.  
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Regarding proliferation glucose is required for murine and human T cells. Under glucose 
deprivation T cell expansion is strongly impaired (Chang et al. 2013, Renner et al. 2015, 
Tripmacher et al. 2008). Glut1 deficient CD4 and CD8 T cells have an impaired capacity to 
proliferate in vitro and in vivo (Macintyre et al. 2014). Nevertheless, LDHA deficiency in murine 
CD4 T cells had no impact on proliferation (Peng et al. 2016). These results suggest the major 
importance of glucose but not glucose fermentation for proliferation in the murine system. 
Interestingly, Glut1 deletion seemed to interfere also with CD4 T cell differentiation into Th1, Th2 
and Th17 lineage, but differentiation into CD8 CTLs and CD4 Tregs were not affected (Macintyre 
et al. 2014). 
 
 
1.3.3.2. Amino acids play an essential role in T cell activation and metabolism 
Beside glucose, amino acids are regarded as key nutrients for activated T cells. It has been 
demonstrated that amino acids rather than glucose account for the majority of cell mass in 
proliferating mammalian cells, providing carbon and nitrogen to proliferating cells (Hosios et al. 
2016). Amino acids fuel metabolic processes such as the TCA cycle (Newsholme et al. 2003b). 
Moreover amino acids are used as biosynthetic precursors for protein and nucleic acid 
biosynthesis. Antigen signaling through the TCR increases the uptake of several amino acids, 
such as phenylalanine, leucine, arginine, serine, glutamate and glutamine into T cells (Carr et al. 
2010; Sinclair et al. 2013; Geiger et al. 2016). Detailed studies on the importance of amino acids 
for T cell function have been performed lately. 
Recent work reveals that serine metabolism is enhanced in activated T cells. Serine is 
required for optimal T cell expansion by fueling the one-carbon metabolism and nucleotide 
biosynthesis (Ma et al. 2017). In addition, enzymes required for the transport or the conversion 
of arginine into downstream metabolites like ornithine or proline are upregulated in activated 
T cells. In the absence of arginine, T cells showed a reduced capacity to proliferate, impaired 
activity and decreased cytokine secretion (Choi et al. 2009). T cells with increased intracellular 
levels of arginine shift their metabolism from glycolysis to OXPHOS and display enhanced 
survival as well as anti-tumor activity, which is linked to the generation of CM T cells (Geiger et 
al. 2016).  
Nevertheless, glutaminolysis plays a crucial role in T cell activation. Glutamine is with a 
concentration range between 550–750 µM the most abundant amino acid in the peripheral blood 
(Gleeson 2008). The degradation of glutamine provides precursors for the synthesis of other 
amino acids, proteins or nucleotides for instance (Dang 2010). When glutamine is oxidized into 
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glutamate, glutamate may be metabolized to produce other amino acids or may be used as 
anaplerotic substrate to replenish TCA cycle (Newsholme et al. 2003a; Newsholme et al. 
2003b). Glutamine is converted by the glutaminase (GLS) to glutamate and two isoforms can be 
distinguished: the kidney- and the liver-type glutaminase. Besides glutaminase, T cell activation 
coordinately enhances expression of enzymes associated with glutaminolysis as the glutamic-
oxaloacetic transaminase (GOT) or the glutamate dehydrogenase (GDH) (Carr et al. 2010; 
Sinclair et al. 2013). Subsequently, glutamate can be transformed into α-ketoglutarate by 
aminotransferases, transferring nitrogen to pyruvate or oxaloacetate to form aspartate or 
alanine, respectively. In turn α-ketoglutarate enters the TCA cycle to gain energy. Moreover, 
glutamate is one of the three building blocks of the antioxidant glutathione (GSH) which is 
comprised of three amino acids: cysteine, glutamate and glycine. GSH scavenges reactive 
oxygen species (ROS) and prevents thereby cellular damage. Specifically in T cells, it was 
shown that GSH is essential for the accelerated energy metabolism required for T cell effector 
functions (Mak et al. 2017). Moreover glutamine is essential for nucleotide synthesis as it acts as 
nitrogen donor in purine as well as in pyrimidine synthesis (Cory and Cory 2006). 
Glutamine depletion blocked murine T cell growth, proliferation and cytokine production such 
as IFNγ and IL-2. Interestingly, this effect could not be rescued by substitution of biosynthetic 
precursors (proline or asparagine) or products (glutamate) of glutamine (Carr et al. 2010). 
Glutamine deprivation in CD4 T cells resulted in reduced mechanistic target of rapamycin 
complex 1 (mTORC1) activity and led to a differentiation toward a Treg cell phenotype (Klysz et 
al. 2015). Metzler and colleagues demonstrated that the differentiation into Tregs induced by 
glutamine restriction is caused by an impaired glutamine dependent nucleotide synthesis 
(Metzler et al. 2016). Another study assigned Treg formation under glutamine restriction to an 
inhibited conversion of glutamate into α-ketoglutarate and thereby preventing the production 
of 2-hydroxyglutarate. The formation of 2-hydroxyglutarate was essential to reduce the 
methylation of the Foxp3 gene locus (Xu et al. 2017). 
Taken together, glutamine is involved in a variety of pathways, summarized in Figure 2. 
Although glutamine is generally not regarded as an essential amino acid, T cells seem to lack 
the ability to compensate for glutamine deprivation, even when other pathway intermediates are 
provided. However, it is still not clear which pathway glutamine is involved in and which one is 
crucial for T cell activation as providing different intermediates only partially rescues T cell 
activation.  
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Figure 2: Pathways linked to glutamine metabolism. Glutamate is produced from glutamine through glutaminase 
(GLS). The reverse reaction is catalyzed by the glutamine synthetase (GLUL) producing glutamine from glutamate. 
Glutamate can be used as an amino group donor for the transamination of other amino acids as aspartate or alanine 
and is converted to α-ketoglutarate via glutamate dehydrogenase (GLDH) which is a TCA intermediate. Glutamate is 
one of the three building blocks for the antioxidant glutathione which is synthesized by the glutamate cysteine ligase 
(GCL) and protects cells from reactive oxygen species (ROS). 
 
 
1.3.3.3. Mitochondrial respiration in T cells  
During the last years the importance of glucose and amino acids for T cell function has been 
studied intensively. Only recently mitochondrial involvement in T cell activation and function 
regained attention.  
Oxidative metabolism was shown to be important for T cell response in the murine and the 
human system (Sena et al. 2013; Okoye et al. 2015; Desdín-Micó et al. 2017). For murine 
T cells mitochondrial mass increases during the first hours of activation (Baixauli et al. 2015; Tan 
et al. 2017) and Fischer and colleagues described the critical role of mitochondrial biogenesis for 
cytokine production in human CD8 T cells (Fischer et al. 2018). Moreover, genetic approaches 
by deletion of the mitochondrial transcription factor A (Tfam) (Baixauli et al. 2015) or the 
apoptosis inducing factor (AIF) (Milasta et al. 2016), both leading to defective mitochondrial 
respiration, caused a strong decrease in proliferation. Interestingly, Tfam deficient CD4 T cells 
showed increased numbers of IFNγ cells (Baixauli et al. 2015). Balmer and Hess have shown 
that dysfunction of mitochondrial respiration correlates with exhaustion in murine and human 
CD8 T cells (Balmer and Hess 2016). T cells which lost mitochondrial mass within the tumor 
microenvironment were characterized by a very low cytokine production in the murine and the 
human system (Scharping et al. 2016; Siska et al. 2017).  
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Recently, Buck and colleagues reported that remodeling of mitochondria ultrastructure is 
critical for modulation of T cell differentiation into various subsets and moreover has an impact 
on anti-tumor immune response during adoptive cell transfer (ACT) (Buck et al. 2016). These 
findings suggest that activated T cells require not only glycolysis but also mitochondrial 
respiration for immune response. Therefore, the role of mitochondrial respiration has to be 
considered in light of the development of mitochondrial inhibitors for cancer therapy and needs 
further analysis. 
 
 
1.3.3.4. Subset specific differences in the metabolic phenotype of T cells 
Most of the studies on the link between T cell metabolism and function have been performed 
in bulk T cell cultures. Some publications indicate that the metabolic profile and the metabolic 
demands differ between T cell subsets. It has been proposed that murine CD8 memory T cells 
rely on lipid oxidation (Pearce et al. 2009; O'Sullivan et al. 2014). However, this finding is 
discussed controversially as in this study very high concentrations of etomoxir, an irreversible 
inhibitor of carnitine palmitoyltransferase-1 (CPT-1A), were applied (O'Sullivan et al. 2014), 
probably leading to unspecific side effects. In contrast, a complete CPT-1A knockout in CD8 
T cells is dispensable for the development of CD8 T cell memory and protective immunity (Raud 
et al. 2018) . Nevertheless, memory differentiation involves oxidative phosphorylation and 
changes in mitochondrial structure, as over-expression of a protein promoting mitochondrial 
membrane fusion fosters the generation of memory T cells in vivo (Buck et al. 2016). Moreover, 
inhibiting glycolytic metabolism by 2-deoxyglucose (2-DG) enhances memory generation in 
murine CD8 T cells (Sukumar et al. 2013). The metabolic profile of activated T cell subsets has 
been less investigated. Ecker and colleagues recently reported that IFNγ production is glucose 
sensitive in naïve and CM CD4 T cells (Ecker et al. 2018). Similar data have been shown for 
CD4 EM T cells (Dimeloe et al. 2016). In line, Gubser and colleagues showed that the 
accelerated effector functions of human CD8 memory T cells but not of naïve T cells is glycolysis 
dependent (Gubser et al. 2013). Nevertheless, it has to be taken into consideration, that those 
analyses have been performed in the absence of serum, which is regarded as a crucial factor for 
T cell activation.  
Taken together T cells have a high metabolic demand. Therefore, the metabolic conditions in 
the tumor microenvironment could contribute to diminished anti-tumor immune responses 
probably in a subset dependent manner. 
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1.4. Impact of tumor metabolism on tumor infiltrating immune cells 
Tumor cells are characterized by an altered and highly elevated metabolism in comparison to 
normal cells. Tumor cells reprogram and accelerate pathways including nutrient up-take and 
degradation in order to meet their bioenergetic, biosynthetic and redox demands. The resulting 
metabolic tumor microenvironment actively influences the surrounding tissue and the behavior of 
surrounding cells. Low nutrient levels and the accumulation of metabolites in the tumor 
microenvironment, produced and released by tumor cells themselves or stromal cells inside the 
tumor, mediate tumor promotion, invasion and metastasis (Hanahan and Coussens 2012).  
The tumor microenvironment is hostile to T cells in many perspectives and many different 
mechanisms contribute to the failure of T cells to eradicate tumor cells. Nutrient supply is limited 
due to the highly elevated metabolic activity of tumor cells but also other stroma cells in the 
tumor microenvironment. As T cells undergo metabolic reprogramming upon stimulation to 
support their cell growth and effector functions, the need for nutrients is likewise elevated. This 
leads to a competition for nutrients between tumor cells and stroma cells including tumor 
infiltrating lymphocytes (TILs).  
The classical example of a reprogrammed metabolic pathway in cancer is the accelerated 
aerobic glycolytic activity even in the presence of oxygen, the already mentioned Warburg effect 
(Warburg et al. 1927; Warburg 1956). As glucose is rapidly taken up by proliferating tumor cells, 
TILs are exposed to lowered extracellular glucose concentrations. Glucose consumption by 
tumor cells might metabolically restrict T cells by leading to decreased mTOR activity, glycolytic 
capacity and reduced effector functions (Chang et al. 2015). Ho and colleagues identified a 
mechanism by which glucose metabolism directly controls effector functions. Due to lowered 
phosphoenolpyruvate concentrations by glucose deprivation, calcium and nuclear factor of 
activated T cells (NFAT) signaling was suppressed, resulting in diminished anti-tumor effector 
functions. Nevertheless, glucose seems not to be the main restricting substrate for T cells within 
tumors, since in most human tumor entities an average glucose concentrations above 1 mM has 
been measured (Walenta et al. 2017), which has been shown to be sufficient for T cell function 
(Renner et al. 2015). 
Besides glucose, amino acids are crucial for tumor growth (Mayers and Vander Heiden 2015; 
Altman et al. 2016). Many oncogenic mutations are associated with the glutamine metabolism 
(Altman et al. 2016). Glutamine metabolism was shown to be linked to mTORC1, and the 
oncogenes KRAS, MYC and p53 (Choi and Park 2018). 
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A variety of amino acids as glutamine, arginine, tryptophan or other amino acids are highly 
consumed by various tumor cell types as they are essential nutrients for tumor growth. 
Accordingly, Pan and colleagues showed that glutamine concentrations were consistently and 
significantly lower in tumor core regions (less than 100 µM) compared to the tumor periphery   
(about 400 µM) (Pan et al. 2016). Moreover, higher gene expression of enzymes involved in 
glutaminolysis are correlated with poor survival as shown in patients with ovarian cancer (Yang 
et al. 2014). Others demonstrated that glutamine is an important metabolite to drive tumor 
growth and metastasis (Zhang et al. 2014). In addition, asparagine and arginine levels correlate 
with tumor growth (Patil et al. 2016; Knott et al. 2018) and lowered levels of arginine are found in 
the tumor microenvironment (Rodriguez et al. 2009). Arginine is used by tumor cells but also 
other immune cells as T cells or myeloid-derived suppressor cells (MDSCs) (Renner et al. 2017). 
In addition, degradation of arginine by arginase secreted by MDSCs inside the tumor results in 
an impaired T cell responsiveness (Bronte and Zanovello 2005; Fletcher et al. 2015).  
As amino acid metabolism is also important for activated T cells and other immune cells such 
as macrophages found in the tumor stroma, amino acid concentrations might become limiting in 
the tumor microenvironment (Renner et al. 2017).  
Despite nutrient restriction, the secretion of metabolites formed in the course of glycolysis or 
amino acid degradation contributes to an immunosuppressive microenvironment. Highly 
glycolytic tumor cells need to efficiently export lactate to maintain glucose flux. The lactate 
export by the MCTs is proton-linked (Halestrap and Wilson 2012), which results in lactate 
accumulation and concomitantly a decrease in the extracellular pH inside the tumor. It was 
shown that tumor derived lactic acid suppresses proliferation and cytokine production of human 
cytotoxic T cells in vitro and in vivo, hence is regarded as an immunosuppressive metabolite 
(Fischer et al. 2007; Calcinotto et al. 2012; Mendler et al. 2012). In line, Cascone and colleagues 
demonstrated that increased tumor glycolysis is associated with a lower therapeutic response to 
adoptive T cell transfer due to suppression of anti-tumor immunity (Cascone et al. 2018). 
Moreover, tryptophan degradation results in the production and secretion of kynurenine 
regarded as an immunosuppressive metabolite (Frumento et al. 2002; Uyttenhove et al. 2003; 
Fallarino et al. 2006). Additionally, the adenosine metabolism is regarded as a possible pathway 
harming immune cell response in the tumor microenvironment. An upregulated expression of an 
ecto-5′-nucleotidase (CD73) was shown to result in adenosine production, affecting T and NK 
cells (Huang et al. 1997; Häusler et al. 2011). The accumulation of methylthioadenosine (MTA) 
caused by the loss of methylthioadenosine phosphorylases impairs T cell function (Henrich et al. 
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2016). Other waste products as prostaglandin E2 (PGE2) are also known as 
immunosuppressive metabolite (Kalinski 2012). 
Taken together, the metabolic microenvironment in tumors has a strong impact on a T cell 
mediated anti-tumor immune response. On the one hand a competition for nutrients is observed, 
on the other hand the secretion of immunosuppressive metabolites impairs T cell function 
(Figure 3). 
 
Figure 3: Metabolic hallmarks of tumor cells and the 
interplay between tumor cells and immune cells, 
according to Renner et al. 2017. Tumor cells exhibit high 
expression of glucose transporters (GLUT), lactate 
dehydrogenase (LDH), cyclooxygenase (COX), arginase 
(ARG), indolamine 2,3-dioxygenase (IDO), glutaminase 
(GLS), and oxidative phosphorylation (OXPHOS). As a 
consequence, glucose and the amino acids arginine, 
tryptophan, and glutamine are depleted from the tumor 
microenvironment and nutrient restriction contributes to an 
anergic state of anti-tumoral cytotoxic T cells. In addition, 
accelerated glycolysis by tumor cells results in lactate 
production and secretion via monocarboxylate-
transporters (MCT). Lactate and other secreted 
metabolites, such as glutamate, prostaglandins (PGE2), 
and kynurenines, affect immune cells. Overexpression of 
the ecto-5′-nucleotidase (CD73) leads to adenosine 
formation; loss of methylthioadenosine phosphorylase 
(MTAP) results in methylthioadenosine (MTA) 
accumulation in the tumor environment.  
 
 
1.5. State of the art: Targeting the tumor metabolism as an emerging 
strategy in cancer therapy 
Targeting and thereby restricting tumor metabolism could be an interesting strategy in 
different perspectives; (i) metabolic restriction affects proliferation and viability of tumor cells and 
(ii) blocking metabolic pathways reduces the secretion of immunosuppressive metabolites. 
During the past decades targeting cancer metabolism has emerged as a promising strategy 
and selective drugs, targeting glucose metabolism, mitochondrial activity or glutaminolysis have 
been developed. 
As tumor cells and immune cells show overlaps in their metabolic profile it will be a major 
challenge to develop protocols affecting tumor cell metabolism but preserving immune cell 
function. This is of special importance, since an effective anti-tumor immune response is known 
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to positively affect patient outcome (Galon et al. 2006). Therefore it is essential to understand 
this link and the metabolic demand in T cells which is required for a successful immune 
response. 
A huge variety of drugs has been developed during the last years targeting different 
metabolic pathways. While initial studies have mainly focused on glucose metabolism, it is now 
clear that inhibiting mitochondrial function is another emerging approach (Tennant et al. 2010). 
Besides glycolysis and OXPHOS, amino acid metabolism has also been considered as a target 
of cancer therapy (Altman et al. 2016). 
 
 
1.5.1. Targeting glucose metabolism as a promising concept for anti-tumor therapy 
Glucose metabolism can be targeted at different levels. As glucose enters cells via specific 
transporters several inhibitors for glucose transporters have been developed and clinical trials 
are ongoing to test toxicity and efficacy (Cao et al. 2007; Zhan et al. 2011). An alternative 
strategy for inhibiting glucose metabolism relies on the inhibition of glycolytic enzymes. 
Compounds such as the glucose analog 2-DG or 3-bromopyruvate (HK), lonidamine (pyruvate 
kinase M2 and hexokinase), gossypol (LDH), dichloroacetate (pyruvate dehydrogenase kinase) 
are able to inhibit glucose catabolism and are currently tested in clinical trials (Yu et al. 2001; Di 
Cosimo et al. 2003; Maschek et al. 2004; Murray et al. 2005; Michelakis et al. 2008; Ovens et al. 
2010b; Pedersen 2012).  
Targeting lactate metabolism is another attractive strategy for cancer therapeutics (Doherty 
and Cleveland 2013). Lactic acid produced by tumor cells has emerged as a critical factor of 
cancer development, metastasis as well as patient survival probability (Walenta et al. 2000; 
Gatenby and Gillies 2004). Blocking lactate secretion affects the tumor cells itself and at the 
same time accumulation of the immunosuppressive metabolite lactic acid is reduced. The main 
transporters involved in lactate secretion are MCTs. MCTs are plasma membrane transporters 
carrying monocarboxylates, such as lactate, pyruvate or ketone bodies, across biological 
membranes (Halestrap and Wilson 2012). MCTs are encoded by the solute carrier family 16 
genes (SLC16). Within this family 14 members have been identified so far in mammals 
(Halestrap and Price 1999; Juel and Halestrap 1999; Halestrap and Wilson 2012). However, 
only the MCTs 1 to 4 have been demonstrated to facilitate monocarboxylate transport up to now. 
While MCT1, 3 and 4 use the basignin protein (CD147) as ancillary protein, MCT2 uses 
embidigin (Halestrap and Wilson 2012).  
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MCT2 (SLC16A7) and MCT3 (SLC16A8) seem to play a less significant role in human tissue 
and have a more restricted expression pattern (Halestrap and Wilson 2012). MCT1 (SLC16A1) 
is expressed almost ubiquitously in all tissues such as the kidney, the liver, the heart and the 
skeletal muscle (Halestrap and Price 1999). MCT1 has a high lactate affinity with a Km value of 
3.5 mM and is responsible for lactate entry into or efflux out of cells depending on the metabolic 
state (Halestrap 2012). High expression levels of this transporter in tumors are associated with a 
poor outcome (Kong et al. 2016). MCT1 expression was shown to be highly elevated in breast, 
colorectal, gastric and cervical cancer (Pinheiro et al. 2008; Pinheiro et al. 2010; de Oliveira, 
Talvane Torres Antônio et al. 2012). However, a single MCT1 knockdown in human colon 
adenocarcinoma cells neither impaired glycolysis nor the rate of tumor growth (Le Floch et al. 
2011). In line, in breast cancer cells MCT1 inhibition did not consistently alter lactate transport. 
However, reduced pyruvate export has been observed suggesting MCT1 to also promote 
pyruvate export (Hong et al. 2016).  
In highly glycolytic cells such as tumor cells lactate transport is not only mediated by MCT1 
but also by MCT4 (SLC16A3) (Halestrap and Wilson 2012). MCT4 expression is a direct 
downstream target of the transcription factor HIF-1α and is upregulated in response to hypoxia 
(Ullah et al. 2006; Perez de Heredia et al. 2010). Due to its low affinity for lactate (Km value: 22 
to 28 mM) MCT4 is in particular adapted to the release of lactate in a microenvironment already 
containing high amounts of lactate (Dimmer et al. 2000). MCT4 plays a key role in 
tumorigenesis. Knockdown experiments have shown that MCT4 is not essential for survival but 
required for migration and invasion of tumor cells (Gallagher et al. 2007; Izumi et al. 2011; Kong 
et al. 2016). Elevated levels of MCT4 have been detected in colorectal and prostate cancer 
(Pinheiro et al. 2008; Pértega-Gomes et al. 2011). 
The elevated levels of MCT1 and MCT4 in various tumor entities provide a promising target 
structure. Several potent MCT1/2 inhibitors have already been developed (Murray et al. 2005; 
Ovens et al. 2010a; Doherty et al. 2014) and some are currently tested in clinical trials (Doherty 
and Cleveland 2013). However, these compounds are inactive in the presence of MCT4. Hence, 
the development of potent pan-MCT inhibitors or inhibitors selectively targeting MCT4 is needed. 
Recently, Sasaki and colleagues demonstrated that diclofenac, a nonsteroidal anti-inflammatory 
drug (NSAID), is capable to block lactate transport by MCT4 (Sasaki et al. 2016). Diclofenac is 
able to reduce glucose uptake and lactate secretion in tumor cells. In in vivo experiments 
diclofenac significantly impaired tumor growth (Chirasani et al. 2013; Gottfried et al. 2013). New 
data of our laboratory demonstrate that diclofenac is capable to directly block MCT1 and MCT4 
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(Renner et al. under revision). Therefore diclofenac might be a candidate for a pan-MCT inhibitor 
used as an anti-cancer drug. 
 
1.5.2. Targeting mitochondrial respiration in the context of tumor therapy 
Besides glycolytic activity, mitochondrial respiration displays a possible target in tumor cells 
as well. The clinically applied multikinase inhibitor sorafenib interferes with mitochondrial 
function and reduces mitochondrial respiration (Tesori et al. 2015). Additionally, sorafenib was 
shown to decrease Treg frequency in metastatic renal cell carcinoma patients (Busse et al. 
2011).  
The anti-diabetic drug metformin, a biguanide, is also able to block mitochondrial respiration 
(Owen et al. 2000). Type 2 diabetes patients treated with metformin are known to be at lower 
risk for developing cancer (Dowling et al. 2007; Libby et al. 2009). Moreover, metformin was 
proposed as adjuvant therapy for glioma, as preliminary results reported a survival benefit of 
patients with grade III glioma using metformin (Seliger et al. 2019). As metformin is a frequently 
applied and well tolerated drug, it might be applied for tumor therapy. However, it has to be 
taken into consideration that metformin as well as sorafenib induce compensatory glycolytic 
activity (Tesori et al. 2015; Renner et al. 2018), which could in turn contribute to immune escape. 
Thus a combination of a glycolytic inhibitor with those drugs might be a more promising strategy 
(Gerthofer et al. 2018; Renner et al. 2018). 
 
 
1.5.3. Targeting amino acid metabolism for tumor therapy 
As tumor cells are characterized by an elevated amino acid metabolism, these pathways are 
also regarded as a possible target for tumor therapy and various drugs have been developed. 
The application of an enzyme degrading arginine resulting in arginine deprivation showed 
promising results in patients with leukemia (Miraki-Moud et al. 2015). Moreover, the inhibitor CB-
1158 blocked arginase released by MDSCs within the tumor microenvironment, diminished 
tumor growth and was able to reduce suppressive capacity of these cells (Steggerda et al. 
2017).  
Asparaginase, the enzyme catalyzing the degradation of asparagine, is used to treat acute 
lymphoblastic leukemia and lymphomas for decades (Avramis 2012). Asparagine displays an 
important metabolite for tumor cells especially under glutamine restricted conditions (Zhang et 
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al. 2014). Due to this fact, the treatment with asparaginase in combination with drugs targeting 
glutamine metabolism could maximize the therapeutic efficacy.  
Phenylacetate reduces the biologic availability of glutamine in the blood stream and is able to 
inhibit the proliferation of tumor cells (Samid et al. 1993). Most compounds targeting glutamine 
metabolism are still in the preclinical stage (Altman et al. 2016). Allosteric inhibitors of GLS, such 
as CB-839 or BPTES (bis-2-(5-phenylacetamido‑1,2,4‑thiadiazol‑2‑yl) ethyl sulfide), have 
shown promising results in preclinical models of triple-negative breast cancer and human B cell 
lymphoma (Shukla et al. 2012; Gross et al. 2014). CB-839 is currently under investigations in 
clinical trials for solid tumors, hematological tumors as well as leukemia (Clem et al. 2016). 
Other compounds targeting glutamine dependent pathways as acivicin ((2S)-amino-(5S)-3-
chloro-4,5-dihydro-1,2-oxazol-5-yl ethanoic acid) or DON (6-diazo-5-oxo-L-norleucine) failed to 
get approval due to severe toxicity (Adolphson et al. 1986; Rais et al. 2016).  
 
 
1.5.4. Application of anti-metabolic drugs in immunotherapy: opportunities and 
challenges 
Tumor cells have developed several strategies to escape and suppress the immune system 
(Figure 3) summarized as the hallmarks of cancer (Hanahan and Weinberg 2011), including the 
deregulated energy metabolism and immune escape, which seem to be closely related. As the 
metabolic tumor microenvironment limits endogenous anti-tumor immune responses it is likely to 
limit the efficacy of newly developed immunotherapeutic approaches. During the last decades 
immunotherapy has become an important approach in treating cancer (Callahan et al. 2016). 
Currently investigated immunotherapies include antibodies against immune checkpoints, such 
as PD-1 or CTLA-4, displaying receptors with a regulatory function. CD8 T cells in tumors 
express high levels of PD-1 associated with an exhausted phenotype and impaired effector 
functions (Ahmadzadeh et al. 2009). A therapy combining nivolumab and ipilimumab, 
monoclonal antibodies targeting PD-1 or CTLA-4 on T cells, has shown promising response 
rates in metastatic melanoma (Postow et al. 2015), but in the meantime also in other tumor 
entities. 
ACT is another promising type of immunotherapy. After isolation, genetic engineering and in 
vitro expansion of patient derived T cells, anti-tumor T cells are applied to cancer patients in 
order to recognize, target and destroy tumor cells. ACT of antigen-specific T cells was shown to 
mediate regression of established tumors (Yee et al. 2002). Moreover, ACT of chimeric antigen 
receptor (CAR) T cells is another promising immunotherapeutic approach. In this therapy T cells 
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are genetically engineered in vitro to potently recognize and attack tumors (Riet and Abken 
2015). CAR T cells specific for CD19 (CTL019) redirecting toward leukemic cells were able to 
induce remission in several patients (Kalos et al. 2011; Kochenderfer et al. 2013).  
Tumor infiltrating immune cells as CD8 T or NK cells can be harmed in the tumor 
microenvironment by nutrient restriction or immunosuppressive metabolites (Renner et al. 2017). 
A combination of immunotherapy with anti-metabolic agents could be a promising strategy to 
enhance responses to immunotherapy. However, such treatment strategies could also restrict 
T cell function, which needs to be considered.  
 
 
1.6. Hypothesis and objectives  
The metabolic profile and the link to effector functions of human CD8 T cells in particular of 
subsets have been insufficiently analyzed. In light of the metabolic microenvironment in solid 
tumors it is of crucial importance to investigate which T cell subpopulation is the most robust in 
terms of nutrient restriction. These subset specific analyses would allow selecting the most 
promising subpopulation for adoptive T cell transfer. As activated T cells and tumor cells show 
an overlap in their metabolic profile the application of metabolic inhibitors could adversely affect 
CD8 T cell function and limit their anti-tumor immune response. Therefore, the interaction 
between metabolically active drugs and CD8 T cell function has to be elucidated.  
The aim of this project was to characterize the metabolic activity and the nutrient dependency 
of effector functions in human CD8 T cell subsets. Moreover, effects of clinically relevant anti-
metabolic drugs, inhibiting glycolysis, glutaminolysis or cellular respiration were investigated to 
avoid adverse effects on T cell function when combining immunotherapeutic approaches with 
anti-metabolic drugs. 
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2. Material and methods 
2.1. Materials 
2.1.1. Equipment 
Aria cell sorter     BD Bioscience, Heidelberg, Germany 
Autoclave      Technomara, Fernwald, Germany  
Balance LP1200S     Sartorius, Göttingen, Germany  
Biofuge fresco     Heraeus, Osterode, Germany  
CASY Cell Counter    Innovatis/Roche, Basel, Switzerland  
Dimension Vista    Siemens, Munich, Germany 
EVOS Cell Imaging System   OLS-Omni Life Science, Bremen, Germany  
FACS Calibur flow cytometer   BD Biosciences, Franklin Lakes, NJ, USA  
Forceps      Aesculap, Tuttlingen, Germany  
Fusion Pulse 6     Vilber Lourmat, Collégien, France 
Hemocytometer     Marienfeld, Lauda-Königshofen, Germany  
Incubators      Heraeus, Hanau, Germany  
Laminar Flow Cabinet Herasafe   Thermo Scientific, Waltham, MA, USA 
LSR II flow cytometer    Becton Dickinson, Heidelberg, Germany  
LSR Fortessa     Becton Dickinson, Heidelberg, Germany  
MACSiMAG separator   Miltenyi Biotec, Bergisch Gladbach, Germany 
Microscopes     Zeiss, Jena, Germany  
Multifuge 3S-R     Heraeus, Osterode, Germany  
Multifuge 3.0R     Thermo Scientific, Waltham, MA, USA 
Pipette (repetitive) HandyStep  Brand GmbH & CO KG, Wertheim, Germany 
pH meter      Knick, Berlin, Germany  
Picofuge      Heraeus, Osterode, Germany  
Pipetboy      Integra Biosciences, Fernwald, Germany  
Pipettes      Eppendorf, Hamburg, Germany or 
      Gilson, Milddleton, WI, USA  
Precision microplate reader   Molecular Devices, Sunnyvale (CA, USA) 
QuadroMACSTM separator   Miltenyi Biotec, Bergisch Gladbach, Germany 
Seahorse XFe96 Analyzer   Agilent, Santa Clara, CA, USA 
SenSorDish-Reader    PreSens, Regensburg, Germany  
Sepatech Megafuge 1.0    Heraeus, Osterode, Germany 
Sepatech Megafuge 3.0     Heraeus, Osterode, Germany 
Sonorex Ultrasonic Bath    Branson, Danbury, CT, USA  
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Thermo VarioSkan    Thermo Scientific, Waltham, MA, USA 
Thermomixer     Eppendorf, Hamburg, Germany  
Vortexer      Scientific Industries Ink., Bohemia, NY, USA  
Water purification system    Millipore, Eschborn, Germany  
Waterbath      Julabo, Seelstadt, Germany 
 
 
2.1.2. Consumables 
Cell culture dishes    BD, Franklin Lakes, NJ, USA or  
Eppendorf, Hamburg, Germany 
Cell culture dishes (U-bottom)  Falcon, Heidelberg, Germany 
Cell culture flasks     Costar, Cambridge, MA, USA or  
Eppendorf, Hamburg, Germany 
Cell strainer (70 μm, 100 μm)   Falcon, Heidelberg, Germany 
Combitips for Eppendorf multipette  Eppendorf, Hamburg, Germany 
Cryo tubes      Corning, Corning, NY, USA 
Hyperfilm ECL     Amersham/GE Healthcare, Chalfont St Giles, UK 
Immobilon-P PVDF membrane   Merck Millipore, Billerica, MA, USA 
LS columns    Miltenyi Biotec, Bergisch Gladbach, Germany 
Micro test tubes (1.5 ml, 2.0 ml)   Eppendorf, Hamburg, Germany 
Micropore filters     Sartorius, Göttingen, Germany 
Microtiter plates (6, 12, 24, 96 wells)  Costar, Cambridge, MA, USA 
Petri dishes     Falcon, Heidelberg, Germany 
Pipette tips     Eppendorf, Hamburg, Germany 
Plastic pipettes     Costar, Cambridge, MA, USA or 
       Nerbe plus, GmbH Winsen/Luhe, Germany 
Polystyrene test tubes    Falcon, Heidelberg, Germany 
Scalpels, disposable    Feather, Osaka, Japan 
Syringe Filters, sterile    Sartorius, Göttingen, Germany 
Syringes and needles    BD, Franklin Lakes, NJ, USA 
Tubes (5 ml, 15 ml, 50 ml, 225 ml)  Falcon, Heidelberg, Germany 
 
 
 
 
 
  Material and methods 
                                                                                                                                                           
23 
 
2.1.3. Media, buffers and solutions 
AB serum, human    Blutspendedienst des BRK, Munich, Germany 
Acrylamide     Carl Roth, Karlsruhe, Germany 
Ammonium persulfate (APS)  Merck Millipore, Billerica, MA, USA 
ß-mercaptoethanol    Gibco/Life Technologies, Carlsbad, CA, USA 
Biocoll Separating Solution   Biochrom/Merck Millipore, Billerica, MA, US 
Bovine serum albumine (BSA)  Sigma-Aldrich, St. Louis, MO, USA 
Dimethylsulfoxide (DMSO) Honeywell Riedel-de Haen /Sigma-Aldrich, St. 
Louis, MO, USA 
Ethanol Carl Roth, Karlsruhe, Germany 
FACS clean     BD Biosciences, Franklin Lakes, NJ, USA 
FACS flow      BD Biosciences, Franklin Lakes, NJ, USA 
FACS rinse     BD Biosciences, Franklin Lakes, NJ, USA 
Fetal calf serum (FCS)   PAA/GE Healthcare, Chalfont St Giles, UK or 
Gibco/Life Technologies, Carlsbad, CA, USA or 
Merck Millipore, Billerica, MA, USA, 
heat-inactivated by 56 °C, 30 minutes 
Glycerin      Merck Millipore, Billerica, MA, USA 
Glycine      Merck, Darmstadt, Germany 
H2O2      Merck, Darmstadt, Germany 
ddH2O     B. Braun Melsungen, Melsungen, Germany 
Hanks' Balanced Salt solution  Sigma-Aldrich, St. Louis, MO, USA 
Isoton II     Beckman Coulter, krefeld, Germany 
Isopropanol     B. Braun Melsungen, Melsungen, Germany 
L-Alanyl-L-Glutamine    PAN Biotech, Aidenbach, Germany 
MEM Non-Essential Amino Acid Solution  Gibco/Life Technologies, Carlsbad, CA, USA 
MEM Sodium Pyruvate    Gibco/Life Technologies, Carlsbad, CA, USA 
MEM Vitamin Solution    Gibco/Life Technologies, Carlsbad, CA, USA 
PBS      Sigma-Aldrich, St. Louis, MO, USA or 
Gibco/Life Technologies, Carlsbad, CA, USA 
RIPA buffer     Sigma-Aldrich, St. Louis, MO, USA 
RPMI 1640     Gibco/Life Technologies, Carlsbad, CA, USA 
RPMI 1640 w/o glucose   Sigma-Aldrich, St. Louis, MO, USA 
TEMED      Sigma-Aldrich, St. Louis, MO, USA 
Tris      USB/Affymetrix, Santa Clara, CA, USA 
Triton X100     Sigma-Aldrich, St. Louis, MO, USA 
Tween 20      Sigma-Aldrich, St. Louis, MO, USA 
Typsin-EDTA     PAN Biotech, Aidenbach, Germany 
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2.1.3.1. Medium for cultivation of human T cells 
Instable L-glutamine   5 ml (2 mM) 
Non-essential amino acids  5 ml (0.1 mM each) 
Sodium pyruvate    5 ml (1 mM) 
Vitamins     2 ml 
β-mercaptoethanol    0.5 ml (0.05 mM) 
Penicillin/Streptomycin   2.5 ml (50 IU/ml) 
AB serum, human    50 ml (10 %) 
RPMI 1640     ad 500 ml 
 
The medium was filtered through a 0.22 µm filter by the SteriCup® quick release filter system 
(Merck) and stored at 4 °C. Before utilization, T cell medium was supplemented with IL-2 (end 
concentration of 25 IU/ml, PeproTech). 
 
 
2.1.3.2. Medium for cultivation of human DCs 
Instable L-glutamine   5 ml (2 mM) 
Penicillin/Streptomycin    2.5 ml (50 IU/ml) 
FCS     50 ml (10 %) 
RPMI 1640     ad 500 ml 
 
The medium was stored at 4 °C. Before utilization, medium was supplemented with IL-4 and 
GM-CSF (end concentration of 144 IU/ml and 280 IU/ml, PeproTech). 
 
 
2.1.3.3. Medium for cultivation of murine T cells 
Instable L-glutamine   5 ml (2 mM) 
Nonessential amino acids   5 ml (0.1 mM each) 
Sodium pyruvate    5 ml (1 mM) 
β-mercaptoethanol    0.5 ml (0.05 mM) 
Penicillin/Streptomycin    2.5 ml (50 IU/ml) 
FCS     50 ml (10 %) 
RPMI 1640     ad 500 ml 
 
The medium was stored at 4 °C. Before utilization, T cell medium was supplemented with IL-2 
(end concentration of 10 IU/ml, PeproTech). 
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2.1.3.4. Freezing medium 
FCS      80 %  
DMSO     20 % 
 
 
2.1.3.5. FACS staining buffer 
FCS      10 ml (2 %) 
PBS     ad 500 ml 
 
 
2.1.3.6. MACS buffer 
FCS      5 ml (1 %) 
EDTA     5 ml (2 mM) 
PBS     ad 500 ml 
 
 
2.1.3.7. EDTA (200 mM) 
EDTA     2.924 g  
ddH2O     ad 50 ml 
 
The pH was adjusted to 8.0, the solution was filtered through a 0.20 µm filter to sterilize and 
stored at room temperature. 
 
 
2.1.3.8. ACK lysis buffer (6x) 
NH4Cl (ammonium chloride)   49.64 g  
KHCO3 (potassium bicarbonate)   6.00 g    
EDTA disodium, dihydrate   0.222 g   
ddH2O     ad 1000 ml 
 
The pH was adjusted to 7.4, the buffer was filtered through a 0.22 µm filter by the SteriCup® 
quick release filter system (Merck) and stored at 4 °C. Before utilization, buffer was diluted 1:6 
with ddH2O. 
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2.1.4. Kits, reagents and chemicals 
Acivicin in medium    Santa Cruz Biotechnology, Dallas, TX, USA 
Amersham ECL Prime Western Blotting  
Detection Reagent    Amersham/GE Healthcare, Chalfont St Giles, UK 
Ammonium chloride (NH4Cl)  Merck, Darmstadt, Germany 
Annexin binding buffer   BD Biosciences, Franklin Lakes, NJ, USA 
Arginine     Sigma-Aldrich, St. Louis, MO, USA 
Asparagine     Sigma-Aldrich, St. Louis, MO, USA 
Aspartate     Sigma-Aldrich, St. Louis, MO, USA 
BD Comp Beads     BD Biosciences, Franklin Lakes, NJ, USA 
Protein transport inhibitor (monensin)  BD Biosciences, Franklin Lakes, NJ, USA 
Bio-Rad DC protein assay   Bio-Rad, Munich, Germany 
BPTES in medium    Sigma-Aldrich, St. Louis, MO, USA 
Trypan blue     Sigma-Aldrich, St. Louis, MO, USA 
CB-839 in medium    Selleckchem, Munich, Germany 
CD4 (L3T4) MicroBeads, mouse  Miltenyi Biotec, Bergisch Gladbach, Germany 
CD4 MicroBeads, human   Miltenyi Biotec, Bergisch Gladbach, Germany 
CD8a T cell Isolation Kit, mouse  Miltenyi Biotec, Bergisch Gladbach, Germany 
CD8 MicroBeads, human   Miltenyi Biotec, Bergisch Gladbach, Germany 
Diclofenac sodium salt in medium  Fagron, Rotterdam, The Netherlands 
Dimethyl α-ketoglutarate   Sigma-Aldrich, St. Louis, MO, USA 
DON in medium    Sigma-Aldrich, St. Louis, MO, USA 
DuoSet ELISA human IFNγ   R&D Systems, Minneapolis, MN, USA 
DuoSet ELISA human TNF   R&D Systems, Minneapolis, MN, USA 
DuoSet ELISA mouse IFNγ   R&D Systems, Minneapolis, MN, USA 
DuoSet ELISA mouse TNF   R&D Systems, Minneapolis, MN, USA 
Dynabeads™ T-Activator CD3/CD28  Gibco/Life Technologies, Carlsbad, CA, USA  
EDTA (ethylenediaminetetraacetic acid) Sigma-Aldrich, St. Louis, MO, USA 
Glucose (HK) Assay Kit   Sigma-Aldrich, St. Louis, MO, USA 
Glutamic acid monosodium salt hydrate  Sigma-Aldrich, St. Louis, MO, USA 
Glutathione (GSH)    Sigma-Aldrich, St. Louis, MO, USA  
FcR-Blocking reagent mouse  Miltenyi Biotec, Bergisch Gladbach, Germany 
FoxP3 transciption factor staining   
buffer set  eBioscience, San Diego, CA, USA 
GM-CSF     PeprochTech, Hamburg, Germany 
Hypoxanthine-Thymidine Media  
Supplement (50x)     Sigma-Aldrich, St. Louis, MO, USA 
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Ionomycin      Enzo Life Sciences, Farmingdale, NY, USA 
α-ketoglutaric acid sodium salt   Sigma-Aldrich, St. Louis, MO, USA 
L-lactic acid (C3H6O3)   Sigma-Aldrich, St. Louis, MO, USA 
Lipopolysaccharide (LPS)   Enzo Life Sciences, Farmingdale, NY, USA 
Luminol      Sigma-Aldrich, St. Louis, MO, USA 
Lumiracoxib in DMSO   Selleckchem, Munich, Germany 
Metformin hydrochlorid in medium Sigma-Aldrich, St. Louis, MO, USA 
Oligomycin in ethanol   Sigma-Aldrich, St. Louis, MO, USA 
Potassium hydrogen carbonate (KHCO3) Fluka, Buchs, Switzerland 
IL-2       PeprochTech, Hamburg, Germany 
IL-4      PeprochTech, Hamburg, Germany 
IL-7      PeprochTech, Hamburg, Germany 
IL-15      PeprochTech, Hamburg, Germany 
Phorbol-12-myristat-13-acetat (PMA) Calbiochem, San Diego, CA, USA 
SDS      Sigma-Aldrich, St. Louis, MO, USA 
Sodium bicarbonate (NaHCO3)  Merck, Darmstadt, Germany 
Sodium L-lactate (C3H5NaO3)  Sigma-Aldrich, St. Louis, MO, USA 
SR13800 (10 mM in DMSO)  kindly provided by Prof. Dr. JL Cleveland 
UDP-N-acetylglucosamine  Sigma-Aldrich, St. Louis, MO, USA 
 
 
2.1.5. Antibodies 
2.1.5.1. Antibodies for western blotting 
Table 1: Antibodies for western blotting 
 
 
 
 
 
 
 
 
 
 
 
Specificity Source 
Species cross 
activity 
Molecular 
weight 
Dilution Manufacturer 
α -Actin Rabbit 
Human,        
animal 
42 kDa 1:2000 Sigma-Aldrich 
α -MCT4 Rabbit 
Mouse, rat, 
human 
43 kDa 1:1000 
Santa Cruz 
Biotechnologies 
α -GLUL Rabbit 
Mouse, rat, 
human 
42 kDa 1:5000 Abcam 
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2.1.5.2. Antibodies for flow cytometry 
2.1.5.2.1. Anti-human antibodies 
Table 2: Anti-human antibodies for flow cytometry 
Specificity Function Conjugation clone company 
α-CCR7* lymph node homing receptor FITC 
150503 
REA 
BD Biosciences, 
Miltenyi Biotech 
α-CD62L* lymph node homing receptor APC 
DREG-56 
145-15 
BD Biosciences, 
Miltenyi Biotech 
α-CD45RA* 
activity related marker, 
differentiation between naïve  
and memory T cells 
Pe-Cy7 
L48 
REA 
BioLegend, 
Miltenyi Biotech 
α-CD45RO* 
activity related marker, 
differentiation between naïve 
and memory T cells 
Pe 
UCHK1 
REA 
BD Biosciences, 
Miltenyi Biotech 
α-CD3* T cell marker APC-H7 
SK7 
REA 
BD Biosciences, 
Miltenyi Biotech 
α-CD8* part of the T cell co-receptor Pacific Blue 
RPA-T8 
REA 
BD Biosciences, 
Miltenyi Biotech 
α-CD8 part of the T cell co-receptor Pe-Cy7 SK1 BioLegend 
α-granzyme B effector molecule FITC GB11 BD Biosciences 
α-perforin effector molecule APC dG9 BioLegend 
α-CD25 activity related marker for T cells Pe-Cy7 M-A251 BD Biosciences 
α-CD69 activity related marker for T cells APC FN50 BD Biosciences 
α-CD137 activity related marker for T cells Pe 4B4 ThermoFisher 
α-phospho-
mTOR 
activity of mTOR Pe MRRBY 
eBioscience™ 
ThermoFisher 
* antibodies used for fluorescence activated cell sorting 
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2.1.5.2.2. Anti-mouse antibodies 
Table 3: Anti-mouse antibodies for flow cytometry 
Specificity Function Conjugation clone company 
α-CD62L lymph node homing receptor BV421 Mel-14 BD Biosciences  
α-CD69 activity related marker for T cells FITC H1.2F3 BD Biosciences  
α-CD11b myeloid marker APC-Cy7 M1/70 BD Biosciences  
α-CD8a part of the T cell co-receptor APC-Cy7 53-6.7 BioLegend  
α-CD44  marker for memory T cells  Pe IM7 BioLegend  
α-CD137 activity related marker for T cells APC 17B5 BioLegend  
α-CD19 B cell marker Pe 6D5 BioLegend  
α-CD3e T cell marker FITC 145-2C11 ThermoFisher  
α-CD4 part of the T cell co-receptor APC RM4-5 ThermoFisher  
α-CD25 activity related marker for T cells Pe-Cy7 PC61.5 ThermoFisher  
α-NK1.1 NK cell marker APC PK136 ThermoFisher  
 
 
2.1.5.2.3. Other antibodies and dyes 
Table 4: Other antibodies and dyes for flow cytometry 
Specificity Function Conjugation clone company 
MitoTracker Green mitochondrial content   ThermoFisher 
2-NBDG glucose analogue   ThermoFisher 
7AAD viability   BD Biosciences 
Annexin V viability FITC  BD Biosciences 
α-CD3 stimulation of murine T cells - 145-2C11 BD Biosciences 
α-CD28  stimulation of murine T cells - 37.51 BD Biosciences 
 
 
2.1.6. Databases and software 
The following software tools were used to design experiments and process data. 
CellQuest Pro    BD, Heidelberg, Germany 
Citavi 5.7.1.0   Swiss Academic Software gmbH, Wädenswil, Switzerland 
FACSDiva     BD, Heidelberg, Germany 
FlowJo v9.9.6 or v10.4.1  FlowJo, LLC, Ashland, OR, USA 
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GraphPad Prism 8.0.0   GraphPad Software, La Jolla, CA, USA 
Microsoft Excel 2003/2007/2010  Microsoft Deutschland GmbH  
SenSorDish-Reader Software PreSens, Regensburg, Germany 
 
 
2.2. Methods 
2.2.1. Cell culture methods for human immune cells 
All cells were handled under a laminar flow cabinet with sterile consumables. If not otherwise 
noted, cells for cell cultivation were centrifuged at 1300 rpm for 7 minutes at 4 °C. In case of cell 
staining for flow cytometry, cells were centrifuged at 1600 rpm for 4 minutes at 4 °C. 
 
 
2.2.1.1. Cell counting and cell size monitoring using the Casy system 
The measurement of proliferation and cell size was performed on the Casy system (Casy® 
Modell TT, OLS Omni Life Science). These two parameters are indicators for T cell function. The 
Casy system uses an electric field to distinguish between living and dead cells. Besides cell 
number and viability, the Casy cell counter can analyze the cell diameter. 50 µl of the cell 
suspension were mixed with 10 ml IsoTon® II diluent (Beckman Coulter). A significant statistical 
certainty was obtained with a triple measurement. 
 
 
2.2.1.2.  Freezing and thawing of cells 
In case of monocytes, cells were mixed with freezing medium (FCS with 20 % DMSO) in cryo 
tubes in a ratio of 1:2. The cells were slow-frozen in cryo freezing containers at -80 °C.  
Frozen cells were thawed at room temperature and immediately washed with medium. After 
centrifugation cells were resuspended in fresh medium.  
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2.2.1.3. Isolation of human immune cells 
2.2.1.3.1. Isolation of human mononuclear cells by density gradient centrifugation 
Mononuclear cells (MNCs) were isolated from the blood of healthy donors. A process called 
apheresis provided the blood cells. A volunteer donor undergoes a plateletpheresis or a 
leukapheresis which are normally used to harvest platelets or leukocytes, respectively. The 
addition of citrate prevents blood coagulation.  
MNCs were separated from other cells, as erythrocytes and granulocytes, with a Ficoll 
density gradient centrifugation. In case of a plateletpheresis about 8 ml blood were mixed with 
42 ml PBS, in case of a leukapheresis about 70 ml with PBS to an end volume of 400 ml. The 
Ficoll solution (15 ml) was carefully covered with a layer of diluted blood (25 or 30 ml) in a 
centrifuge vial, without mixing the phases. After a centrifugation for 30 minutes with 1801 rpm at 
room temperature, the interphase of the MNCs was harvested and washed three times with 
PBS. The cell number was determined and the cells were used either for elutriation or for T cell 
isolation. 
 
 
2.2.1.3.2. Separation of monocytes by counterflow centrifugation elutriation 
The elutriation enables the separation of different cell populations based on their cell size. 
The principle of separation is the balance between centrifugal force and the counter flow drag 
force. It allows the enrichment of B cells (fraction I, with a diameter of 7 µm), T cells (fraction II, 
8 to 9 µm) and monocytes (fraction III, 10 µm). 
After the elutriation chamber was attached into the elutriator’s rotor, the complete elutriation 
system was sterilized with 6 % H2O2 and washed with PBS. The settings of the peristaltic pump 
were calibrated with Hanks buffer (Sigma-Aldrich) to determine the required flow rate. 
After harvesting the MNCs by density gradient centrifugation, cells were injected into the 
elutriation chamber with a flow rate of 52 ml/min. Fractions were collected using different pump 
flow rates (52–111 ml/min) using a fixed rotor speed of 2500 rpm at 4 °C. 
Based on their size, monocytes were washed out in the last fraction, achieving more than 
85 % purity. The cells were centrifuged and resuspended in medium. After cell counting, 
10 x 106 cells were frozen. The surface markers CD3, CD14 and CD20 were analyzed by flow 
cytometry after each elutriation. Supernatants of overnight cultures (RPMI with 2 % AB serum, 
2 mM glutamine and Penicillin/Streptomycin) were used to confirm the unstimulated state of the 
monocytes by an IL-6 elisa. 
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2.2.1.3.3. Maturation of monocytes to DCs 
DCs for T cell stimulation were generated by incubating monocytes in medium with FCS 
(10 %), 224 IU/ml GM-CSF and 144 IU/ml IL-4 (both PeproTech) for four days. After two days, 
the DCs were matured with 100 ng/ml lipopolysaccharide (LPS, Enzo Life Sciences GmbH). 
After four days, matured DCs (mDCs) were harvested and were used to stimulate T cells 
(2.2.1.4). 
 
 
2.2.1.3.4. Isolation of human CD8 T cells 
CD8 T cell isolation was based on the MACS separation technique from Miltenyi Biotech. 
T cells are magnetically labeled with MicroBeads which are linked to a specific antibody. 
Magnetically labeled cells retain within a column, while unlabeled cells run through.  
After determination of the cell number, MNCs were centrifuged, the supernatant was aspired 
and the cell pellet was resuspended in MACS buffer (40 µl per 10 x 106 cells). After addition of 
10 µl of MicroBeads cells were incubated at 4 °C for 15 minutes. Unlabeled MicroBeads were 
removed with a washing step and cell pellet was resuspended in 500 µl MACS buffer. The LS 
column (Miltenyi Biotech) was placed in the magnetic field of a MACS separator and the column 
was rinsed with 3 ml MACS buffer. Cell suspension was applied onto the column. Cells labeled 
with MicroBeads are retained within the column, while unlabeled cells pass through. Washing 
steps were performed three times with 3 ml MACS buffer. The column was removed from the 
separator and the magnetically labeled cells were flushed out with 5 ml MACS buffer in a 
collection tube by firmly pushing the plunger into the column. Cells were centrifuged, the 
supernatant was aspired, cell pellet was resuspended in T cell medium and cell number was 
determined. About 12 % of the MNCs were CD8 positive.  
After isolation overall purity of the CD8 T cells was checked by flow cytometry and reached 
always more than 98 %. The cells were stored overnight at 37 ˚C with a cell number of 10 x 106 
cells per ml. The inactive state was checked and maintained after overnight storage (Figure 4). 
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Figure 4: Analysis of the inactive state of CD8 T cells after overnight storage. CD8 T cells were 
isolated from MNCs of healthy donors and were stained for CD25, CD69 and CD137 before (light blue) 
and after overnight storage (dark blue) at 37 °C with a cell concentration of 10 x 10
6
 cells per ml in RPMI 
with all supplements. Unstained cells were used to determine autofluorescence (grey line). 
 
 
2.2.1.4. T cell stimulation, cultivation and experimental setup for human T cells 
After the overnight storage the cells were harvested. To confirm the unstimulated state of the 
T cells, supernatants were served to measure cytokines to a later time point. The purity, the 
subset distribution and the activation state were checked by flow cytometry.  
T cells were cultured in T cell medium with IL-2 (end concentration of 25 IU/ml, PeproTech) in 
a humidified atmosphere (5 % CO2) at 37 °C in a Heraeus incubator. 
CD8 T cell subsets were cultured with additional IL-7 and IL-15 (both end concentration of 
5 ng/ml, PeproTech). Cells were stimulated with anti-CD3/CD28 dynabeads obtaining a bead-to-
cell ratio of 1:1. 0.1 x 106 T cells were seeded in a 96 well U-bottom plate in 220 µl medium 
resulting in a cell concentration of 0.444 x 106 cells per ml.  
Cells and supernatants were harvested after 24, 48, 72 hours and 6 days. Cells were counted 
to monitor proliferation and cell size. The expression of the activation related surface markers or 
the viability were analyzed by flow cytometry (2.2.4). Supernatants were frozen at -20 °C to 
determine cytokine production, lactate accumulation and glucose consumption to a later time 
point. To prevent nutrient restriction and acidification the cells were diluted after 72 hours, by 
removing 100 µl cell suspension and adding fresh medium containing IL-2. 
Alternatively T cells were stimulated in a mixed leukocyte reaction (MLR) with 0.01 x 106 
allogeneic mDCs in a 96 well U-bottom plate in 220 µl medium resulting in a cell concentration of 
0.444 x 106 cells per ml.  
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In order to activate expanded T cells to a maximum, T cells were stimulated with phorbol-12-
myristate-13-acetate (PMA, 0.018 µg/ml) and ionomycin (0.89 µM) for 4 hours. Supernatants 
were frozen at -20 °C to determine cytokine production to a later time point. 
 
 
2.2.1.5. Cultivation under metabolic restriction 
Glucose and glutamine metabolism was analyzed in glucose (Sigma-Aldrich) or glutamine 
free RPMI 1640 (Gibco/ Thermofisher). The addition of the human AB serum (10 %) resulted in 
a final concentration of 0.4 mM in comparison to 10.4 mM glucose or 0.05 to 0.075 mM in 
comparison to 2.05 to 2.075 mM glutamine in standard RPMI. The required glutamine 
concentration for the entire stimulation was analyzed by addition of different glutamine 
concentrations. 
Respiration was analyzed with the inhibition of the mitochondrial ATP production by the 
complex V inhibitor oligomycin (final concentration 5 µM).  
 
 
2.2.2. Cell culture methods for murine immune cells 
2.2.2.1. Mice  
To analyze MCT4 deficiency in immune cells, a MCT4-/- mouse model with a C57/BL6 
background was used, kindly provided by Prof. Dr. John L. Cleveland (Moffitt Cancer Center & 
Research Institute, Tampa, FL, USA). All experiments used age- and sex-matched mice. 
 
 
2.2.2.2. Isolation of murine immune cells 
2.2.2.2.1. Tissue preparation of the spleen for the isolation of splenocytes 
Spleens of wildtyp and MCT4-/- mice were collected in RPMI. A single-cell suspension was 
processed by scratching out cells with curved forceps in 7 ml medium with 2 mM glutamine and 
50 IU/ml Penicillin/Streptomycin in a petri dish. Cells were filtered through a 100 μm cell strainer 
and were centrifuged. To remove erythrocytes 2 ml ACK lysis buffer (2.1.3.8) was added. After 
incubation for 3 minutes at room temperature, the reaction was stopped by adding 10 ml 
medium. After a centrifugation step the cells were resuspended in 1 ml medium and were filtered 
through a 100 µm cell strainer. The cell strainer was washed with 19 ml medium. The 
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splenocytes were counted and stored for at least 2 hours in a humidified atmosphere (5 % CO2 
at 37 °C). 
To analyze the immune cell composition in the spleen 1.0 x 106 cells were analyzed by flow 
cytometry (2.1.5.2.2). To analyze the impact of MCT deficiency on T cell function, splenocytes 
were used to isolate CD4 and CD8 T cells (2.2.2.2.2). 
 
 
2.2.2.2.2. Isolation of murine CD4 and CD8 T cells 
Similar to the human T cell isolation, the murine CD4 and CD8 T cells were isolated with the 
MACS technology from Miltenyi Biotech. CD4 T cells were isolated by positive selection       
(130-049-201). The effluent after the CD4 isolation with the unlabeled remaining splenocytes 
was used to isolate the CD8 T cells. CD8 T cells were separated untouched by depletion     
(130-104-075). 
The procedure for the positive selection of the murine CD4 T cells was similar to the isolation 
of human T cells. In short, after the centrifugation step, the cell pellet was resuspended in MACS 
buffer (2.1.3.6, 10 µl per 10 x 106 cells). The splenocytes were incubated at 4 °C for 15 minutes 
with MicroBeads, were washed to remove unbound beads and resuspended in 500 µl MACS 
buffer. The cell suspension was applied onto the prepared column. After three washing steps, 
CD4 T cells were flushed out, centrifuged and resuspended in medium. 
CD8 T cells were isolated from the effluent after CD4 T cell isolation. After the determination 
of cell number, splenocytes were centrifuged, the supernatant was aspired and the cell pellet 
was resuspended in MACS buffer (40 µl per 10 x 106 cells). After addition of 10 µl of the biotin-
antibody cocktail per 10 x 106 cells, cells were incubated at 4 °C for 5 minutes. After adding 30 µl 
MACS buffer and 20 µl of anti-biotin MicroBeads per 10 x 106 cells, cells were incubated at 4 °C 
for 10 minutes. Cells were applied onto the prepared column and the column was washed once 
with 3 ml MACS buffer. The flow through was collected containing unlabeled cells, representing 
the enriched CD8 T cells. CD8 T cells were centrifuged and resuspended in medium.  
After isolation the overall purity of the CD4 and CD8 T cells was checked by flow cytometry. 
In contrast to the human T cells, the murine T cells were directly stimulated (2.2.2.2.3). 
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2.2.2.2.3. Stimulation, cultivation and experimental setup for murine T cells 
After isolation (2.2.2.2.2), murine T cells were cultured in RPMI medium with IL-2 (end 
concentration of 10 IU/ml, PeproTech) in a humidified atmosphere (5 % CO2) at 37 °C. 
Cells were stimulated with anti-CD3e antibody (purified NA/LE hamster anti-mouse CD3e, 
clone 145-2C11, BD Biosciences, 553057, 5 µg/ml) plus anti-CD28 antibody (purified NA/LE 
hamster anti-mouse CD28, clone 37.51, BD Biosciences, 553294, 1 µg/ml). 96 well flat-bottom 
plates were coated with anti-CD3e antibody for at least two hours at 37 °C. 0.2 x 106 T cells 
were seeded in 200 µl medium resulting in a cell concentration of 1.0 x 106 cells per ml.  
Cells and supernatants were harvested after 24 and 48 hours. Cells were counted to monitor 
proliferation. The expression of activation related surface markers or the viability were analyzed 
by flow cytometry. Supernatants were frozen at -20 °C to determine cytokine production, lactate 
accumulation and glucose consumption to a later time point.  
 
 
2.2.3. Western blot analysis 
Samples were lysed in RIPA (Sigma-Aldrich) in case of human T cells or in lysis buffer (50 
mM HEPES with pH 7.5, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 0.1 % Tween 20, 1 mM 
PMSF, 1 mM NaF, 10 mM ß-glycerophosphate, 1 mM Na orthovanadate) in case of murine 
T cells, separated by 10 % SDS-PAGE and transferred to PVDF membranes, blocked with 5 % 
milk  (Sucofin) in TBS buffer with 0.1 % Tween for one hour, and incubated with primary 
antibodies overnight (α-MCT4, α-GLUL, α-β-Actin, 2.1.5.1). Detection was performed by 
chemiluminescence (ECL, Amersham Bioscience) and analyzed using the chemiluminescence 
system Fusion Pulse 6 (Vilber Lourmat).   
 
 
2.2.4. Flow cytometry 
Flow cytometry is a method for analyzing the expression of cell surface and intracellular 
molecules, characterizing and defining different cell types in a heterogeneous cell population. It 
allows simultaneous multi-parameter analysis of single cells. Surface marker and intracellular 
molecules are stained with fluorescence labeled antibodies. Next to the granularity by the 
sideward scatter (SSC) and the size by the forward scatter (FSC), cells can be analyzed 
regarding their fluorescence signal. For this thesis a BD Aria, a BD FACS Calibur, a BD LSR 
Fortessa and a BD LSR II were used.  
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In this study different markers were used for the classification and characterization of T cells 
(Table 2, Table 3, Table 4). Activity related surface markers as CD25 or CD69 or effector 
molecules as granzyme B and perforin allowed the analysis of T cell function. The results were 
analyzed with the Flowjo software. 
BD compbeads or cells were used to determine compensation values, according to 
manufacturer’s instructions. To determine cell autofluorescence, unstained cells were used. 
 
 
2.2.4.1. Staining of extracellular surface marker 
Cells were harvested in FACS tubes and washed with 1 ml of FACS wash buffer (2.1.3.5). 
After addition of the antibodies, cells were incubated at 4 °C for 20 minutes in the dark. The 
optimal antibody concentration was determined by titration for every antibody. After a washing 
step with 1 ml FACS wash buffer, cells were resuspended in 200-300 µl of FACS wash buffer 
and immediately analyzed by flow cytometry.  
 
 
2.2.4.2. Antibody staining of intracellular molecules for flow cytometry 
For staining of intracellular antigens as perforin or granzyme B, the intracellular staining kit 
from eBioscience/Thermofisher was used, following manufacturer’s protocol. In short, T cells 
were incubated in the presence of monensin for three hours, harvested and permeabilized for 
15 minutes at 4 °C. After T cells were washed twice with permeabilization buffer, T cells were 
stained with respective intracellular markers and incubated for 20 minutes at 4 °C in the dark. 
After a washing step with 1 ml FACS wash buffer, cells were resuspended in 200-300 µl of 
FACS wash buffer and immediately analyzed by flow cytometry. 
 
 
2.2.4.3. Cell viability measurement by 7AAD and Annexin V staining 
To analyze the viability of cells, 7AAD (7-amino-actinomycin D) and Annexin V were used. 
Cells with damaged plasma membranes are unable to prevent 7AAD from entering the cell. 
Once inside the cell, 7AAD binds to intracellular DNA. After initiating apoptosis, cells translocate 
the membrane phosphatidylserine from the inner face of the plasma membrane to the cell 
surface. Phosphatidylserine can be easily detected by staining with a fluorescent conjugate of 
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Annexin V. With this staining procedure viable (double negative), apoptotic (7AAD negative, 
Annexin V positive)   and dead cells (double positive) can be distinguished. 
The cells were harvested in FACS tubes and washed with 1 ml of PBS. The staining solution 
was prepared as follows: 360 µl ddH2O, 40 µl Annexin V binding buffer, 10 µl 7AAD and 5 µl 
Annexin V. After addition of the staining solution the cells were incubated at room temperature 
for 20 minutes in the dark. The cells were immediately analyzed by flow cytometry.  
 
 
2.2.4.4. Analysis of mitochondrial content by MitoTracker Green staining 
In order to analyze mitochondrial content in murine T cells, cells were stained with 
MitoTracker Green (ThermoFisher). Unstimulated T cells were incubated with 10 nM 
MitoTracker Green for two hours in 1 ml RPMI medium without FCS in a humidified atmosphere 
(5 % CO2) at 37 °C. After a washing step with 1 ml FACS wash buffer, cells were resuspended 
in 200-300 µl of FACS wash buffer and immediately analyzed by flow cytometry. 
 
 
2.2.4.5. Determination of glucose uptake with 2-NBDG by flow cytometry 
The fluorescent glucose analog 2-NBDG (2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-
deoxyglucose, ThermoFisher) is a tracer used for monitoring glucose uptake into living cells. 
T cells stimulated for 2 hours were washed with PBS and incubated in w/o glucose medium in a 
humidified atmosphere (5 % CO2) at 37 °C. After one hour 2-NBDG was added with an effective 
concentration of 50 µM. After 45 minutes of incubation in a humidified atmosphere (5 % CO2) at 
37 °C, cells were washed twice with PBS and analyzed by flow cytometry. 
 
 
2.2.4.6. Fluorescence activated cell sorting 
In case of fluorescence activated cell sorting, T cells were harvested after overnight storage 
and washed with sterile FACS wash buffer. CD8 T cells were stained with six antibodies to 
distinguish between naïve (CD3+, CD8+, CCR7+, CD62L+, CD45RA+, CD45RO-), CM (CD3+, 
CD8+, CCR7+, CD62L+, CD45RA-, CD45RO+) and EM (CD3+, CD8+, CCR7-, CD62L-, CD45RA-, 
CD45RO+) subsets (Table 5).  
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Table 5: Antibodies used for fluorescence activated cell sorting with used volume for 10 x 10
6
 cells 
Specificity  Conjugation  Volume [µl] 
CD3  APC-Cy7  20 
CD8  PB  30 
CCR7 (CD197)  FITC  20 
CD62L  APC  60 
CD45RO  Pe  90 
CD45RA  Pe-Cy7  15 
 
Cells were incubated with the antibodies at 4 °C for 20 minutes in the dark. After a washing 
step the cells were resuspended in FACS wash buffer to get a concentration of about 20-
30 x 106 cells per ml. The cell suspension was filtered through a 35 µm nylon mesh to prevent a 
blockage and fluorescence activated cell sorting was performed immediately at a BD FACS Aria. 
In order to confirm separation of subpopulations, a reanalysis of all subsets was performed after 
fluorescence activated cell sorting (Figure 5). 
 
                  
Figure 5: Purity of CD8 T cell subsets was confirmed by reanalysis after fluorescence activated 
cell sorting. Naïve (CD3
+
, CD8
+
, CCR7
+
, CD62L
+
, CD45RA
+
, CD45RO
-
), CM (CD3
+
, CD8
+
, CCR7
+
, 
CD62L
+
, CD45RA
-
, CD45RO
+
) and EM (CD3
+
, CD8
+
, CCR7
-
, CD62L
-
, CD45RA
-
, CD45RO
+
) subsets were 
separated by staining of indicated markers. 
  Material and methods 
                                                                                                                                                           
40 
 
2.2.5. Methods for metabolic analysis   
2.2.5.1. Determination of glucose consumption  
To analyze glucose consumption, glucose concentration in supernatants was determined 
enzymatically after a stimulation of 24, 48 and 72 hours with the Glucose (HK) Assay Kit (Sigma-
Aldrich). The glucose is phosphorylated to glucose-6-phosphate which is oxidized in the 
presence of nicotinamide adenine dinucleotide (NAD). During this reaction, an equimolar amount 
of NAD is reduced to NADH which absorbs light at a wavelength of 340 nm. The NADH increase 
in absorbance is directly proportional to the glucose concentration. 
The measurement was performed according to the manufacturer's protocol at a Thermo 
VarioSkan photometer (Thermo Scientific). The glucose concentration of each sample was 
calculated by using a prepared standard curve. 
 
 
2.2.5.2. Determination of lactate accumulation 
Lactate concentration was determined enzymatically using a Dimension Vista (Siemens) and 
specific reagents (Roche). 
 
 
2.2.5.3. Measurement of the cellular oxygen consumption with the PreSens technology 
The PreSens technology (PreSens Precision Sensing GmbH) enables the measurement of 
respiration using viable, non-fixed cells, in real time under cell culture conditions for several 
days. The concentration of oxygen is measured in a 24 well plate with a small 24-channel SDR 
SensorDish® Reader. O2 sensors are integrated at the bottom of each well. 
To measure oxygen consumption in human T cells, 0.8 x 106 cells were prepared with α-
CD3/CD28 Microbeads in a cell to bead ratio of 1:1. The cell-bead mix was seeded in a volume 
of 1 ml per well. With each experiment wells were generated with medium and unstimulated 
T cells, respectively. 
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2.2.5.4. Measurement of the cellular oxygen consumption and extracellular acidification 
rate with the Seahorse technology 
Extracellular acidification rate (ECAR, mpH/min) and oxygen consumption rate (OCR, 
pmol/min) of murine T cells were analyzed by a Seahorse XFe96 Analyzer (Agilent 
Technologies). ECAR and OCR were measured in non-buffered XF base medium (Agilent 
Technologies) supplemented with 2 % FCS. CD4 and CD8 T cells were immobilized onto 
Seahorse cell plates (0.2 x 106 cells per well) coated with 50 µg/ml poly-D-lysine (Sigma-Aldrich). 
 
 
2.2.6. Determination of cytokines by ELISA 
Cytokine secretion was determined in culture supernatants by commercially available 
sandwich enzyme-linked immunosorbent assays (ELISA; R&D Systems; human: DY285 for IFNγ 
and DY210 for TNF; murin: DY485 for IFNγ and DY410 for TNF) according to the manufacturer's 
protocol. In short a 96 well plate was coated with a capture antibody overnight. The plate was 
blocked with blocking buffer (1 % BSA) for at least one hour. The samples and the standard 
were incubated for two hours at room temperature. After the incubation with the detection 
antibody for two hours at room temperature, the plate was incubated with Streptavidin-HRP 
working dilution for 20 minutes. After incubation with the substrate solution for another 20 
minutes the reaction was stopped with stop solution. The optical density of each well was 
immediately determined at 450 nm at a Precision microplate reader using a wavelength 
correction set to 540 nm. 
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3. Results 
3.1. Characterization of human CD8 T cells 
Tumor cells are characterized by a strongly elevated glucose and glutamine metabolism 
which results in reduced availability of those nutrients in the tumor microenvironment (Chang et 
al. 2015; Pan et al. 2016). After stimulation, primary T cells display a similar metabolic 
phenotype compared to tumor cells and show an accelerated glucose metabolism and glutamine 
dependency. A direct link between effector functions and metabolic activity has been described. 
Therefore, reduced nutrient levels in the tumor microenvironment could contribute to the 
impaired anti-tumor immune response of T cells. However, conflicting results on metabolic 
requirements for T cell effector functions are published (Cham and Gajewski 2005; Chang et al. 
2013; Sukumar et al. 2013; Renner et al. 2015) which might result from species related 
differences but could also be ascribed to subset specificity. Whether CD8 T cell subsets show 
differences in their metabolic phenotype, this could make them more or less sensitive to the 
metabolic tumor microenvironment, which ultimately contribute to therapy outcome during ACT. 
Therefore, in a first step the metabolic characteristics of human CD8 T cell subpopulations were 
analyzed in relation to their function. 
 
 
3.1.1. Distribution and functional characterization of CD8 T cell subsets  
CD8 T cells were isolated from MNCs of healthy donors and a purity of more than 98 % was 
achieved (data not shown). Cells were stored overnight at a high density in culture medium. The 
unstimulated state of the T cells was confirmed by the determination of cytokines in the 
supernatant and by staining of activation related surface markers (CD25, CD69 and CD137) by 
flow cytometry. Purity, subset distribution and the quiescent state were maintained after 
overnight storage (Figure 4). 
In 58 healthy donors aged from 20 to 63 years, distinct differences were evidenced between 
circulating CD8 T cell populations. CD8 T cells are conventionally divided into three main 
subsets: Naïve and memory T cells, the latter are further subdivided in central (CM) and effector 
memory (EM) T cells.  
These subsets can be distinguished by a specific expression pattern of the surface markers 
CD45RA, CD45RO, CD62L and CCR7 (Figure 6). Naïve T cells are characterized by expression 
of CCR7, CD62L and CD45RA whereas CD45RO is not expressed. Memory subsets are 
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CD45RO positive and CD45RA negative. Regarding the two homing receptors CCR7 and 
CD62L, the CMs are double positive, the EMs double negative.  
 
 
                    
 
 
Figure 6: Staining of surface markers associated with differentiation state of CD8 T cell subsets. 
CD8 T cells were isolated by magnetic bead separation, stored overnight, stained for surface markers and 
analyzed by flow cytometry. In case of fluorescence activated cell sorting, cells were stained for CD3 and 
CD8 together with the differentiation markers to guarantee highest possible purity. Naïve: CD45RA
+
 
CD45RO
-
 CCR7
+
 CD62L
+
, CM: CD45RA
-
 CD45RO
+
 CCR7
+
 CD62L
+
, EM: CD45RA
-
 CD45RO
+
 CCR7
-
 
CD62L
-
. Data from one representative donor are shown. 
 
 
On average about 36.6 % of CD8 T cells were assigned to the naïve, about 18.9 % to the EM 
and 7.2 % to the CM T cell subset (Figure 7 A). The remaining cells were not clearly assignable. 
The percentage of naïve CD8 T cells decreased whereas CD8 memories accumulated linearly 
with age, while CM number increased only slightly (Figure 7 B).  
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Figure 7: Distribution of naïve, CM and EM subsets in bulk CD8 T cells. CD8 T cells were isolated 
from healthy donors and were stained for CD45RA, CD45RO, CCR7 and CD62L to differentiate between 
naïve (light grey), CM (grey) and EM cells (black). (A) Percentage for naïve, CM and EM T cell subsets in 
total T cells. Horizontal lines indicate the median (n=58). (B) Frequency distribution of naïve, CM and EM 
subsets in bulk CD8 T cells correlated with age. The linear regression is shown. The corresponding p 
values are shown in the graphs for each regression line, determined by Pearson’s r (n=52). 
 
 
IFNγ levels were determined in supernatants after 48 hours of α-CD3/CD28 stimulation in 
bulk T cells by ELISA. The more T cells were assigned to the EM subset in total CD8 T cells the 
more IFNγ was produced by trend (Figure 8). 
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Figure 8: Relation between IFNγ secretion and T cell subset distribution in bulk CD8 T cells. CD8 T 
cells were isolated from healthy donors and were stained for CD45RA, CD45RO, CCR7 and CD62L to 
distinguish between naïve (light grey), CM (grey) and EM cells (black). CD8 T cells were stimulated with 
α-CD3/CD28 beads at a cell to bead ratio of 1:1. IFNγ levels were determined in culture supernatants after 
48 hours by ELISA. The linear regression for naïve, CM and EM are shown. The corresponding p values 
are shown in the graphs for each regression line, determined by Pearson’s r (n=30). 
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To get the highest possible purity, CD8 T cell subsets were separated by fluorescence 
activated cell sorting. After gating on CD3 and CD8 double positive T cells, the subsets were 
sorted according to their expression profile of CD45RA, CD45RO, CD62L and CCR7 (Figure 6). 
The separation of the subpopulations was confirmed by reanalysis of all subsets after sorting 
(Figure 5). 
In line with the observed differences in the capability of bulk CD8 T cells to secrete 
cytokines depending on subset composition, the capability to produce IFNγ was different in the 
sorted subsets (Figure 9, Table 6). In contrast to naïve T cells, memory subpopulations were 
characterized by a high production of IFNγ (Figure 9 A) as well as TNF (Figure 9 B). CM T cells 
showed superior capacity to produce IFNγ over EM T cells after 48 hours. According to the 
literature, cytokine levels produced by memory T cells peaked already after 24 hours upon 
stimulation and did not markedly increased after 48 hours, whereas in naïve T cells cytokine 
production was further increased after 48 hours. 
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Figure 9: Cytokine secretion of CD8 T cell subsets. CD8 T cells were stimulated with α-CD3/CD28 
beads at a cell to bead ratio of 1:1. (A) IFNγ and (B) TNF levels were determined in culture supernatants 
after 24 and 48 hours by ELISA; horizontal lines indicate the median from independent donors (n≥7). 
Significance was determined by one-way ANOVA and post hoc Dunnett’s multiple comparisons test. 
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Table 6: Average IFNγ and TNF production of CD8 T cell subsets. 
  IFNγ [pg/ml]  TNF [pg/ml] 
  24 hours  48 hours  24 hours  48 hours 
NV  677  1018  566  1051 
CM  6717  7080  4428  5412 
EM  2628  2899  3036  3263 
CD8 T cells were stimulated with α-CD3/CD28 beads at a cell to bead ratio of 1:1. IFNγ and 
TNF levels were determined in culture supernatants after 24 and 48 hours by ELISA; median 
from data from Figure 9 are shown. For results for statistical significance see Figure 9. 
 
 
As a first read out, proliferation was monitored as an indicator for the quality of T cell culture 
with the CASY system. After 24 hours a slight proliferation was already observed in naïve 
T cells, in line with a rather low cytokine production, whereas CM and EM, producing high 
cytokine levels within the first 48 hours, started to proliferate beyond 48 hours (Figure 10). 
However, proliferative capacity was similar in naïve, CM and EM T cells. 
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Figure 10: Proliferation of CD8 T cell subsets. CD8 T cells were stimulated with α-CD3/CD28 beads at 
a cell to bead ratio of 1:1. Cell number was determined after 24, 48, 72 hours and 6 days of stimulation by 
the CASY system. Data are shown as mean±SEM (n=5 for naïve, n=3 for CM, n=4 for EM). 
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3.1.2.  Metabolic characteristics of CD8 T cell subsets 
Due to the fact that CD8 T cell subsets showed differences regarding their cytokine profile 
and their proliferative activity, the metabolic phenotype of the sorted CD8 subsets was 
investigated. Therefore glucose metabolism and respiratory activity were analyzed in the course 
of stimulation.  
Glucose consumption and lactate production were determined as parameters for glycolytic 
activity of stimulated CD8 T cells (Figure 11). Lactate production was only slightly detectable in 
the first 24 hours of activation in all subsets (data not shown) but was increased beyond 24 
hours and accelerated after 48 hours concomitant with proliferation in all three subsets (Figure 
10). Although there was a slight difference regarding proliferation kinetics in naïve T cells 
compared to memory T cells, glycolytic activity was similar in all three subsets. 
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Figure 11: Glycolytic activity of CD8 T cell subsets. CD8 T cells were stimulated with α-CD3/CD28 
beads at a cell to bead ratio of 1:1. Glucose and lactate concentrations were determined in cell culture 
supernatants after 48 and 72 hours and were normalized to cell number. Glucose concentration was 
determined by the Glucose (HK) Assay Kit, lactate secretion by enzymatic assays in culture supernatants. 
Horizontal lines indicate the median from independent donors (n≥4). Significance was determined by one-
way ANOVA and post hoc Dunnett’s multiple comparisons test.  
 
 
To analyze cellular respiration the PreSens technology was applied. Respiration was 
immediately elevated upon stimulation in all three subsets; however naïve T cells showed a 
higher mitochondrial respiratory activity compared to the memory subsets (Figure 12).  
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Figure 12: Mitochondrial respiration of CD8 T cell subsets. CD8 T cells were stimulated with              
α-CD3/CD28 beads at a cell to bead ratio of 1:1. Cellular respiration was measured with the PreSens 
technology in bulk CD8 T cells or CD8 T cell subsets at a concentration of 0.8 x 10
6
 cells per ml under cell 
culture conditions (n=6 for naïve and EM, n=5 for CM).  
 
 
CD8 T cell subsets showed some differences in metabolic activity upon stimulation. Although 
all three subsets had a similar glycolysis rate, naïve showed a higher oxygen consumption rate 
in comparison to CM and EM cells, suggesting that mitochondrial activity is of special 
importance for the naïve subpopulation. 
 
 
3.2. Nutrient restriction in CD8 T cells - Characterization of CD8 T cell 
subsets under nutrient restriction 
Within a tumor competition for nutrients between tumor cells and immune cells might 
contribute to the impaired anti-tumor immune response. To investigate a possible impact of 
nutrient restriction on the function of CD8 T cell subpopulations, the metabolic requirements for 
effector functions were characterized in all three subsets. The relevance of different metabolic 
pathways for T cell function was determined by stimulating T cells under nutrient restricted 
conditions. 
To mimic nutrient restriction T cell function was analyzed under glucose (w/o glc) or glutamine 
(w/o gln) deprived conditions and mitochondrial inhibition with the ATP synthase inhibitor 
oligomycin (mtATPi). The effect of glucose deprivation was analyzed in glucose free RPMI 1640 
supplemented with 10 % AB serum, which resulted in a final concentration of 0.4 mM glucose. 
The effect of glutamine deprivation was analyzed in glutamine free RPMI 1640 supplemented 
with 10 % AB serum which leads to a glutamine amount of 0.05 to 0.075 mM. 
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Viability of T cells was not affected under nutrient restricted conditions after 72 hours (Figure 
13). After 6 days viability was still not affected in CM T cells, whereas naïve and EM T cells 
showed a reduction in viability under glutamine deprivation by trend (naïve: 93.7 % in control 
cells to 84.7 % under glutamine deprivation, CM: 92.7 % to 87.0 %, EM: 86.7 % to 67.9 %). 
Lactate production was analyzed as a parameter for glycolytic activity. 
 
0
20
40
60
80
100
v
ia
b
le
 c
e
lls
 [
%
]
ctrl w/o
glc
w/o
gln
mtATPi
NV
0
20
40
60
80
100
ctrl w/o
glc
w/o
gln
mtATPi
CM
0
20
40
60
80
100
crtl w/o
glc
w/o
gln
mtATPi
EM
 
 
Figure 13: Impact of nutrient restriction on viability of CD8 T cell subsets. T cells were stimulated 
with α-CD3/CD28 beads at a cell to bead ratio of 1:1. As medium for control (ctrl) cells RPMI medium 
supplemented with 2 mM glutamine and 10 % AB serum (total of 10.4 mM glucose) was used. Glucose 
restricted conditions (w/o glc) were defined as glucose free medium supplemented with 10 % AB serum 
resulting in a total of 0.4 mM glucose. For glutamine restricted conditions (w/o gln) a glutamine free RPMI 
medium was used supplemented with 10 % AB serum resulting in a total of 0.05 to 0.075 mM glutamine. 
Mitochondrial ATP production was blocked by oligomycin (mtATPi) treatment (5 µM). (A, B, C) After 72 
hours of stimulation viability was determined with the CASY system. Data are shown as median (n≥3, with 
exception of the CMs under glucose deprivation: n=2). Significance was determined by one-way ANOVA 
and post-hoc Dunnett’s multiple comparisons test.  
 
 
In contrast to the glycolytic activity, mitochondrial activity was similar to controls in all three 
subsets under glucose free conditions even initially elevated in EM T cells (Figure 14). 
Surprisingly, mitochondrial inhibition significantly reduced lactate production in the naïve subset 
but had no impact on CM and EM T cells. Again, the reduced lactate secretion under 
mitochondrial inhibition in naïve cells could be either the result of a delayed activation or pointing 
towards a direct contribution of glutamine degradation to lactate production via the citric acid 
cycle. To answer this question flux experiments need to be performed.  
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Figure 14: Impact of nutrient restriction on glycolysis in human CD8 T cell subsets. T cells were 
stimulated with α-CD3/CD28 beads at a cell to bead ratio of 1:1. For detailed cultivation conditions see 
Figure 13. Glycolysis was investigated by measuring lactate accumulation in supernatants after 48 hours. 
Data are shown as median normalized to control (n≥3, with exception of the CMs treated with mtATPi: 
n=2). Asterisks show significant differences between control and treatment. Significance was determined 
by one-way ANOVA and post-hoc Dunnett’s multiple comparisons test (*p<0.05, ***p<0.001). 
 
 
Glutamine deprivation did not affect respiration in the early phase of activation, but led to a 
strong decrease in mitochondrial activity in all the subsets beyond 8 hours, comparable to 
mitochondrial inhibition with oligomycin (Figure 15). 
 
 
 
Figure 15: Impact of nutrient restriction on mitochondrial respiration of CD8 T cell subsets. CD8 
T cells were stimulated with α-CD3/CD28 beads at a cell to bead ratio of 1:1. For detailed cultivation 
conditions see Figure 13. Cellular respiration was measured with the PreSens technology in freshly 
stimulated CD8 T cell subsets at a concentration of 0.8 x 10
6
 cells per ml under cell culture conditions. 
Data from one representative donor are shown. 
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The results obtained on glycolytic activity and respiration under glutamine deprivation 
denoted a deficient activation. Upon stimulation, human T cells go through an initial growth 
phase - the so called “on-blast” formation. Glutamine restriction had a strong effect on the       
on-blast formation indicating an impaired activation. In contrast, increase in cell size was only 
slightly affected by glucose deprivation in naïve T cells and preserved in the memory subsets. 
Inhibiting mitochondrial function affected cell size in naïve, slightly in CM but not in EM cells 
(Figure 16).  
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Figure 16: Impact of nutrient restriction on increase in cell size in CD8 T cell subsets. Quiescent 
CD8 T cell populations (quies) were stimulated with α-CD3/CD28 beads at a cell to bead ratio of 1:1. For 
detailed cultivation conditions see Figure 13. Cell diameter was determined after 48 hours of stimulation 
under various conditions by the CASY system. Data are shown as median (n≥3, with exception of the CMs 
treated with mtATPi: n=2). Asterisks show significant differences between stimulated control and 
treatment. Significance was determined by one-way ANOVA and post-hoc Dunnett’s multiple comparisons 
test (*p<0.05, ***p<0.001).  
 
 
Cytokine production precedes proliferation and takes place immediately after stimulation. 
Although, we detected no significant effect of glucose deprivation and only partially of 
mitochondrial inhibition on IFNγ secretion in CD8 T cells subsets, donor dependent effects were 
observed (Figure 17 A, B, C).  
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Figure 17: Impact of nutrient restriction on cytokine production of CD8 T cell subsets. CD8 T cells 
were stimulated with α-CD3/CD28 beads at a cell to bead ratio of 1:1. For details on culture conditions see 
Figure 13. (A, B, C) IFNγ or (D, E, F) TNF levels were determined in culture supernatants after 48 hours 
by ELISA. Data are shown as median normalized to control levels (n≥3). Asterisks show significant 
differences between control and treatment. Significance was determined by one-way ANOVA and post-
hoc Dunnett’s multiple comparisons test (*p<0.05, **p<0.01, ***p<0.001).  
 
 
In particular for the naïve and the EM T cells the variation between donors was pretty high. 
Depending on the donor, cytokine production seemed to be induced or strongly reduced under 
glucose deprivation. Similar results were obtained for oligomycin treatment, an effect we could 
not delineate analyzing bulk CD8 T cells (Renner et al. 2015). 
In contrast, glutamine deprivation led to a strongly reduced cytokine production in all three 
subsets. The impact of glutamine deprivation in the naïve T cells was distinct, since only 5 % of 
the control IFNγ level was preserved. In the memory T cell subsets IFNγ production was 
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maintained to 27 % in the CM and to 37 % in the EM subset. Similar results were obtained for 
TNF production (Figure 17 D, E, F). Interestingly, CM and EM T cells from the same donor were 
glutamine dependent to a similar extent. 
In contrast to cytokine secretion proliferation was strongly decreased under glucose 
restricted conditions and a reduction of 50 % was observed by mitochondrial inhibition in all 
three subsets. However, especially in EM T cells the effect of oligomycin on proliferation was 
donor specific. Again, glutamine deprivation exerted a strong inhibitory effect in all three subsets 
(Figure 18).  
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Figure 18: Impact of nutrient restriction on proliferation of CD8 T cell subsets. T cells were 
stimulated with α-CD3/CD28 beads at a cell to bead ratio of 1:1. For detailed cultivation conditions see 
Figure 13. (A, B, C) Cell number after 6 days of stimulation was determined with the CASY system. Data 
are shown as median (n≥3). Dotted line indicates starting cell number. Asterisks show significant 
differences between control and treatment. Significance was determined by one-way ANOVA and post-
hoc Dunnett’s multiple comparisons test (*p<0.05, **p<0.01, ***p<0.001).  
 
 
Taken together CD8 T cell subsets were affected to different extents by nutrient restriction. 
Although a donor specific variation was observed, naïve T cells were quite sensitive to 
mitochondrial inhibition in line with their higher respiration rate. Despite proliferation, CM and EM 
T cells seemed to be only slightly affected by glucose deprivation and mitochondrial inhibition in 
general, although donor specific effects have to be taken into consideration. Glutamine 
restriction distinctly reduced T cell function in all three subsets which indicates a strong 
dependency on glutamine metabolism. 
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3.3. The role of glutamine metabolism in human CD8 T cells 
In contrast to glucose deprivation or mitochondrial inhibition, glutamine deprivation had a 
strong impact on T cell function in all CD8 T cell subsets. Although the glutamine dependency in 
T cells has been shown before, it is still a subject of controversy in the field, which pathway is 
glutamine crucial for. Moreover, there is nothing known about the limiting glutamine 
concentration still allowing functional T cell response. Therefore, in the following part glutamine 
titrations were performed and CD8 T cell function analyzed. Moreover, glutamine derived 
metabolites were supplemented in order to elucidate those glutamine dependent pathways 
essential for CD8 T cell activation. As all three subsets showed a strong glutamine dependency, 
the following set of experiments was performed in bulk CD8 T cell cultures.  
 
 
3.3.1. Glutamine is essential for CD8 T cells, but low concentrations are sufficient to 
maintain effector functions 
To gain more insight into the link between glutamine metabolism and T cell function, bulk 
CD8 T cells were cultured in the presence of various glutamine concentrations. Applied 
glutamine concentrations were chosen in light of blood levels of about 0.5 mM and with regard to 
levels as low as 0.1 mM which have been detected in tumors (Pan et al. 2016). Since glutamine 
is an important precursor molecule for a variety of metabolic pathways, mitochondrial respiration 
and lactate production were analyzed as parameters for metabolic activity of stimulated CD8 T 
cells (Figure 19).  
Surprisingly, respiration was higher beyond 12 hours administering the physiologic glutamine 
concentration of 0.5 mM and 0.25 mM compared to the standard culture concentration (2 mM). 
As observed in the single subsets, there was no difference in cell respiration between control 
and glutamine deprived T cells within the first 12 hours, indicating that the TCA is not restricted 
(Figure 19 A). However, beyond 12 hours, respiration was reduced under glutamine 
concentrations lower than 0.25 mM. Similar results were obtained for lactate secretion 
determined in supernatants after 48 hours of stimulation, which was significantly reduced at 
concentrations lower than 0.25 mM glutamine. 
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Figure 19: Impact of glutamine concentration on metabolic activity in human bulk CD8 T cells. CD8 
T cells were stimulated with α-CD3/CD28 beads at a cell to bead ratio of 1:1. (A) Cellular respiration was 
measured with the PreSens technology in freshly stimulated CD8 T cells under indicated glutamine 
concentration at a concentration of 0.8 x 10
6
 cells per ml under cell culture conditions (n= 4 for control and 
w/o glutamine, n=3 for 0.5, 0.25, 0.1, 0.05 mM glutamine. (B) Glycolysis was investigated by measuring 
lactate accumulation in supernatants after 48 hours. Data are shown as median normalized to control 
levels (n≥4). Asterisks show significant differences between control and treatment. Significance was 
determined by one-way ANOVA and post-hoc Dunnett’s multiple comparisons test (***p<0.001).  
 
 
 
Glutamine restriction caused a decrease in the metabolic activity of CD8 T cells in a 
concentration dependent manner (Figure 19). The limiting concentration affecting T cell function 
in terms of the expression of CD25 expression, on-blast formation, cytokine secretion and 
proliferation were investigated (Figure 20). It has to be mentioned that glutamine concentrations 
might be slightly higher as indicated due to the additional glutamine level added with the serum 
(0.05 to 0.075 mM).  
The increase in cell size and proliferation were reduced when glutamine concentrations 
were as low as 0.25 mM glutamine, half the level normally detected in blood. A concentration of 
0.1 mM was limiting for CD25 expression and the secretion of IFNγ (Figure 20 E) and TNF 
(Figure 20 F). However, cytokine secretion was not completely inhibited. Under glutamine 
deprivation IFNγ production was maintained to 29.0 %, TNF production to 32.4 % of the levels 
observed in control CD8 T cells. 
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Figure 20: Impact of glutamine concentration on T cell function in human bulk CD8 T cells. CD8 
T cells were stimulated with α-CD3/CD28 beads at a cell to bead ratio of 1:1. (A) The surface expression 
of the activation related marker CD25 was determined after 48 hours by antibody staining and subsequent 
analysis by flow cytometry, shown is the median fluorescence intensity (MFI). (B) Cell size and (C) 
granularity were analyzed by flow cytometry with forward and side scatter plots. (C) One representative 
donor is shown. (B, D) Cell diameter after 48 hours and proliferation after 6 days were determined in 
T cells by the CASY system. (E) IFNγ and (F) TNF levels were determined in culture supernatants after 
48 hours by ELISA. (A, B, D, E, F) Data are shown as median and (E, F) are normalized to control (each 
n≥3). Asterisks show significant differences between control and treatment. Significance was determined 
by one-way ANOVA and post-hoc Dunnett’s multiple comparisons test (*p<0.05, **p<0.01, ***p<0.001).  
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To analyze whether glutamine is only important for the on-set of T cell activation or also 
required later on, T cells were activated in the presence or absence of 2 mM glutamine for the 
first 24 hours and subsequently deprived for glutamine. For comparison all groups were washed 
after 24 hours and new medium with or without glutamine depending on the treatment group was 
added. When glutamine was deprived after 24 hours, CD8 T cell function was again strongly 
affected (Figure 21).  
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Figure 21: Glutamine is required in the whole course of stimulation. CD8 T cells were stimulated with 
α-CD3/CD28 beads at a cell to bead ratio of 1:1. T cells were activated in the absence or presence of 
2 mM glutamine for 48 hours in comparison to T cells stimulated in the presence of glutamine (2.0 mM) for 
the first 24 hours, and subsequently cultured in the absence of glutamine. For comparison all groups were 
washed after 24 hours and new medium was added. (A) CD25 expression was determined after 48 hours 
by antibody staining and subsequent analysis by flow cytometry, shown is the median fluorescence 
intensity (MFI). (B) Proliferation was determined after 72 hours in T cells by the CASY system. (C) IFNγ 
levels were determined in culture supernatants after 48 hours by ELISA. (A, B, C) Data are shown as 
median (n=3). Asterisks show significant differences between treatments. Significance was determined by 
one-way ANOVA and post-hoc Dunnett’s multiple comparisons test (*p<0.05, **p<0.01,***p<0.001).  
 
 
CD25 expression was significantly elevated in comparison to a complete glutamine 
deprivation but still reduced by more than 50 % in comparison to control level (Figure 21 A). 
Similar results were obtained for proliferation (Figure 21 B). IFNγ secretion was strongly reduced 
after glutamine removal similar to the amount of a complete deprivation (Figure 21 C). Those 
data show, that glutamine is constantly required even when T cells are pre-activated.  
mTOR is a master regulator of different cellular processes including cell growth, proliferation 
or survival for instance. Moreover mTOR was shown to regulate T cell differentiation and 
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function as well as metabolic activity (Waickman and Powell 2012). Although glutamine does not 
directly affect mTORC1 activity in the murine system, transport processes in which glutamine is 
involved induce mTORC1 (Cohen and Hall 2009). To investigate whether glutamine is required 
for mTOR activity for the early activation in human T cells, mTOR activation was analyzed by 
flow cytometry. In the presence of glutamine mTOR activation was strongly increased after 
24 hours and remained high (Figure 22 A). Under glutamine deprivation mTOR upregulation was 
blocked. mTOR activation was reduced when glutamine was removed after 24 hours of 
stimulation in the presence of glutamine (Figure 22 B), indicating that glutamine presence is an 
absolute requirement for mTOR activity. 
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Figure 22: Impact of glutamine deprivation on mTOR activity in human bulk CD8 T cells. CD8 
T cells were stimulated with α-CD3/CD28 beads at a cell to bead ratio of 1:1. (A) mTOR expression was 
analyzed after 24 and 48 hours in the presence or absence of glutamine. (B) T cells were activated in the 
presence or absence of 2 mM glutamine for 48 hours in comparison to T cells stimulated in the presence 
of glutamine (2.0 mM) for the first 24 hours, and subsequently cultured in the absence of glutamine. For 
comparison all groups were washed after 24 hours and new medium was added. mTOR expression was 
determined by antibody staining and subsequent analysis by flow cytometry, shown is the median 
fluorescence intensity (MFI). Data are shown as median (n=3). Asterisks show significant differences 
between (A) quiescent and stimulated cells and (B) between treatments. Significance was determined by 
one-way ANOVA and post-hoc Dunnett’s multiple comparisons test (*p<0.05, **p<0.01).  
 
T cells cultured in glutamine concentrations lower than 0.25 mM remained in a quiescent 
state, maybe cohesive to blocked mTOR activation. Reduced proliferation, CD25 expression and 
in particular on-blast formation indicated insufficient T cell activation at glutamine concentrations 
lower than blood levels. Regarding cytokine secretion glutamine deprivation led to different 
results. IFNγ secretion was reduced at concentrations lower than 0.1 mM, but strongly inhibited 
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under glutamine deprived conditions. In contrast the impact of glutamine reductions lower than 
0.1 mM on TNF production was similar as the impact of a glutamine deprivation.  
In order to elucidate for which pathway glutamine is essential, experiments were performed to 
rescue T cell activation by providing those metabolites glutamine is a precursor for.  
 
 
3.3.2. Biosynthetic  precursors  and  other  amino  acids  are  not  able  to  substitute  for   
glutamine  
T cells were highly sensitive to glutamine deprivation. To define the crucial pathway requiring 
glutamine, T cells were analyzed in the absence of glutamine but in the presence of various 
metabolites which glutamine is the precursor for. Glutamine can be degraded to glutamate and 
subsequently to α-ketoglutarate, an important intermediate of the TCA cycle, delivering 
substrates for oxidative phosphorylation. Moreover, glutamate, together with cysteine and 
glycine, is a component of GSH which acts as an antioxidant and prevents oxidative stress. 
Glutamine also serves as an amino group donor for nucleotide synthesis (Figure 2). Therefore, 
T cells were stimulated in the absence of glutamine but providing GSH (2 mM), glutamate 
(1 mM), cell permeable dimethyl-α-ketoglutarate (1 mM) as well as the purine and pyrimidine 
derivates hypoxanthine and thymidine (100 and 16 µM). The addition of hypoxanthine and 
thymidine has been shown to partially rescue glutamine deprivation in the murine system (Wang 
et al. 2011). Single supplementation of these metabolites was not sufficient to replace glutamine 
(data not shown). Even the addition of all metabolites simultaneously did not rescue T cell 
activation (subst., Figure 23). Low CD25 expression as well as blocked increase in cell size 
clearly indicated an inactive state of T cells stimulated in the presence of all above mentioned 
metabolites (Figure 23 A, B). Moreover, CD8 T cells were not capable to produce IFNγ (Figure 
23 C) or to proliferate (data not shown). These results indicate that glutamine is primarily 
essential for T cell activation. 
Glutamine can also fuel protein glycosylation contributing to the formation of UDP-N-acetyl-
glucosamine (Swamy et al. 2016). However, the addition of UDP-N-acetyl-glucosamine was not 
able to rescue T cell function under glutamine deprived conditions (data not shown). 
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Figure 23: Exogenous addition of metabolites directly linked to glutamine metabolism is not able 
to substitute for glutamine. CD8 T cells were stimulated with α-CD3/CD28 beads at a cell to bead ratio 
of 1:1 under indicated conditions: w/o gln - in absence of glutamine, subst – T cells were treated with GSH 
(2 mM), glutamate (1 mM), α-ketoglutarate (1 mM), hypoxanthine (100 µM) and thymidine (16 µM). (A) 
Expression of CD25 was determined after 48 hours by antibody staining and subsequent analysis by flow 
cytometry, shown is the median fluorescence intensity (MFI). Data are normalized to control. (B) Cell 
diameter of unstimulated (quies) and stimulated T cells was determined after 48 hours by the CASY 
system. (C) IFNγ levels were determined in culture supernatants after 48 hours by ELISA. (A, B, C) Data 
are shown as median and (A, C) normalized to control (n=3). Asterisks show significant differences 
between control and treatment. Significance was determined by one-way ANOVA and post-hoc Dunnett’s 
multiple comparisons test (**p<0.01, ***p<0.001).  
 
 
Other potential amino group donors are arginine and asparagine. Both amino acids 
administered at a concentration of 2 mM were not able to compensate for glutamine deprivation 
(data not shown). Additionally, according to a study with murine T cells (Carr et al. 2010), the 
amino acids aspartate and low levels of glutamate (2 mM) alone were tested, which were also 
not able to replace glutamine (data not shown). However, we have to admit, that the uptake of 
those metabolites might be limited and thus the supplementation is not efficient. To test this 
notion, higher concentrations of glutamate were tested. Indeed, first results indicate that a high 
concentration of glutamate (20 mM) is partially able to compensate for glutamine. Although the 
applied concentration of 20 mM glutamate seems not to be reachable under physiological 
conditions, this is the first time showing that T cell function is not completely blocked in the 
absence of glutamine. However, this warrants further investigations. 
Taken together, these results indicate that glutamine itself is essential for T cell activation and 
is hardly replaceable by its degradation products.  
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In parallel with this project, myeloid cells were cultured under glutamine deprived conditions 
(performed by R. Schöppe in line with a medical doctoral thesis). Monocytes and macrophages 
were unaffected by glutamine deprivation (data not shown), indicating that myeloid cells are able 
to substitute for glutamine. A possible explanation why macrophages are not affected by 
glutamine deprivation might be their high expression of glutamine synthetase (GLUL), an 
enzyme converting glutamate and ammonia to glutamine (Figure 2). In contrast to macrophages, 
neither bulk, nor naïve or EM CD8 T cells did express this enzyme, even after a longer period of 
stimulation (Figure 24). Furthermore, the expression of the enzyme could not be elevated by 
glutamine deprivation as observed in myeloid cells (data not shown). These data indicate that 
glutamine sensitivity of CD8 T cells might be attributed to the lack of GLUL and thereby the 
inability to synthesize glutamine. 
 
 
Figure 24: GLUL is expressed in myeloid cells, but not in CD8 T cells. T cells were stimulated with   
α-CD3/CD28 beads at a cell to bead ratio of 1:1. Immunoblot analyses of GLUL in quiescent and 
stimulated CD8 T cells after 48 hours are shown. Macrophages (MΦ) were used as positive control. Actin 
was used as loading control. One representative experiment is shown. 
 
 
Therefore, artificial overexpression of GLUL might be a strategy to support T cell function in a 
tumor microenvironment characterized by low glutamine concentrations. This approach is 
currently under investigation.  
 
 
3.4. Anti-metabolic targeting to restore immune cell effector functions 
of human CD8 T cells in the tumor microenvironment 
Tumor cells are addicted to glutamine, suggesting glutamine metabolism as a possible 
therapeutic target. Compounds targeting glutamine metabolism have shown promise in 
preclinical trials (Altman et al. 2016). However, glutamine is also an essential amino acid during 
T cell stimulation. The supplementation of glutamine-derived metabolites was not able to 
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substitute for glutamine. Due to these facts, the application of glutamine analogs or drugs 
blocking glutamine metabolism as currently investigated in the context of cancer therapy could 
lead to a strong block in the T cell mediated anti-tumor immune response. Therefore, in the next 
chapter the impact of such drugs was analyzed. 
Besides nutrient restriction within the tumor microenvironment immune cells have to deal with 
the accumulation of waste metabolites released by tumor cells. The highly glycolytic phenotype 
of tumor cells leads not only to reduced glucose levels, but also to an accumulation of lactic acid. 
Lactic acid strongly suppresses the function and viability of T cells (Fischer et al. 2007). In line, 
we demonstrated that reduction of tumor derived lactic acid by down-regulation of LDHA 
improved T and NK cell function and thereby immunosurveillance and tumor growth control 
(Brand et al. 2016). Since lactic acid is known as immunosuppressive metabolite, the reduction 
of the lactic acid secretion might restore tumor-directed immune response. Therefore, the 
application of anti-glycolytic drugs could be a promising strategy to strengthen the endogenous 
anti-tumor immune response, but also the response to immunotherapeutic approaches. As in 
this study in some donors an impact of glucose deprivation on cytokine secretion of CD8 T cells 
was observed, especially in the naïve subset, adverse effects of such drugs need to be carefully 
investigated.  
 
 
3.4.1. Pharmacologic blockade of glutamine metabolism in human CD8 T cells 
In light of our data on the importance of glutamine for T cell activation, the application of 
drugs inhibiting glutamine metabolism for the treatment of cancer might be a double edged 
sword. To investigate the impact of such inhibitors, CD8 T cells were treated with the two 
glutamine analogues acivicin and DON in comparison to two inhibitors specifically blocking 
glutaminase. As acivicin and DON are analogs of glutamine they inhibit all glutamine utilizing 
enzymes. Due to their structural similarity to glutamine those two substances enter the catalytic 
center of glutamine utilizing enzymes and inhibit by covalent binding, therefore those two drugs 
can be regarded as pan-inhibitors. For DON an IC50 value of 235 µM was proposed in fibroblasts 
(Crosby et al. 2015), but it was shown to have a strong inhibitory effect already at a 
concentration of 5 µM on glutaminase activity in rat CD4 T cells (Lee et al. 2015). For acivicin an 
inactivation of the glutamine dependent aldehyde dehydrogenase was shown at a concentration 
of 5.4 µM, which inhibited growth of human hepatocyte carcinoma cell line. In this study 0.2 and 
0.4 µM for acivicin and 5 and 10 µM for DON were supplemented. In comparison to the two pan-
inhibitors, CD8 T cells were treated with two inhibitors specifically targeting the transformation of 
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glutamine to glutamate. BPTES and CB-839 were used as specific glutaminase inhibitors (Gross 
et al. 2014). BPTES as well as CB-839 were shown to have an impact on cell growth and 
viability in various tumor cell lines in vitro and in vivo (Gross et al. 2014; Xiang et al. 2015; Le et 
al. 2012; Nagana Gowda et al. 2018). An IC50 value of 3.3 µM was shown for BPTES in P493 
human lymphoma B cells (Shukla et al. 2012) and between 25 and 35 µM for CD4 T cells. IC50 
values for glutaminase inhibition by CB-839 were shown to be lower than 50 nM (Gross et al. 
2014). To ensure an inhibitory effect of both substances, higher concentrations (BPTES: 25 and 
50 µM, CB-839: 0.1 and 1.0 µM) were applied. 
Similar to the results obtained for glutamine deprivation, DON and acivicin reduced the 
expression of activation related surface markers as well as blocked on-blast formation, indicating 
that T cell activation is inhibited (Table 7).  
 
Table 7: Impact of pan-inhibition of glutamine metabolism in comparison to glutaminase inhibition 
on T cell function.  
 
ctrl  acivicin [µM]  DON [µM]  CB-839 [µM]  BPTES [µM] 
  
 0.2 0.4  5 10  0.1 1.0  25 50 
diameter 
[µm] 
11.3 
±0.2 
 9.1 
 
9.2 
 
 
9.8** 
±0.1 
9.3*** 
±0.0 
 
11.3 
±0.5 
11.2 
±0.5 
 
10.1* 
±0.2 
10.2* 
±0.1 
CD25 
[MFI] 
299 
±14 
 58.9 
 
40.2 
 
 
325 
±72 
141 
±48 
 
338 
±81 
323 
±77 
 
294 
±114 
277 
±125 
IFNγ 
[pg/ml] 
1945 
±262 
 607 
 
486 
 
 
866* 
±231 
593** 
  ±108 
 
1827 
±153 
2333 
±174 
 
1127 
±283 
1166 
±317 
TNF 
[pg/ml] 
2354 
±407 
 637 
 
659 
 
 
1252 
±189 
1066 
±266 
 
2130 
±502 
2124 
±367 
 
2576 
±100 
3464 
±466 
viability 
72h [%] 
76 
±4 
 93 
 
93 
 
 
62 
±10 
62 
±12 
 
79 
±3 
80 
±5 
 
66 
±5 
65 
±5 
viability 
6d [%] 
71 
±6 
 74 
 
75 
 
 
43 
±14 
39 
±15 
 
76 
±7 
79 
±6 
 
68 
±6 
66 
±10 
cell no    
[x 10
6
/ml] 
4.0 
±0 
 0.4 
 
0.4 
 
 
0.6*** 
±0.1 
0.4*** 
±0.1 
 
4.1 
±0.5 
4.1 
±0.5 
 
2.9 
±0.8 
3.3 
±0.5 
CD8 T cells were stimulated with α-CD3/CD28 beads at a cell to bead ratio of 1:1. Inhibitors were applied at the 
following concentrations: 0.1 or 1.0 µM CB-839, 25 or 50 µM BPTES, 10 or 25 µM DON and 0.2 or 0.4 µM acivicin. 
The surface expression of the activation related surface marker CD25 was determined after 48 hours by antibody 
staining and subsequent analysis by flow cytometry, shown is the median fluorescence intensity (MFI). Cell diameter 
after 48 hours and proliferation after 72 hours and 6 days were determined by the CASY system. Cytokine levels were 
determined in culture supernatants after 48 hours by ELISA. Data are shown as mean±SEM. Asterisks show 
significant differences between control and treatment (n=2 for acivicin, n=3 for DON, CB-839 and BPTES). 
Significance was determined by one-way ANOVA and post-hoc Dunnett’s multiple comparisons test (*p<0.05, 
**p<0.01, ***p<0.001). 
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Moreover, both inhibitors induced proliferation arrest, reduced or even blocked cellular 
respiration (Figure 25 A, B) and decreased cytokine secretion by more than 50 %. Viability was 
not affected within the first 72 hours. In contrast to acivicin, DON induced cell death after 
72 hours by trend and an even stronger effect was observed after 6 days. Taken together, the 
application of the two pan-inhibitors resembled the phenotype observed under glutamine 
deprived conditions. As glutamine deprivation did not affect viability of T cells, these results point 
towards an unspecific effect of DON.  
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Figure 25: Impact of pan-inhibition on glutamine metabolism in comparison to specific 
glutaminase inhibition on respiration. CD8 T cells were stimulated with α-CD3/CD28 beads at a cell to 
bead ratio of 1:1. Cellular respiration was measured with the PreSens technology in freshly stimulated 
cells at a concentration of 0.8 x 10
6
 cells per ml under cell culture conditions (n=2). Inhibitors were applied 
at the following concentrations: (A) 5 and 10 µM DON or (B) 0.2 and 0.4 µM acivicin and (C) 0.1 and 1.0 
µM CB-839 or (D) 25 and 50 µM BPTES. 
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In contrast to the pan-inhibition, the application of the glutaminase inhibitors had no impact 
on CD8 T cell function (Table 7). Neither BPTES nor CB-839 reduced the expression of the 
activation related surface marker CD25 or affected cytokine production in CD8 T cells (Table 7).  
Moreover, the application of 50 µM BPTES led to a slightly increased TNF secretion. 
Viability, proliferation and activation state of CD8 T cells were not affected by glutaminase 
inhibition. Contrary to expectations, not even cellular respiration was reduced (Figure 25 C, D).  
Taken together, the application of glutamine analogs has a strong negative impact on T cell 
function. However, glutaminase inhibitors did not affect T cells. Either glutaminase is not 
essential for a T cell response or the inhibitors do not enter the cells. As high concentrations of 
glutamate partially rescued T cell activation, an involvement of glutaminase in T cell activation 
cannot be excluded. Taken together, BPTES and CB-839 inhibitors might display two promising 
drugs in the context of cancer therapy. 
 
 
3.4.2. Pharmacological blockade of glucose metabolism by MCT inhibitors - Impact of  
NSAIDs on the function of human CD8 T cell subsets in the early phase of activation  
Previously, the non-steroidal anti-inflammatory drug (NSAID) diclofenac was shown to be 
capable to block lactate secretion in a variety of tumor cell lines and is capable to reduce in vivo 
tumor growth of B16 mouse melanoma cells (Gottfried et al. 2013, Renner et al. under revision). 
Further analysis revealed that diclofenac and lumiracoxib, which shows a very high structural 
similarity, directly block MCT1 and MCT4 (Renner et al. under revision). Diclofenac has Ki of 
1.45 µM for MCT1 and 0.14 µM for MCT4 (Renner et al. under revision). In line, lumiracoxib 
displaying a Ki value of 4.15 µM for MCT1 and 1.12 µM for MCT4 blocks lactate secretion in 
different melanoma cell lines (Brummer et al. 2019). Therefore, both NSAIDs might be promising 
drugs in the context of ACT.  
In order to elucidate whether there are subset specific effects, the impact of diclofenac and 
lumiracoxib was analyzed in CD8 T cell subsets. These analyses allowed the determination of 
the most promising subset for immunotherapy in combination with anti-metabolic drugs. 
While quiescent human CD8 T cells express very low levels of MCT1 and MCT4, both 
transporters are upregulated upon stimulation (Renner et al. under revision). As the first 
stimulation represents a primary immune response, the following experiments were performed to 
identify the impact of MCT inhibition on the efficacy of primary activation. Within the first 
48 hours of stimulation, diclofenac as well as lumiracoxib inhibited glycolysis. Both substances 
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reduced glucose consumption and significantly lactic acid secretion in naïve and EM CD8 T cells 
(Figure 26).  
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Figure 26: Impact of NSAIDs on glycolytic activity of CD8 T cell subsets. CD8 T cells were stimulated 
with α-CD3/CD28 beads at a cell to bead ratio of 1:1. Each symbol represents an individual donor. 
Horizontal lines indicate the median. Inhibitors were applied at the following concentrations: 0.2 mM 
lumiracoxib (lum) and 0.2 mM diclofenac (dic). (A) Glucose and (B) lactic acid levels were measured 
enzymatically in culture supernatants after 48 hours of stimulation (n≥2). Dotted line in (B) indicates 
lactate level in culture medium. Asterisks show significant differences between control and treatment. 
Significance was determined by one-way ANOVA and post-hoc Dunnett’s multiple comparisons test 
(*p<0.05, **p<0.01, ***p<0.001). 
 
 
In contrast to glycolytic activity, on-blast formation was not affected in naïve or EM T cells 
(Figure 27 A). Long-term diclofenac treatment led to a decreased proliferation in naïve T cells, 
and induced a proliferation arrest in EM T cells (Figure 27 B). Surprisingly, although lumiracoxib 
reduced lactate secretion in naïve T cells, the proliferation was not affected. In the EM subset, 
the negative impact of lumiracoxib on proliferation was distinct, but not significant. These results 
might be explained with the lower Ki values of diclofenac for both MCTs, also reflected in a 
stronger impact on lactate secretion (Figure 26 B). Regarding cytokine production, NSAID 
treatment had no significant impact on IFNγ and TNF secretion. Nevertheless, naïve T cells 
produced less IFNγ in the presence of lumiracoxib by trend. 
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Figure 27: Impact of NSAIDs on T cell function in CD8 T cell subsets. CD8 T cells were stimulated 
with α-CD3/CD28 beads at a cell to bead ratio of 1:1. Inhibitors were applied at the following 
concentrations: 0.2 mM diclofenac (dic) and 0.2 mM lumiracoxib (lum). (A) Cell diameter were determined 
after 48 hours and (B) proliferation after 6 days by the CASY system (n=2 for diclofenac, n≥4 for 
lumiracoxib). (C) IFNγ and (D) TNF levels were determined in culture supernatants after 48 hours by 
ELISA. Each symbol represents an individual donor. Horizontal lines indicate the median. Significance 
was determined by one-way ANOVA and post-hoc Dunnett’s multiple comparisons test.  
 
 
Taken together, the NSAIDs diclofenac and lumiracoxib exerted a significant impact on 
glucose metabolism in both subsets. However, cytokine secretion was preserved and CD8 
T cells still proliferated at least to some extent in the course of primary stimulation.  
Both NSAIDs did not completely block lactate secretion most likely due to a remaining activity 
of MCT1 and MCT4. Thus, the impact of a complete blockade of either transporter was 
investigated in the next set of experiments.  
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3.5. Impact of MCT4 deficiency on T cell function  
Quiescent human T cells show very low levels of MCT1 and MCT4, however, expression of 
both MCTs is strongly increased after stimulation (Renner et al. under revision). The role of 
MCT1 has been investigated in the murine system applying a specific MCT1/2 inhibitor. Blocking 
lactate transport by this inhibitor reduced lactate secretion and in line proliferation of human 
T cells (Murray et al. 2005). Data of our group show a minor and transient effect of a MCT1/2 
inhibition in human T cells due to an increased MCT4 expression in the course of activation. The 
impact of a MCT4 blockade alone or even a complete blockade of MCT1 and MCT4 was not 
elucidated so far. Unfortunately, there is no MCT4 inhibitor commercially available. Nevertheless 
a MCT4 knock out mouse model is available (kindly provided by Prof. John L. Cleveland) and 
combining the MCT1/2 inhibitor to T cells from these knockout mice mimics a complete blockade 
of both transporters. As there is little known about the role of MCT4 for immune cell development 
and function, basic characteristics of these mice with special focus on T cells were investigated.  
 
 
 
 
Figure 28: Immunoblot analysis of MCT4 expression in murine CD4 and CD8 T cells. T cells were 
stimulated with plate-bound α-CD3 (5 µg/ml) and soluble α-CD28 (1 µg/ml). Expression level of MCT4 
from (A) wildtyp (WT) and (B) MCT4 knockout mice (MCT4
-/-
) in quiescent (quies) and stimulated CD4 and 
CD8 T cells after 48 and 72 hours is shown. Actin was used as loading control. One representative 
experiment is shown.  
 
 
In a first step, the MCT4 expression in WT and MCT4 deficient T cells was examined to 
confirm the genetic knock out. Protein levels were quantified in quiescent and activated murine 
T cells (Figure 28). In quiescent WT CD4 as well as in CD8 T cells MCT4 was not expressed but 
expression increased upon stimulation (Figure 28 A). As expected, MCT4 expression was not 
detectable in T cells isolated from spleens from MCT4-/- mice, even after 72 hours of stimulation 
(Figure 28 B). 
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3.5.1. Immune cell composition in spleens from wildtyp and MCT4 deficient mice 
The MCT4-/- mice developed phenotypically normal. To analyze the immune cell composition 
splenocytes were isolated from healthy mice and were analyzed by flow cytometry (see Figure 
29 A, C for gating strategies). The percentage of B cells (CD19+), myeloid cells (CD11b+), NK 
(CD3ɛ-, NK1.1+) and NKT (CD3ɛ+, NK1.1+) cells relative to levels of total living cells was 
determined. The level of B cells was significantly lowered and the percentage of myeloid cells by 
trend in MCT4-/- mice. While numbers of B cells and myeloid cells were reduced, the NK and 
NKT cell compartment showed a higher frequency in spleens of MCT4-/- mice (Figure 29 B). 
Moreover, a greater proportion of T cells (CD3ɛ+) was detected in MCT4-/- mice among entire 
living cell, reflected in increased percentage of CD4 (CD3ɛ+, CD4+) and CD8 (CD3ɛ+, CD8α+) 
T cells. However, the CD4 to CD8 ratio was not altered by MCT4 deficiency (Figure 29 E). 
Taken together, the immune cell composition in splenocytes of MCT4-/- mice was altered in 
some aspects; however, the observed differences were not strongly pronounced.  
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Figure 29: MCT4 deficiency does moderately alter immune cell composition in spleens. (A) Gating 
strategy for flow cytometry analysis of living singular cells (FSC-W
low
), B cells (CD3ɛ
-
, CD19
+
), myeloid 
cells (CD3ɛ
-
, CD11b
+
), NK cells (CD3ɛ
-
, NK1.1
+
), and NKT cells (CD3ɛ
+
, NK1.1
+
) in spleens from WT and 
MCT4
-/-
 mice. One representative WT spleen is shown. (B) Percentage of immune cell populations within 
living cells: B cells, myeloid cells, NK and NKT cells isolated from spleens from WT (light grey) and  
MCT4
-/-
 (dark grey) mice. Each symbol represents cells from an individual mouse; horizontal lines indicate 
the median. (C) Gating strategy for flow cytometry analysis of living singular cells (FSC-W
low
): T cells 
(CD3ɛ
+
), CD4 T cells (CD3ɛ
+
, CD4
+
) and CD8 T cells (CD3ɛ
+
, CD8α
+
) in spleens from WT and MCT4
-/-
 
mice. One representative WT spleen is shown. (D) Percentage of immune cell populations within living 
cells: T cells, CD4 and CD8 T cells. Each symbol represents an individual mouse; horizontal lines indicate 
the median. (E) CD4/CD8 ratio in spleens from WT and MCT4
-/-
 mice. Asterisks show significant 
differences. Significance was determined by Mann-Whitney test (*p<0.05, **p<0.01). 
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3.5.2. Metabolic and functional characterization of murine MCT4-/- CD4 and CD8 T cells 
Next, CD4 and CD8 T cells were isolated from spleens of healthy WT and MCT4-/- mice and 
stimulated with α-CD3 and α-CD28 antibodies. Glucose metabolism, respiration as well as T cell 
function were investigated. 
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Figure 30: MCT4 deficiency has no impact on glycolytic activity in CD4 and CD8 T cells. T cells 
were stimulated with plate-bound α-CD3 (5 µg/ml) and soluble α-CD28 (1 µg/ml). (A) CD4 and (B) CD8 
T cells were stimulated for 2 hours and incubated with 2-NBDG, followed by subsequent analysis by flow 
cytometry (n=3, mean+SEM). (C, D) Glucose and (E, F) lactate concentration were measured 
enzymatically in culture supernatants of (C, E) CD4 and (D, F) CD8 T cells after 48 hours of stimulation 
(n≥8, mean+SEM). Significance was determined by Mann-Whitney test. 
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Early glycolytic activity was investigated by measuring the incorporation of the fluorescent 
glucose analogue 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) by 
flow cytometry. Neither in CD4 nor in CD8 T cells, MCT4 deficiency showed an effect on glucose 
uptake immediately after stimulation (Figure 30 A, B). To quantify the long-term effect of MCT4 
deficiency on glucose metabolism, glucose and lactate concentrations were measured in the 
supernatants after 48 hours of stimulation. Interestingly, although the MCT4 level is strongly 
increased in WT cells after 48 hours (Figure 28 A), there was no difference in glucose uptake 
(Figure 30 C, D) or lactate secretion (Figure 30 E, F) observed in WT and MCT4-/- T cells.  
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Figure 31: MCT4 deficiency does not affect mitochondrial mass, but has an impact on respiration. 
Mitochondrial mass of (A) CD4 and (B) CD8 T cells was determined by MitoTracker Green staining and 
subsequent analysis by flow cytometry (n=6, mean+SEM). Oxygen consumption rate was measured in  
(C) CD4 and (D) CD8 T cells stimulated with plate-bound α-CD3 (5 µg/ml) and soluble α-CD28 (1 µg/ml) 
for 2 hours, using the Seahorse Technology, in the presence of 2 % serum (n=3, mean+SEM). 
Significance was determined by Mann-Whitney test. 
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Since MCT4 deficiency could impact other pathways than glycolysis, we examined 
mitochondrial mass and activity. Therefore, mitochondrial mass was analyzed by MitoTracker 
Green staining and respiration using the Seahorse technology in the presence of 2 % serum 
(Figure 31). Although WT and MCT4-/- T cells showed a similar mitochondrial content (Figure 31 
A, B), MCT4-/- T cells were characterized by a tentatively higher oxygen consumption rate (OCR) 
than WT cells (Figure 31 C, D). 
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Figure 32: MCT4 deficiency has no impact on cytokine production in CD4 and CD8 T cells. T cells 
were stimulated with plate-bound α-CD3 (5 µg/ml) and soluble α-CD28 (1 µg/ml). (A, B) IFNγ (n≥11) and 
(C, D) TNF levels (n≥8) were determined in culture supernatants from (A, C) CD4 and (B, D) CD8 T cells 
after 24 and 48 hours by ELISA; horizontal lines indicate the median. Asterisks show significant 
differences. Significance was determined by Mann-Whitney test (***p<0.001).  
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To investigate whether MCT4 deficiency has a direct impact on effector functions, IFNγ and 
TNF secretion was measured in supernatants after 24 and 48 hours by ELISA (Figure 32). CD4 
as well as CD8 T cells produced already high levels of IFNγ and TNF in the first 24 hours, but 
concentration in the supernatants was still increased after 48 hours. MCT4 deficiency did not 
impair cytokine secretion, rather accelerated IFNγ and TNF production at least in CD4 T cells. 
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Figure 33: MCT4 deficiency only moderately affects T cell function in CD4 and CD8 T cells, even in 
combination with MCT1/2 inhibition. T cells were stimulated with plate-bound α-CD3 (5 µg/ml) and 
soluble α-CD28 (1 µg/ml). SR13800 was applied at a concentration of 1 µM. Lactate levels were 
measured enzymatically in 48 hour culture supernatants of (A) CD4 and (B) CD8 T cells (n=6, 
mean+SEM). IFNγ levels were determined after 48 hours in supernatants of stimulated (C) CD4 and (D) 
CD8 T cells by ELISA (n≥5, median). Asterisks show significant differences between control and 
treatment. Significance was determined by one-way ANOVA and post-hoc Dunnett’s multiple comparisons 
test (*p<0.05, **p<0.01, ***p<0.001). 
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In comparison to WT T cells, MCT4-/- T cells showed a similar glycolytic activity and 
preserved effector functions when stimulated in vitro. These findings suggest that MCT4 is not 
essential at least during primary stimulation to maintain effector functions and metabolic steady 
state conditions in murine T cells. However, whether there is a negative effect in vivo needs to 
be investigated. 
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Figure 34: Diclofenac shows a comparable effect on lactate production and IFNγ secretion as a 
combined blockade of MCT1, MCT2 and MCT4 in CD4 and CD8 T cells. T cells were stimulated with 
plate-bound α-CD3 (5 µg/ml) and soluble α-CD28 (1 µg/ml). Inhibitors were applied at the following 
concentrations: 1 µM SR13800 (SR), 0.1 mM and 0.2 mM diclofenac (diclo). Lactate levels were 
measured enzymatically in 48 hour culture supernatants of (A) CD4 and (B) CD8 T cells. IFNγ levels were 
determined in supernatants after 48 hours of stimulated (C) CD4 and (D) CD8 T cells by ELISA (n=2, 
median).  
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As tumor cells are characterized by the expression of several MCT transporters, anti-
metabolic therapy could be optimized using pan-MCT inhibitors, blocking MCT1, MCT2 and 
MCT4. To mimic a pan-MCT inhibition, MCT4-/- T cells were analyzed in the presence of the 
MCT1/2 inhibitor SR13800, kindly provided by Prof. John L. Cleveland. WT as well as MCT4-/- 
T cells showed a strong reduction in lactate release in the presence of 1.0 µM SR13800 after 
48 hours of stimulation (Figure 33 A, B).  
In the presence of the MCT1/2 inhibitor SR13800 lactate secretion was reduced to about 
40 % of control cells of WT CD4 and CD8 T cells. In MCT4-/- CD4 and CD8 T cells, SR13800 
application led to a reduction in lactate secretion to about 15 % of control cells. Although both 
transporters were blocked and lactate release was strongly diminished, MCT4-/- T cells still 
produced high amounts of IFNγ, although a decrease was detected (Figure 33 C, D). 
Finally, the impact of diclofenac targeting MCT1 and MCT4 was analyzed in comparison to 
the treatment with SR13800 targeting MCT1 and MCT2 in MCT4-/- T cells (Figure 34). High 
concentrations of diclofenac reduced lactate secretion comparably in WT and MCT4-/- cells. 
However the impact was slightly lower compared to a complete MCT1 and MCT4 blockade as 
achieved by the application of the MCT1/2 inhibitor to MCT4-/- T cells. IFNγ secretion was 
comparably affected by 0.2 mM diclofenac in comparison to a pan-MCT blockade. These data 
show on the one hand that a pan-MCT inhibition still allows the secretion of important effector 
cytokines such as IFNγ and on the other hand that diclofenac exerts similar effects as a specific 
MCT inhibition. 
 
 
3.6. Sorting through CD8 subsets: Which T cell subset is appropriate 
for adoptive immunotherapy in combination with anti-metabolic 
therapy? 
In freshly isolated and activated T cells an inhibition of MCTs showed only minor effects, 
probably due to their low expression. For ACT therapy, an ex vivo expansion of modified antigen 
specific T cells is required, which might also alter the sensitivity of T cells to metabolic inhibition.  
 
 
3.6.1. Optimizing the expansion protocol of CD8 T cell subsets for adoptive T cell transfer 
In a first step, different stimulation/ expansion protocols were evaluated. One objective was to 
preserve the expression of the homing receptors CCR7 and CD62L in naïve and CM T cells. 
T cell subpopulations were stimulated either with α-CD3/CD28 beads or in a mixed lymphocyte 
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reaction (MLR) with allogeneic mDCs in the presence of IL-2 and expanded for two weeks. 
A MLR represents a more physiological stimulus, compared to activation with α-CD3/CD28 
beads. Different interleukin cocktails combining IL-7, IL-15 and IL-21 were tested and viability, 
overall yield in cell number and capacity to produce important effector cytokines as IFNγ, 
granzyme B or perforin and the expression of the two homing receptors were examined after two 
weeks of expansion.  
The yield in cell number is an important parameter for choosing the stimulation protocol for an 
ex vivo expansion. The yield after 13 days of expansion was calculated (Figure 35 A, B, C). 
Surprisingly, in all three subsets the yield was four times higher by stimulation with mDCs 
compared to stimulation with α-CD3/CD28 beads. The supplementation of IL-7 and IL-15 
additionally to IL-2 had no further promoting effect on proliferation of CD8 T cell subsets. Viability 
was high and comparable between stimulation with α-CD3/CD28 beads or mDCs and additional 
supplementation of IL-7 and IL-15 had only a slightly positive effect (Figure 35 D, E). The 
addition of IL-21 to the interleukin cocktail of IL-2, IL-7 and IL-15 did not improve the outcome 
(data not shown).  
CCR7 expression was stable when stimulated with α-CD3/CD28 beads in naïve T cells, but 
decreased upon cultivation with mDCs (Figure 36). CD62L expression was comparably reduced 
under both stimulation protocols (Figure 37). The addition of IL-7 or IL-15 did not show a clear 
positive effect on the preservation of CCR7 or CD62L in the long-term. Particularly, CM T cells 
lost their CCR7 receptor independent of the stimulation protocol (Figure 36).  
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Figure 35: Impact of various stimulation methods on proliferation and viability of CD8 T cell 
subsets. CD8 T cells were stimulated either with α-CD3/CD28 beads at a cell to bead ratio of 1:1 or in a 
MLR with mDCs in the presence of IL-2 alone (25 IU/ml) or the interleukin cocktail IL-2 (25 IU/ml), IL-7 
(5 ng/ml) and IL-15 (5 ng/ml) for 13 days. Proliferation of (A) naïve, (B) CM and (C) EM CD8 T cells was 
determined with the CASY system (n≥3, with the exception of CM and EM stimulated in a MLR in the 
presence of single IL-2: n=2, median). Asterisks show significant differences between indicated 
conditions. Significance was determined by one-way ANOVA and post-hoc Dunnett’s multiple 
comparisons test (**p<0.01, ***p<0.001). (D, E) Viability was measured by Annexin V/ 7-AAD antibody 
staining and subsequent analysis by flow cytometry. Data from one representative donor are shown.  
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Figure 36: Impact of different stimulation methods on the expression of CCR7 in CD8 T cell 
subsets. CD8 T cells were stimulated either with α-CD3/CD28 beads at a cell to bead ratio of 1:1 or in a 
MLR with mDCs in the presence of single IL-2 (25 IU/ml) or the interleukin cocktail IL-2 (25 IU/ml), IL-7 
(5 ng/ml) and IL-15 (5 ng/ml). Expression of CCR7 in (A, B, C) naïve and (A, B, D) CM CD8 T cells was 
measured in quiescent (quies) state and after 13 days of expansion by antibody staining and subsequent 
analysis by flow cytometry (n≥3, with the exception of CM stimulated in a MLR in the presence of single 
IL-2: n=2, median). (A, B) One representative donor is shown. Asterisks show significant differences 
between indicated conditions. Significance was determined by one-way ANOVA and post-hoc Dunnett’s 
multiple comparisons test (*p<0.05, ***p<0.001). 
 
 
Regarding CD62L expression, a strong reduction was observed (Figure 37), but nearly one-
third was preserved with both stimulation methods. Comparable to the results in naïve cells, the 
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addition of the different interleukins did not preserve the CCR7 or CD62L expression profile in 
CM cells during expansion. 
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Figure 37: Impact of different stimulation methods on the expression of CD62L in CD8 T cell 
subsets. CD8 T cells were stimulated either with α-CD3/CD28 beads at a cell to bead ratio of 1:1 or in a 
MLR with mDCs in the presence of single IL-2 (25 IU/ml) or the interleukin cocktail IL-2 (25 IU/ml), IL-7 
(5 ng/ml) and IL-15 (5 ng/ml). Expression of CD62L in (A, B, C) naïve and (A, B, D) CM CD8 T cells was 
measured in quiescent (quies) state and after 13 days of expansion by antibody staining and subsequent 
analysis by flow cytometry (n≥3, with the exception of CM stimulated in a MLR in the presence of single 
IL-2: n=2, median). (A, B) One representative donor is shown. Asterisks show significant differences 
between indicated conditions. Significance was determined by one-way ANOVA and post-hoc Dunnett’s 
multiple comparisons test (*p<0.05, ***p<0.001). 
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As we observed a slightly better cell viability in the presence of the interleukin cocktail IL-2, 
IL-7 and IL-15 and as in the literature this combination is recommended (Geginat et al. 2003; 
Cha et al. 2010; Gargett and Brown 2015), the interleukin cocktail IL-2 in combination with IL-7 
and IL-15 was used in further experiments. Next the capability to secret IFNγ and to express 
perforin and granzyme B was analyzed after expansion with α-CD3/CD28 beads or mDCs. 
T cells were stimulated with PMA/ ionomycin in order to activate T cells to a maximum      
(Figure 38).  
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Figure 38: Impact of various stimulation methods on effector functions of CD8 T cell subsets. CD8 
T cells were expanded either with α-CD3/CD28 beads at a cell to bead ratio of 1:1 or in a MLR with mDCs 
in the presence of the interleukin cocktail IL-2 (25 IU/ml), IL-7 (5 ng/ml) and IL-15 (5 ng/ml). IFNγ secretion 
of expanded (A) naïve, (B) CM and (C) EM CD8 T cells was determined in culture supernatants after 4 
hours stimulation with PMA/ionomycin by ELISA. Asterisks show significant differences between indicated 
conditions (n=3). Horizontal lines indicate the median. Significance was determined by Mann-Whitney test. 
(D) Production of perforin and granzyme B was measured by intracellular antibody staining and 
subsequent analysis by flow cytometry. Data from one representative donor out of two are shown. 
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Naïve T cells expanded with mDCs were more potent in producing effector molecules like 
IFNγ or perforin and granzyme B. CM and EM T cells secreted high amounts of IFNγ as well as 
perforin and granzyme B, independently which stimulation method was used. 
The stimulation with mDCs seemed to be the most promising strategy regarding yield and 
capability to produce important effector molecules, in particular for naïve T cells. However, 
stimulation with α-CD3/CD28 beads seemed to be favorable regarding CCR7 expression, 
particularly in the naïve subset. Due to results obtained in this thesis, expanding T cells in a MLR 
in combination with the interleukin cocktail IL-2, IL-7 and IL-15 seemed to be favorable and was 
used in further experiments.  
 
 
3.6.2. Impact of metabolic targeting on T cell function in expanded human CD8 T cell 
subsets  
The impact of metabolic inhibition on T cell function was analyzed in CD8 T cell subsets 
(Table 8). After expansion with mDCs, T cells were restimulated with anti-CD3/CD28 to foster 
the production of effector cytokines. Besides both NSAIDs diclofenac (0.2 mM) and lumiracoxib 
(0.2 mM), T cell function was examined in the presence of metformin (1.0 and 10.0 mM), the 
glutaminase inhibitor CB-839 (0.1 and 1.0 µM) and the glutamine analogue DON (5.0 and 
10.0 µM). Metformin is an anti-diabetic drug, inhibiting complex I of the respiratory chain and 
was shown to reduce tumor growth (Owen et al. 2000; Dowling et al. 2007).  
Comparable to the results obtained in primary activated CD8 T cells subsets, diclofenac and 
lumiracoxib had only a slight impact on T cell function in expanded T cell subsets (Table 8). 
Neither the activation state analyzed by CD25 expression and on-blast formation nor cytokine 
secretion were affected. However, in long-term both NSAIDs reduced proliferation after 6 days. 
While proliferation in naïve T cells was not and in CM T cells was only slightly affected, even a 
proliferation arrest in the EM subset was detected. 
For metformin similar results as for NSAIDs were achieved. Activation status as well as 
cytokine production were not reduced. However, long-term treatment with metformin reduced 
proliferation after 6 days in all three subsets significantly applying a rather high concentration of 
metformin. The impact was not as strong applying 1 mM metformin, which rather reflects a 
concentration achievable under physiologic conditions. 
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Table 8: Impact of metabolic inhibition on T cell function in CD8 T cell subsets after expansion.  
  
ctrl  
dic 
[mM] 
 
lum  
[mM] 
 met [mM]  DON [µM]  CB-839 [µM] 
   
 0.2  0.2  1.0 10.0  5.0 10.0  0.1 1.0 
cell 
number  
[x 10
6
/ml] 
NV 
1.2  0.8  1.0  1.1 0.6*  1.1 0.8  1.6 1.5 
±0.2  ±0.1  ±0.0  ±0.0 ±0.0  ±0.1 ±0.2  ±0.2 ±0.2 
CM 
2.7  1.0  1.9  1.4 0.7*  1.7 1.0  2.7 2.6 
±0.7  ±0.2  ±0.7  ±0.3 ±0.0  ±0.5 ±0.5  ±0.6 ±0.5 
EM 1.8  0.4***  0.6***  0.9** 0.4***  1.2 0.7**  1.8 1.7 
±0.2  ±0.0  ±0.0  ±0.1 ±0.0  ±0.3 ±0.3  ±0.2 ±0.1 
cell 
diameter 
[µm] 
NV 
9.5  9.9  9.7  9.6 9.3  9.4 9.2  9.6 8.5 
±0.2  ±0.1  ±0.1  ±0.0 ±0.1  ±0.0 ±0.1  ±0.0 ±1.0 
CM 
10.1  10.0  10.0  9.8 9.6  9.8 9.5*  9.9 9.9 
±0.1  ±0.1  ±0.1  ±0.1 ±0.1  ±0.0 ±0.1  ±0.2 ±0.1 
EM 9.0  9.0  9.0  9.0 9.0  8.9 8.9  8.8 8.9 
±0.0  ±0.1  ±0.1  ±0.1 ±0.1  ±0.1 ±0.0  ±0.0 ±0.1 
CD25 
[MFI] 
NV 
561  678  788  583 428  571 585  587 497 
±73  ±170  ±38  ±100 ±7  ±58 ±93  ±18 ±50 
CM 
669  763  777  650 625  794 609  673 665 
±27  ±15  ±24  ±20 ±66  ±27 ±58  ±25 ±66 
EM 653  614  688  579 393  622 499  672 585 
±54  ±114  ±73  ±81 ±166  ±108 ±53  ±96 ±55 
IFNγ 
[pg/ml] 
NV 
3640  4342  4264  4359 6465  4737 3653  4695 3984 
±349  ±975  ±462  ±316 ±368  ±1112 ±527  ±859 ±631 
CM 
6471  7737  6454  7091 7795  6215 6018  5642 5546 
±822  ±765  ±453  ±910 ±1037  ±1623 ±1348  ±1468 ±1112 
EM 6736  7659  6247  5750 7274  5485 5570  6115 5128 
±1000  ±436  ±751  ±443 ±263  ±332 ±311  ±76 ±291 
 
TNF 
[pg/ml] 
 
NV 
2671  2149  2741  2408 2653  3089 2224  2641 2472 
±479  ±146  ±675  ±554 ±629  ±1156 ±636  ±659 ±363 
CM 
5548  6326  5120  5647 5239  4215 4903  5151 4865 
±2096  ±2761  ±1598  ±1838 ±1738  ±1397 ±1442  ±1611 ±1114 
EM 5325  5395  5527  4569 4508  3472 3755  4403 3931 
±2072  ±2120  ±1773  ±1524 ±1571  ±266 ±373  ±487 ±446 
CD8 T cells were expanded with mDCs for 13 days and afterwards stimulated with α-CD3/CD28 beads at a cell to 
bead ratio of 1:1. Inhibitors were applied at the following concentrations: 0.2 mM diclofenac (dic), 0.2 mM lumiracoxib 
(lum), 1.0 and 10.0 mM metformin (met), 5.0 and 10.0 µM DON as well as 0.1 and 1.0 µM CB-839. After 48 hours cell 
diameter and after 6 days cell number were determined by the CASY system. Expression of the activation related 
surface marker CD25 was measured after 48 hours by antibody staining and subsequent analysis by flow cytometry. 
IFNγ and TNF levels were determined in culture supernatants after 48 hours by ELISA. Data are shown as 
mean±SEM (n=3). Asterisks show significant differences between control and treatment. Significance was 
determined by one-way ANOVA and post-hoc Dunnett’s multiple comparisons test (*p<0.05, **p<0.01, ***p<0.001). 
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Targeting glutamine metabolism, neither DON nor CB-839 had a strong impact on T cell 
function. Preserved effector functions in the presence of DON is in sharp contrast to results 
obtained on primary stimulated T cells. There are two possible explanations, either glutamine 
metabolism is not required in expanded T cells or they become resistant to the inhibitor. To test 
whether glutamine metabolism is essential also for expanded T cells, CD8 T cells subsets were 
deprived for glutamine after expansion and restimulated. Glutamine deprivation still strongly 
reduced IFNγ secretion, in particular in naïve and CM T cells (naïve: 3041 in control T cells to 
710 pg/ml under glutamine deprivation, CM: 8086 to 2322 pg/ml, EM: 6708 to 4399 pg/ml), 
comparable to freshly isolated T cells. Since this experiment was performed only once, these 
results warrant further investigation. Nevertheless, 10 µM DON reduced on-blast formation in 
CM after 48 hours and proliferation of EM T cells after six days.  
Taken together, anti-metabolic drugs did not impair T cell effector functions in all three 
subsets after expansion; however, an effect on proliferation was detected. Based on our 
findings, substances targeting tumor metabolism should be feasible in combination with ACT in 
all three subsets. 
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4. Discussion  
4.1. Nutrient competition in the tumor microenvironment - does 
nutrient restriction blunt T cell function? 
Accelerated metabolic activity is not only a well-characterized property of tumor cells but also 
observed in several types of immune cells upon stimulation, including T cells. Both tumor cells 
and T cells have a high demand for nutrients as glucose, amino acids and fatty acids (Vander 
Heiden et al. 2009; Lunt and Vander Heiden 2011; Bantug et al. 2018). Thus similar metabolic 
pathways are activated in tumor cells and T cells. This overlap in the metabolic profile results in 
nutrient competition in the tumor microenvironment (Uyttenhove et al. 2003; Mellor and Munn 
2004; Rodriguez et al. 2009; Srivastava et al. 2010; Munn and Mellor 2013; Chang et al. 2015). 
Furthermore, the high metabolic activity of tumor cells can lead to nutrient restricted conditions 
and has thereby a strong impact on immune cell function as several studies demonstrated a 
direct link between metabolism and T cell fate and function (Pearce et al. 2013; O'Sullivan and 
Pearce 2015; Patsoukis et al. 2016). In line, Irving and colleagues proposed that metabolic 
competition is underestimated in the context of immunotherapeutic approaches (Irving et al. 
2017).  
While in quiescent T cells mitochondrial respiration is regarded as the main energy providing 
pathway, activated T cells rely on glycolysis, mitochondrial respiration and fatty acid oxidation to 
cover their metabolic requirements (Bental and Deutsch 1993; Jones and Thompson 2007; 
Michalek and Rathmell 2010; Pearce 2010; van der Windt and Pearce 2012; MacIver et al. 
2013). It is still a matter of debate, which metabolic pathways are crucial for the different aspects 
of T cell function and whether there are subset specific differences. As CD8 T cells are important 
for the anti-tumor immune response, the impact of the metabolic tumor microenvironment on 
their function is of special interest. 
 
 
4.1.1. Functional and metabolic characteristics of human CD8 T cell subsets 
4.1.1.1. Glucose metabolism and T cell function 
The link between glucose metabolism and T cell function has been investigated, especially in 
the murine system. Several publications show that glycolysis is crucial for effector functions and 
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proliferation of murine T cells (Cham and Gajewski 2005; Chang et al. 2013; Ho et al. 2015; 
Peng et al. 2016; Siska and Rathmell 2016).  
Glucose restriction as well as administration of the non-metabolizable glucose analogue       
2-DG, mimicking glucose deprivation by blocking the first step of glycolysis, suppresses IFNγ, 
but not IL-2 production in murine CD8 T cells (Cham and Gajewski 2005). These results were 
supported by Jacobs and colleagues who demonstrate that IFNγ production is more sensitive to 
glucose availability than IL-2 (Jacobs et al. 2008). Besides inhibition of IFNγ production, other 
effector molecules as perforin, granzymes or TNF are also affected by 2-DG (Cham et al. 2008). 
However, it has to be taken into consideration that 2-DG is not a specific glycolytic inhibitor as 
concentrations as high as 10 mM also block mitochondrial respiration (Renner et al. 2015). 
There are different aspects discussed, how glycolytic activity relates to cytokine secretion. It has 
been reported that glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a glycolytic enzyme, 
is bound to the mRNA of IFNγ thereby blocking translation (Nagy and Rigby 1995; Chang et al. 
2013). When glycolysis is engaged, GAPDH binding to cytokine mRNA is resolved and 
translation is initiated. Furthermore, LDHA activity mediating aerobic glycolysis and therefore 
relieving mitochondrial respiration provides more citrate for the generation of acetyl-coenzyme A 
which fosters histone acetylation and promotes IFNγ expression (Peng et al. 2016). Another 
study shows that glucose restriction (0.1 mM glucose) compromises nuclear translocation of 
NFAT1 in murine CD4 T cells, which is associated with the lack of the glycolytic metabolite 
phosphoenolpyruvate (Ho et al. 2015). IFNγ as well as IL-2 production is impaired, whereas 
TGF-β secretion is induced. 
Not many studies have investigated the link between metabolism and T cell function in the 
human system so far. Comparable to murine T cells, human bulk T cells also upregulate their 
glucose metabolism upon stimulation (Bental and Deutsch 1993; Frauwirth et al. 2002). 
However, glucose deprivation does not affect IFNγ TNF or IL-4 production on mRNA or protein 
level in human bulk CD4 and CD8 T cells (Tripmacher et al. 2008; Renner et al. 2015). A 
possible explanation might be that human T cells are able to compensate a lack in glucose by 
increased OXPHOS, denoted as metabolic plasticity (Frauwirth et al. 2002; Tripmacher et al. 
2008; Renner et al. 2015).  
Only two studies investigated glucose metabolism and mitochondrial function in a subset 
specific manner in human CD4 and CD8 T cells (Gubser et al. 2013; Dimeloe et al. 2016). Thus, 
in this study glycolytic activity and the impact of glucose metabolism on T cell function was 
investigated in CD8 subpopulations.  
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In a first step, naïve, CM and EM CD8 T cells were purified from healthy donors by 
fluorescence activated cell sorting and were characterized in terms of functional capabilities. In 
line with the literature, both memory populations showed a more rapid and higher cytokine 
production in comparison to naïve T cells (Appay et al. 2008; Mahnke et al. 2013). Especially the 
rare CM T cell subset was characterized by a high IFNγ and TNF secretion accordingly to other 
studies (Tussey et al. 2000; Hislop et al. 2001). The rapid recall ability of memory T cells might 
be explained by epigenome remodeling. Open chromatin marks (H3K4me1, H3K4me3, 
H3K27ac) at transcriptional start site of IFNγ correlate with increased expression and inducibility 
of IFNγ in resting memory cell s (Barski et al. 2017). Nevertheless, other reports found that 
memory subsets are equally efficient in acquiring effector functions (Ravkov et al. 2003; Wherry 
et al. 2003).  
With regard to proliferation, no difference was detected between all three subsets in this 
study. Although less differentiated CD8 T cell subsets are shown to have a higher proliferative 
capacity than experienced T cells (Migliaccio et al. 2006), proliferation correlates strongly with 
cytokine availability, while especially memory T cell proliferation depends on the presence of   
IL-7 and IL-15 (Geginat et al. 2003).  
To investigate the link between T cell function and glycolytic activity, T cells were analyzed 
under glucose deprived conditions. There is only little known about this link in human CD8 T cell 
subsets. Gubser and colleagues showed that human EM CD8 T cells display an enhanced 
extracellular acidification rate regarded as a measure for glycolytic activity in comparison to 
naïve T cells upon stimulation, although the expression profile of key glycolytic enzymes is 
similar (Gubser et al. 2013). Glycolytic activity was directly analyzed upon activation with the 
seahorse technology in fixed cells in the absence of serum and linked to the rapid on-set of 
cytokine secretion after 12 hours (Gubser et al. 2013).  
In our study, glycolytic activity was almost undetectable within the first 24 hours in all three 
subsets determined by glucose uptake and lactate secretion in non-fixed T cells in the presence 
of 10 % serum. Nevertheless, cytokine secretion was immediately elevated especially in memory 
CD8 T cells.  
To further elucidate the importance of glucose metabolism for T cell function, CD8 T cell 
subsets were stimulated in glucose free medium in the presence of 10 % serum (final glucose 
concentration: 0.4 mM). Viability and activation-associated increase in cell size were not affected 
by glucose restriction. On average secretion of IFNγ and TNF was only slightly reduced under 
glucose deprived conditions in all three subpopulations. In line, Gubser and colleagues reported 
that low concentrations of glucose (0.5 mM) are sufficient to drive IFNγ production in EM CD8 
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T cells (Gubser et al. 2013). Surprisingly, depending on the donor, cytokine production could be 
either induced or diminished by glucose deprivation in this study. The variation was most 
pronounced in the naïve subset.  
The controversy on the importance of glycolysis for IFNγ secretion in the literature might be 
related to donor variations, species differences or different experimental protocols. A major 
difference in the experimental protocols is the absence of serum or the use of dialyzed serum 
whereas in this study complete serum was applied. Studies which showed a compromised 
cytokine secretion or activation in human T cells (Dziurla et al. 2010; Macintyre et al. 2014) were 
also performed in the presence of dialyzed serum. Recent publications suggest that serum is 
essential for T cell activation (Ecker et al. 2018; Medvec et al. 2018). Finally, in some studies 
rather high concentrations of 2-DG (Gubser et al. 2013; Cham and Gajewski 2005) were used 
which has unspecific side effects as blocking mitochondrial respiration (Renner et al. 2015). 
As an important carbon source, glucose is shown to be indispensable for T cell proliferation in 
the murine (Wang et al. 2011; Chang et al. 2013) and the human system (Tripmacher et al. 
2008; Renner et al. 2015). According to the findings in the literature, glucose deprivation caused 
a block in proliferation in CD8 T cell subsets. Surprisingly, Peng and colleagues showed that 
LDHA, the enzyme converting pyruvate to lactate to regenerate NAD+ from NADH, is not crucial 
for proliferation of murine CD4 T cells (Peng et al. 2016). These findings suggest that not 
glucose fermentation but glucose metabolism is required for T cell proliferation, which is 
supported by the fact that murine as well as human Glut1 deficient CD4 T cells show an 
impaired proliferation (Macintyre et al. 2014),  
Taken together, aside from a diminished proliferation, effector functions of CD8 T cell subsets 
were only partially affected by glucose deprivation. However, a donor specific variation was 
observed, mainly in naïve cells. 
Besides glucose metabolism, oxidative phosphorylation is elevated upon T cell stimulation. 
Therefore the role of oxidative phosphorylation was analyzed in CD8 T cell subsets.  
 
 
4.1.1.2. The dependency on mitochondrial respiration is CD8 T cell subset specific 
Not only glucose, but also oxygen availability is limited in the tumor microenvironment 
(Vaupel et al. 2001). Oxidative phosphorylation is shown to be of crucial importance for T cells in 
the murine system (Chang et al. 2013; Sena et al. 2013; Okoye et al. 2015; Baixauli et al. 2015). 
An immediate increase in mitochondrial respiration is reported upon T cell activation (Chang et 
al. 2013; Sena et al. 2013; van der Windt et al. 2013). Blocking OXPHOS by oligomycin 
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simultaneously with stimulation results in a reduced proliferation, whereas T cells are able to 
proliferate when oligomycin is administered 24 hours postactivation, indicating that respiration is 
essential for the on-set of proliferation (Chang et al. 2013). 
Beside a general increase in respiration upon activation, subset specific differences have 
been reported in murine T cells. IL-15 induced memory T cells have more mitochondrial mass 
and show a higher OCR than naïve T cells (van der Windt et al. 2013). In line, Buck and 
colleagues reported a distinct mitochondrial structure in murine effector and memory T cells 
(Buck et al. 2016). Activated IL-2 induced effector T cells have punctate mitochondria, while IL-
15 induced memory T cells maintain fused networks (Buck et al. 2016). As mitochondrial 
morphology and function are closely linked, those data indicate a subset specific reliance on 
oxidative phosphorylation.  
Mitochondrial respiration is not only important for murine but also for human CD4 and CD8 
T cell populations (Renner et al. 2015; Fischer et al. 2018). However, there is little knowledge 
about mitochondrial respiration in stimulated human CD8 T cell subsets. Human EM CD4 T cells 
have more and morphologically distinct mitochondria than naïve T cells (Dimeloe et al. 2014; 
Dimeloe et al. 2016). Quiescent naïve and EM CD8 T cells show a similar basic respiration 
(Gubser et al. 2013). However, EM T cells have a higher spare respiratory capacity than naïve 
T cells (Gubser et al. 2013).  
To compare mitochondrial activity in human CD8 T cells, naïve, CM and EM CD8 T cells were 
stimulated and respiration was analyzed under culture conditions in the presence of serum. In 
the first eight hours, naïve, CM and EM T cells respired on a similar level; however, afterwards 
mitochondrial respiration was higher in naïve T cells compared to both memory subsets. 
Notably, EM cells showed the lowest oxygen consumption of all three subsets analyzed. In line 
with our data, Fischer and colleagues showed that naïve CD8 T cells rapidly increase 
mitochondrial mass and respiration after activation which is critical for effector functions as 
cytokine secretion (Fischer et al. 2018).  
The importance of OXPHOS was tested in CD8 T cell subsets by blocking mitochondrial ATP 
production with oligomycin. It was shown that oligomycin application, similar to hypoxia, causes 
apoptosis in CD4 naïve T cells (Dimeloe et al. 2016). Viability was not altered by oligomycin 
treatment in all three CD8 T cell subsets analyzed in our hands. T cell function was strongly 
affected in naïve T cells, but only moderately in both memory subsets. A reduced increase in cell 
size, indicating a diminished activation state, was observed in naïve T cells, but not in the 
memory subsets. The reduced activation state in naïve T cells was further supported by a 
lowered lactate secretion after 48 hours, although variation between donors was observed. 
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Inhibiting OXPHOS diminished IFNγ and TNF secretion in naïve but not in EM cells, and in CM 
cells IFNγ secretion was only slightly reduced. Again, a donor variance was observed. 
In bulk CD8 T cells, oligomycin treatment leads to a reduced on-blast formation and 
proliferation, but has no significant effect on cytokine production (Renner et al. 2015). As the 
effect was more pronounced on naïve cells which show limited cytokine secretion, a negative 
effect on naïve cells can be overlooked analyzing bulk cultures. 
Taken together, mitochondrial inhibition mainly affected the naïve subset in line with the most 
pronounced increase in respiration upon stimulation.  
Besides glucose metabolism and mitochondrial respiration, T cells rely on glutamine 
metabolism. Therefore the role of glutamine metabolism was analyzed by glutamine titration and 
restriction experiments. 
 
 
4.1.1.3. Glutamine is an essential substrate during T cell stimulation 
Tumor cells are frequently characterized by an increased consumption of glutamine (Altman 
et al. 2016), which could result in limited glutamine amounts in the tumor microenvironment. 
However, only a limited number of publications determined glutamine concentrations in the 
tumor. Pan and colleagues measured glutamine levels in pancreatic tumors and detected levels 
as low as 100 µM in the core and 400 µM in the periphery (Pan et al. 2016).   
A variety of studies have shown that glutamine is also an essential amino acid for stimulated 
murine and human T cells (Carr et al. 2010; Wang et al. 2011; Newsholme et al. 2003a; 
Newsholme et al. 2003b). Therefore, restricted glutamine concentrations in the tumor 
microenvironment might contribute to tumor immune escape. 
In the murine system glutamine availability is crucial for cell growth, the expression of 
activation-related surface markers and cytokine secretion in CD4 and CD8 T cells (Carr et al. 
2010; Johnson et al. 2018; Wang et al. 2011, Csibi et al. 2013). In line, glutamine was shown to 
be essential for the production of GSH which is required for T cell growth and IL-2, IL-17 and 
IFNγ secretion (Mak et al. 2017).  
Beside an important role for T cell activation, glutamine metabolism is also involved in CD4 
T cell differentiation. Recently Johnson and colleagues reported that glutamine metabolism 
promotes differentiation of CD4 T cells to a Th17 phenotype, but impedes differentiation to Th1 
cells (Johnson et al. 2018). Glutamine restriction is also linked to the induction of a Treg 
phenotype (Klysz et al. 2015).  
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As in the murine system, Metzler and colleagues demonstrated that glutamine restriction 
drives induction of a Treg like phenotype also in human CD4 T cells (Metzler et al. 2016). 
Glutamine dependency of different human T cell subpopulations is less investigated. For CD4 
T cells, flux analyses demonstrated that glutamine can be degraded by the TCA to produce 
either citrate or pyruvate, the latter can be converted into lactate. Moreover, via the conversion 
of citrate into acetyl-CoA, glutamine fuels fatty acid synthesis in naïve and CM T cells, but not in 
EM T cells (Ecker et al. 2018).  
To our knowledge, data on the importance of glutamine for CD8 T cell activation and 
respective subsets are not available. Therefore, CD8 T cells were stimulated under various 
concentrations of glutamine. Glutamine concentrations supplemented were 2 mM, the typical 
amount used for in vitro cultures, 0.5 mM reflecting blood level, and 0.25 to 0.05 mM to mirror 
the tumor situation. The application of serum should result in an additional glutamine 
supplementation of 0.05 to 0.075 mM. Besides the observed decreased glutamine 
concentrations in the tumor, these titration experiments were of special interest as during 
advanced malignant diseases glutamine plasma levels can be reduced by 20-30 % (Klimberg 
and McClellan 1996).  
Already at 0.25 mM glutamine on-blast formation and proliferation were significantly reduced; 
however, IFNγ and TNF secretion were maintained in bulk CD8 T cells. At 0.1 mM glutamine, 
which is detected in tumor cores (Pan et al. 2016), the secretion of both cytokines was strongly 
diminished. Interestingly, metabolic activity in terms of glycolysis and respiration was impaired at 
glutamine concentrations as low as 0.1 mM, but not at higher concentrations. Cell growth and 
proliferation were affected at a concentration of 0.25 mM, but metabolic activity was preserved, 
indicating that glutamine itself seems to be important for proliferation. 
Experiments with CD8 T cell subsets demonstrated that all three subsets were strongly 
affected regarding proliferation, metabolic activity and cytokine secretion by glutamine 
deprivation. Nevertheless, some differences in their dependency for glutamine were detected as 
IFNγ and TNF secretion was not completely blocked in memory subsets as observed in naïve 
T cells. 
In order to elucidate which glutamine dependent pathway is crucial for T cell activation, 
glutamate, α-ketoglutarate, GSH, aspartate, arginine, asparagine alone or a combination of 
glutamate, α-ketoglutarate, GSH, hypoxanthine and thymidine were supplemented. As in other 
studies (Carr et al. 2010), we failed to completely rescue T cell function. In contrast to a study on 
murine T cells, in which CD4 T cell proliferation is partly recovered by the application of α-
ketoglutarate as well as hypoxanthine and thymidine (Wang et al. 2011). These mixture of 
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metabolites administered in the same concentration did not rescue human CD8 T cell activation 
and proliferation in this study. Asparagine, able to rescue proliferation under glutamine starvation 
in tumor cells (Pavlova et al. 2018), could not replace glutamine in CD8 T cells. Glutamine is 
shown to be important for the generation of GSH to scavenge ROS in murine T cells (Mak et al. 
2017), but GSH administration failed to substitute for glutamine in human T cells in our hands. 
Either glutamine could not be replaced or the metabolites administered were not efficiently taken 
up. To partially account for uptake limitations the cell permeable dimethyl-α-ketoglutarate was 
used in this study, but was also not effective. 
According to the study of Geiger and colleagues, stimulated human CD4 T cells are able to 
import glutamate quite efficiently (Geiger et al. 2016). However, there is only little knowledge 
about transporters and receptors for glutamate in human CD8 T cells. To overcome a possible 
limitation due to a low uptake rate, glutamate was supplemented at very high concentrations. 
Indeed, preliminary results denoted that glutamate as high as 20 mM improved cytokine 
secretion to 50 % of control levels; however, glutamate supplementation had no effect on 
proliferation. 
Studies have previously shown that there is a link between mTOR and glutamine metabolism. 
In line, in this study mTOR activation was reduced in the absence of glutamine. Furthermore, 
glutamine withdrawal after 24 hours of stimulation resulted in a drop in phospho-mTOR, 
indicating that glutamine is necessary to sustain mTOR activation.  
Moreover, extracellular glutamine is shown to be an obligatory signal for the mTOR pathway 
(Fumarola et al. 2005). Glutamine acting as an exchange molecule facilitates the uptake of other 
amino acids as leucine and this is linked to mTOR activation (Nicklin et al. 2009). mTOR 
complex 1 activation (mTORC1) promotes glutamine metabolism by activating the glutamate 
dehydrogenase, the enzyme for the deamination of glutamate to α-ketoglutarate (Csibi et al. 
2013). Glutamine metabolism is linked to mTORC1, as α-ketoglutarate stimulates mTORC1 
activation, which indicates that mTORC1 is a downstream target of glutamine (Choi and Park 
2018). However, in this study addition of cell permeable α-ketoglutarate was not able to replace 
glutamine.  
Taken together, the data presented in this thesis strongly underline that glutamine, although 
regarded as non-essential amino acid, seems to be crucial for CD8 T cell activation. Preliminary 
data suggest, that the sensitivity might be related to the observed limited expression of 
glutamine synthetase and thus in the inability of T cells to synthesize glutamine from glutamate. 
Our results implicate that rather glutamine than glucose has to be considered as limiting factor in 
the tumor microenvironment. Already at concentrations half the level normally detected in blood, 
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CD8 T cell proliferation was significantly reduced. Further experiments overexpressing glutamine 
synthetase will reveal whether the sensitivity of T cells to glutamine deprivation can be 
overcome. Such approaches might be a promising strategy in the context of ACT.  
In light of the presented data, the application of anti-metabolic drugs especially inhibitors of 
glutamine metabolism could have adverse effects on T cell function and thereby patient 
outcome.  
 
 
4.2. Impact of drugs targeting tumor metabolism on human CD8 
T cells 
4.2.1. Impact of pharmacologic blockade of glutamine metabolism in CD8 T cells 
Targeting amino acid metabolism has been exploited for quite a long time. Asparaginases are 
a cornerstone of treatment protocols for acute lymphoblastic leukemia and lymphoma (Avramis 
2012). ADI-PEG20, an arginine degrading inhibitor (Miraki-Moud et al. 2015), is already tested in 
clinical trials (NCT01287585). Moreover, blocking glutamine metabolism has become an 
attractive anti-cancer therapeutic target (Altman et al. 2016).  
With regard to the importance of glutamine for T cell activation, the application of glutamine 
analogues or pathway inhibitors has to be regarded with caution. Due to this fact the impact of 
drugs targeting the glutamine metabolism were analyzed in this study.  
In several clinical studies, the glutamine analogue DON demonstrated promising results in 
patients with hematological malignancies or solid tumors (Eagan et al. 1982; Lynch et al. 1982; 
Sullivan M. P. et al. 1962). Moreover, DON is shown to sensitize pancreatic cancer cells to 
chemotherapy in vitro and improved the efficacy of gemcitabine treatment (Chen et al. 2017). 
T cell function of freshly isolated and stimulated bulk CD8 T cells was strongly inhibited in the 
presence of DON and also acivicin as on-blast formation, cytokine secretion as well as 
proliferation were decreased. Notably, due to severe side effects especially due to neurological 
toxicity, acivicin failed to get approval (Adolphson et al. 1986; Olver et al. 1998). Moreover, DON 
was declined due to dose limiting toxicities particularly in the gastrointestinal tract (Rais et al. 
2016).  
In contrast to glutamine analogues, the application of two different glutaminase inhibitors had 
no impact on CD8 T cell function as CD25 expression, on-blast formation, proliferation as well as 
IFNγ and TNF secretion were not altered. These results are in line with other studies, in which 
glutaminase inhibition by BPTES or CB-839 does not impede cell growth and proliferation of 
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primary human T lymphocytes in vitro (Xiang et al. 2015). However, BPTES administration, 
leading to increased intracellular glutamine levels, reduces proliferation and cytokine secretion in 
human CD4 T cells (Sener et al. 2016).  
Johnson and colleagues recently reported that the response to CB-839 treatment in murine 
CD4 T cells is subset specific (Johnson et al. 2018). Proliferation of Th17, but not of Th1 cells is 
reduced. Surprisingly, Th1 T cells produce more IFNγ in the presence of CB-839. Those findings 
are in contrast to the results of Sener and colleagues (Sener et al. 2016) and might indicate a 
species related difference between human and murine T cells. 
Taken together glutaminase inhibition has a moderate effect on T cell function in comparison 
to glutamine analogues and therefore the administration might be an interesting option in the 
context of cancer therapy. Unfortunately, the efficacy of these inhibitors is restricted to only a few 
tumor entities since a variety of tumor cells can fuel their glutamine metabolism by synthetizing 
glutamine from glutamate by the glutamine synthetase (Tardito et al. 2015). 
Surprisingly, in expanded T cells, T cell function was preserved in the presence of DON. An 
experiment with expanded CD8 subsets under glutamine deprived conditions indicated that 
T cells were still dependent on glutamine metabolism. Whether DON was not taken up any 
longer or T cells exported the inhibitor by multidrug resistance (MDR) pumps, as it is observed in 
tumor cells (Gottesman and Pastan 2015), needs further investigation. These observations are 
of interest especially in the context of ACT, as T cells need to be expanded before transfer. 
Moreover, the role of tumor metabolism during cancer therapy has gained attention in the past 
years. Due to this fact, inhibitors of glutamine metabolism could be used as combinatory drug, in 
particular with regard to immunotherapeutic approaches (Cervantes-Madrid et al. 2015). 
Taken together, glutaminase inhibiting drugs did not show any impact on proliferation or T cell 
effector functions as IFNγ or TNF secretion in freshly stimulated CD8 T cells or expanded CD8 
T cell subsets. Promising results were obtained with the glutamine analogue DON, which 
showed no impact on the effector functions in expanded T cell subsets.  
 
 
4.2.2. Targeting glycolysis via inhibition of MCT1 and MCT4 in T cells 
Beside a highly elevated demand for amino acids, tumor cells frequently show an increased 
glycolytic activity. As a result, lactic acid accumulates in the microenvironment of tumors 
displaying the Warburg phenotype. It has been shown by our group and others that lactic acid 
suppresses the anti-tumor immune response not only of T cells (Fischer et al. 2007; Calcinotto 
et al. 2012; Mendler et al. 2012) but also of other cell types as NK cells or monocytes (Dietl et al. 
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2010; Husain et al. 2013). The main transporters responsible for the secretion of lactate, in co-
transport with a proton, are the monocarboxylate transporters (MCTs). MCT1 is ubiquitously 
expressed on normal cells and in line on several tumor entities, as for example colorectal, 
breast, gastric, cervical cancer and glioma (Pinheiro et al. 2008; Pinheiro et al. 2010; de Oliveira, 
Talvane Torres Antônio et al. 2012; Miranda-Goncalves et al. 2013). In addition, MCT4 is 
expressed on highly glycolytic cells and thus frequently detected on tumor cells as renal cell 
carcinoma, cervical or prostate cancer (Doherty and Cleveland 2013). 
Due to their strongly elevated expression in a high proportion of tumors, MCTs represent a 
promising therapeutic target structure. However, blocking only one transporter is of limited 
efficacy. It has already been shown for a human colon adenocarcinoma cell line that cells are 
insensitive to MCT1 inhibition, as they are able to compensate by MCT4 (Marchiq et al. 2015). 
Vice versa, a MCT4 disruption only hardly affects metabolic activity in these cells. However, 
MCT4 disruption combined with MCT1 inhibition does not induce cell death but impairs tumor 
growth. Known MCT inhibitors mainly target MCT1 and MCT2 and are already tested in clinical 
trials (Murray et al. 2005; Ovens et al. 2010a; Ovens et al. 2010b; Doherty et al. 2014), while 
inhibitors for MCT4 are currently developed (Doherty and Cleveland 2013). Since various tumor 
entities are characterized by elevated MCT4 levels, compounds disabling MCT4 to efficiently 
reduce lactate secretion are needed.  
Expression levels and importance of those transporters in T cells has not been systematically 
investigated and especially data on the human system are lacking. Murray and colleagues 
showed that an MCT1/2 inhibitor reduces lactate secretion in primary stimulated human T cells 
and reduces proliferation (Murray et al. 2005). However, they did not investigate effector 
functions. Moreover, in this publication an increased expression of MCT4 in the course of 
stimulation is briefly mentioned. Thus, the application of pan-MCT inhibitors might impede 
T cells.  
Our group has already shown that diclofenac reduces lactate secretion and diminishes tumor 
growth in vivo (Chirasani et al. 2013; Gottfried et al. 2013). New data of Sasaki and colleagues 
and our group show that diclofenac directly targets MCT1 and MCT4 activity (Sasaki et al. 2016; 
Renner et al. under revision). Similar to diclofenac, lumiracoxib, a diclofenac derivative, is 
capable to target both transporter and reduces lactate secretion in human melanoma cell lines 
(Brummer et al. 2019). Diclofenac and lumiracoxib have a high structural similarity, as only one 
chloride is replaced by a fluoride molecule. Both substances are cyclooxygenase (COX) 
inhibitors. Diclofenac inhibits prostaglandin synthesis by inhibiting COX-1 and COX-2 (Gan 
2010) and is used as an anti-inflammatory and analgesic drug, also during cancer therapy 
  Discussion 
                                                                                                                                                           
96 
 
(Mercadante 2001). Lumiracoxib is a selective COX-2 inhibitor (Tacconelli and Patrignani 2004), 
but was withdrawn from the market in a variety of countries due to its potential causing liver 
failure, however only at high concentrations. Besides blockade of lactate accumulation, both 
substances are developed to reduce prostaglandin E2 secretion. Prostaglandin E2 has been 
shown to suppresses T cell function and the response to checkpoint inhibition (Zelenay and Reis 
e Sousa 2016). Thus the application of diclofenac or lumiracoxib might block the secretion of two 
immunosuppressive metabolites, lactate and prostaglandin E2. 
Diclofenac and lumiracoxib exerted similar effects on T cell function in freshly isolated and 
activated human CD8 T cell subsets. Application of both substances led to a reduction in 
glucose consumption and lactate secretion. In accordance with a stronger effect on lactate 
secretion, which can be explained by the higher Ki value of lumiracoxib for both transporters, 
proliferation was stronger reduced under diclofenac treatment after six days. Cytokine secretion 
was only slightly affected in naïve and preserved in EM T cells. Taken together, diclofenac as 
well as lumiracoxib reduced glycolytic activity and proliferation in CD8 T cell subsets. However, 
T cell effector functions were preserved or only slightly lowered by both substances indicating 
that T cells are able to tolerate MCT inhibition. 
This notion was supported by our findings analyzing MCT4-/- T cells. As nothing is known 
about the importance of MCT4 for T cell activation, CD4 as well as CD8 T cells from MCT4-/- 
mice were investigated. Surprisingly, both MCT4-/- T cell populations showed no differences 
regarding glycolytic activity when stimulated with α-CD3/CD28 antibodies in comparison to WT 
T cells. Disruption of the MCT4 gene did not modify the transport of lactate, since both cell types 
secreted the same amount of lactate. These results show again that lacking or inhibition of one 
MCT can be compensated by another MCT transporter. Notably, MCT4 deficiency seemed to 
shift metabolism to respiration indicated by a higher oxygen consumption rate in MCT4-/- T cells. 
Since there was no drop in cytokine secretion caused by MCT4 deficiency, a link between MCT4 
and effector functions in freshly stimulated T cells was not observed, at least in an in vitro 
setting. However, MCT4 expression might be important in expanded T cells, which needs to be 
clarified.  
Our findings in T cells are in contrast to results published for macrophages. In knockdown 
experiments with siRNA specific for MCT4, murine macrophages are characterized by 
intracellular lactate accumulation and decreased glycolytic activity. Moreover, effector functions 
are reduced in MCT4-/- macrophages, measured by expression of inducible nitric oxide synthase 
(iNOS), TNF and IL-6 secretion (Tan et al. 2015). It was recently shown that oral squamous 
carcinoma tumors grow more aggressive in MCT4-/- mice than in WT mice (Bisetto et al. 2018). 
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The number of infiltrating macrophages analyzed by immunohistochemistry is decreased in 
tumors in MCT4-/- mice. Analyzing the circulating monocytes demonstrate significant lower levels 
possibly resulting in a defect in the recruitment of macrophages to the tumors. 
To investigate whether complete blockade of MCT1 and MCT4 has a negative impact, a 
MCT1/2 inhibitor was applied to MCT4-/- T cells in comparison to WT T cells. A mouse with a 
complete knock out of both transporters is not available, as a complete MCT1 knockout has 
shown to be embryonically lethal (Lengacher et al. 2013; Morrison et al. 2014) and mice with a 
basignin knockout, the anchor protein for MCT1 and MCT4, are sterile and show various 
neurological abnormalities (Muramatsu and Miyauchi 2003).  
T cell function of MCT4-/- T cells in comparison to WT T cells was analyzed in the presence of 
the MCT1/2 inhibitor SR13800. In addition, these results were compared to treatment with 
diclofenac. Supplementation of the MCT1/2 inhibitor strongly reduced lactic acid transport in 
both, WT and MCT4-/- T cell populations, but in MCT4-/- T cells to a stronger extent. MCT1 and 
MCT4 inhibition reduced cytokine secretion but did not lead to a complete blockade. WT T cells 
treated with diclofenac leading to a MCT1 and MCT4 inhibition showed a similar impact on IFNγ 
secretion as MCT4-/- T cells treated with the MCT1 inhibitor SR13800. In murine T cells a trend 
to reduced cytokine secretion was observed in the presence of diclofenac. This effect is not 
observed in human T cells (Renner et al. under revision). Those data suggest that there might 
be a difference between the murine and the human system, which should be further 
investigated. 
To our knowledge this is the first study investigating the impact of MCT4 on T cell function. As 
MCT4 deficiency did not show any impact on effector functions in T cells in vitro, MCT4 as well 
as a simultaneous MCT1 blockade could display a promising strategy in cancer therapy. Due to 
the fact, that diclofenac and lumiracoxib inhibit MCT1 as well as MCT4, they might be promising 
candidates for cancer therapy. However, a therapy with MCT inhibitors alone might not be 
effective. In a head and neck squamous cell carcinoma (HNSCC) cell line, the double disruption 
of MCT1 and MCT4 does not show any effects on cell growth under normoxia, but leads to a 
growth inhibition under hypoxic conditions (Boasquevisque et al. 2017). These findings suggest 
that glycolytic inhibition in tumor cells could be compensated by alternative metabolic pathways 
as respiration. 
Nevertheless, the reduction in lactic acid secretion supports an endogenous anti-tumor 
response, regarded as crucial for patient survival (Galon et al. 2006). In accordance, a MCT4 
knockdown in 4T1 breast cancer cells by shRNA or the application of the MCT4 inhibitor 7acc1 
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lead to a strengthened cytotoxicity of NK cells, which is correlated with reduced tumor growth 
(Long et al. 2018). 
Therefore, a combination of anti-glycolytic drugs with immunotherapeutic approaches could 
be extremely beneficial as recently suggested by Cascone and colleagues (Cascone et al. 
2018). In case of an ACT, a sufficient in vitro expansion of patient derived T cells is required. To 
exclude effects of metabolic targeting on expanded T cells, the impact of metabolic inhibitors 
was finally investigated in CD8 T cell subsets after expansion. 
 
 
4.2.3. Impact of anti-metabolic targeting on T cell function in expanded CD8 T cell subsets  
in the context of immunotherapeutic approaches 
So far immunotherapeutic approaches as ACT demonstrate efficacy particularly in patients 
with leukemia and lymphoma. Regarding various solid tumors, the success of ACT is moderate 
and only in a small cohort of patients a tumor regression can be achieved (Goff et al. 2016). In 
contrast to hematologic malignancies, solid tumors display an immunosuppressive metabolic 
microenvironment (Renner et al. 2017). In line, recent publications clearly show that a high 
glycolytic activity impairs the endogenous anti-tumor immune response (Brand et al. 2016) which 
could limit the efficacy of immunotherapeutic approaches (Ascierto et al. 2016; Cascone et al. 
2018).  
Transferred T cells require a successful engraftment, long-term in vivo persistence and 
regeneration of effector as well as memory T cell populations. Beside culture conditions such as 
the duration in culture (Kalos et al. 2011) or the capability to persist in vivo, the outcome 
depends on the differentiation stage of reinfused cells (Klebanoff et al. 2012). It is still 
controversially discussed which T cell subsets could mediate a highly effective cancer 
regression in patients upon ACT. Although effector T cells are poised to rapidly execute effector 
functions upon activation, as evidenced by their capacity to release large amounts of cytokines 
and their ability to rapidly lyse targets, less differentiated T cell subsets seem to be superior in 
mediating antitumor immunity (Klebanoff et al. 2012). There is evidence that adoptively 
transferred T cells derived from CMs have a greater capacity than cells derived from EMs to 
persist in vivo (Berger et al. 2008). In a study with CD19-specific CAR-modified memory stem 
CD8 T cells, it was shown that these cells mediate superior and more durable antitumor 
responses than CD8 T cells generated with clinical protocols currently under investigation 
(Sabatino et al. 2016).  
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Taken together, ACT of less differentiated T cell subsets have consistently demonstrated 
superior in vivo expansion, persistence and antitumor capacities relative to the more 
experienced T cells. However, our results suggest that EM T cells should also be considered for 
ACT, as they were less sensitive to nutrient restriction. Moreover, in particular CD8 EM T cells 
are capable to infiltrate tumors (Siska et al. 2017). Furthermore, tumor infiltrating CD45RO 
positive cells, displaying memory T cells, are reported to be associated with a better prognosis 
during cancer therapy (Hadrup et al. 2013). 
For ACT an ex vivo expansion of T cells is indispensable. Several expansion protocols were 
tested in order to obtain cells with a preserved CD62L and CCR7 expression and a capacity to 
produce important effector molecules. Stimulation in a MLR in combination with the interleukin 
cocktail of IL-2, IL-7 and IL-15 was favorable in comparison to a commonly used α-CD3/CD28 
stimulation due to a higher proliferation rate and a higher capacity to secret IFNγ as well as 
perforin and granzyme B after expansion. 
After expansion, the impact of several drugs targeting tumor metabolism on CD8 T cells was 
determined. T cell function of CD8 T cell subsets was analyzed in the presence of the MCT 
inhibitors diclofenac and lumiracoxib, the anti-diabetic drug metformin displaying a mitochondrial 
inhibitor, and finally DON and CB-839, inhibitors for glutamine metabolism.  
Aside from proliferation, T cell function was not impaired by inhibition of glycolysis in all three 
subsets, reflecting the results obtained in bulk CD4 and CD8 T cells (Renner et al. under 
revision). Metformin is shown to improve T cell function in exhausted CD8 T cells derived from 
patients with breast or lung cancer, as they secret higher amounts of IFNγ, IL-2 and TNF 
(Watanabe et al. 2017). Metformin had no inhibitory effect on expanded CD8 T cell subsets; 
however, supplementation did not improve T cell function. The improved function in T cells 
isolated from patients might be an indirect effect due to a lower tumor growth and thereby a less 
harmful tumor microenvironment.  
Taken together, glycolytic and mitochondrial inhibitors had no impact on T cell function as 
proliferation or cytokine secretion of expanded CD8 T cells. Strikingly, although the application of 
DON impaired the function of freshly isolated T cells, DON did not affect function in expanded 
CD8 T cell subsets. Comparable to the results obtained for primary T cells, CB-839 did not show 
any implication on T cell function comparable to the results on primary activated T cells.  
As T cells expanded in a MLR were resistant to metabolic inhibitors after expansion, the 
application of specific anti-metabolic drugs might be supportive during ACT or other 
immunotherapeutic approaches.  
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4.3. Perspectives: The potential of metabolic targeting to support 
immunotherapy  
In the last decades, immunotherapy has become an important treatment strategy for several 
tumor entities. However, regarding the conditions in the microenvironment of solid tumors 
immunotherapy may require combinatorial treatment regimens (Abken 2015; Beatty and O’Hara 
2016). The combination of anti-metabolic drugs with immunotherapy is an emerging strategy in 
this context. A blockade of CD73, an enzyme that catabolizes the hydrolysis of extracellular 
adenosine monophosphate, which is known to impair T and NK cell immune response (Häusler 
et al. 2011), was shown to enhance PD-1 and CTLA-4 therapy (Allard et al. 2013). Specific 
glutaminase inhibitors do not affect T cell function. Accordingly, glutaminase inhibition has 
already been shown to support immunotherapy with PD-1 and PD-L1 antibodies (Gross et al. 
2016). 
High lactate concentrations in the tumor microenvironment dampens the efficacy of ACT 
(Cascone et al. 2018). In advanced renal cell carcinomas (RCC), the metabolic profile of tumors 
is associated with the response rate and overall survival of patients treated with PD-1 therapy 
(Ascierto et al. 2016).  
However published data suggest that application of anti-glycolytic drugs might impair T cell 
function. The data in this thesis show that glucose metabolism is of minor importance for T cell 
effector functions. In line, the anti-glycolytic NSAIDs diclofenac and lumiracoxib did not block 
T cell effector functions and are therefore promising supplements during immunotherapy. 
Moreover, both NSAIDs are shown to reduce simultaneously extracellular lactate (Sasaki et al. 
2016; Brummer et al. 2019; Renner et al. under revision) and prostaglandin E2 accumulation 
(Gan 2010). The latter is also known as an immunosuppressive metabolite (Kalinski 2012) and 
COX inhibition was shown to support checkpoint therapy (Zelenay and Reis e Sousa 2016). 
However, our group demonstrated that the application of diclofenac, but not aspirin effectively 
supports checkpoint therapy in a subcutaneous model of triple negative breast cancer in vivo 
(Renner et al. under revision). Those data argue for the application of NSAIDs inhibiting lactate 
and prostaglandin E2 secretion at the same time. 
Beside the application of anti-metabolic drugs, a genetic approach to render T cells more 
competitive in nutrient acquisition or making T cells more resistant to inhibitory metabolites in the 
tumor microenvironment could be promising. Overexpression of PPAR-gamma co-activator 1α 
(Scharping et al. 2016; Bengsch et al. 2016), a master regulator of mitochondrial biogenesis (Lin 
et al. 2005), or phosphoenolpyruvate carboxykinase 1 (Ho et al. 2015) improve the efficacy of 
adoptively transferred T cells. Inhibiting cholesterol esterification by genetic ablation or 
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pharmacological inhibition leads to enhanced effector functions and proliferation in CD8 
T cells as well as better controlling of tumor progression (Yang et al. 2016). With regard to 
our results, artificial overexpression of the glutamine synthetase (GLUL) might be also a 
strategy to boost T cell function in a tumor microenvironment characterized by low glutamine 
concentrations. 
Finally, although plasticity remains very challenging, metabolic pathways seem to be 
associated with differentiation into different T cell subsets (Buck et al. 2016; Patsoukis et al. 
2016; Patel and Powell 2017). Manipulation or reprogramming of metabolism with metabolic 
active substances to induce the development of special T cell subsets could ameliorate the 
current protocols for cancer immunotherapy (Zhang and Ertl 2016; Dugnani et al. 2017). 
In conclusion, this study reveals that effector functions of CD8 T cell subsets are only partly 
compromised by drugs targeting glycolysis, glutamine metabolism or cellular respiration. 
Although the application of anti-metabolic drugs affects some aspects of T cell function, the 
highly accelerated metabolism of tumor cells has such a strong immunosuppressive effect that 
the application of anti-metabolic drugs might still be beneficial, especially in the context of 
immunotherapy. 
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5. Summary 
Novel, promising strategies to fight cancer include immunotherapeutic approaches these 
days. Such strategies are regarded as breakthrough of the 21th century. The Nobel Prize of 
medicine was recently awarded to the discovery of ways to remove the immune system’s 
“brakes” (checkpoints) and thereby unleashing immune cells to attack tumors. However, only in 
a limited cohort of patients a persisting tumor regression is achieved. Besides avoiding immune 
recognition by the expression of such checkpoint molecules or the lack of antigen presentation, 
the metabolic tumor microenvironment contributes to diminished anti-tumor immune responses. 
The tumor microenvironment is characterized by low levels of nutrients and at the same time the 
accumulation of immunosuppressive metabolites as lactic acid, both negatively affecting the 
anti-tumor immune response. Therefore, targeting tumor metabolism could improve the efficacy 
of immunotherapeutic approaches. The link between metabolism and T cell effector functions is 
still a matter of debate and data on the human system are rather sparse particularly for different 
CD8 T cell subsets. Understanding this link is a prerequisite for the development of therapies 
targeting tumor cells, but preserving immune cell functions.  
Thus in this thesis, CD8 T cell subsets (naïve, central and effector memory T cells) were 
characterized in terms of their metabolic demands for different aspects of function as 
proliferation or cytokine secretion. Nutrient restriction experiments were performed to reveal 
metabolic dependencies of CD8 T cells and finally the impact of anti-metabolic drugs as 
proposed for cancer treatment was analyzed.  
In comparison to murine T cells, human CD8 T cells seem to be less dependent on glucose 
metabolism, as cell growth and effector functions as cytokine secretion were only slightly 
compromised under glucose deprived conditions. However, proliferation was blocked in all three 
subsets. Interestingly, the variation between donors was pretty high especially in naïve T cells.  
In contrast, glutamine was essential for CD8 T cell function as glutamine restriction led to 
insufficient activation of all CD8 T cell subsets. Nevertheless, effector functions as IFNγ and TNF 
secretion were less compromised under glutamine deprived conditions in memory subsets than 
in naïve T cells. Titration experiments showed that glutamine concentrations as low as 0.1 mM 
inhibited T cell activation and IFNγ and TNF secretion, a concentration which has been already 
detected in tumors. Proliferation was already significantly reduced at a glutamine concentration 
of 0.25 mM. These results showed that not only glucose but also glutamine is a substrate, tumor 
cells and immune cells have to compete for in the tumor microenvironment.  
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Experiments failed to find a combination of metabolites downstream of glutamine degrading 
pathways which can substitute for glutamine, indicating that glutamine itself is crucial for T cells. 
Preliminary results suggest that the lack of glutamine synthetase, an enzyme catalyzing the 
reaction of glutamate to glutamine, could play a role in the dependency on glutamine in T cells. 
Next, the role of cellular respiration was analyzed by application of oligomycin, an ATP 
synthase inhibitor. T cell functions as proliferation as well as IFNγ and TNF secretion were 
diminished in naïve T cells but only slightly in central and effector memory T cells.  
Although effector memory T cells are regarded as an exhausted subset, our findings suggest 
that these cells are less affected by nutrient restriction than naïve T cells. Therefore also effector 
memory T cells should be considered in terms of immunotherapeutic approaches as adoptive 
T cell transfer. 
Finally, as activated T cells show an accelerated metabolism similar to tumor cells, the impact 
of anti-metabolic drugs was investigated in freshly stimulated CD8 T cells. With special regard to 
adoptive T cell transfer, the impact of clinically relevant anti-metabolic drugs was investigated in 
expanded CD8 T cells. 
Due to the importance of glutamine for T cell activation, the application of inhibitors targeting 
glutamine metabolism has to be considered carefully. Due to this fact the impact of glutamine 
analogues (DON and acivicin) as well as glutaminase inhibitors (BPTES and CB-839) was 
analyzed in this study. Inhibition of glutaminase, converting glutamine to glutamate, had no 
impact on T cell function in primary stimulated CD8 T cells, whereas the glutamine analogs 
strongly impaired T cell function and metabolic activity. Surprisingly, DON did not show a strong 
impact on expanded CD8 subsets. 
Since glucose metabolism is of major importance for tumor cells, the impact of drugs 
targeting glycolysis on T cells was analyzed. Inhibition of monocarboxylate transporter (MCTs) in 
tumor cells, to block lactic acid secretion, affects tumor cells itself but might also support the 
anti-tumor immune response by reducing lactate accumulation. Up to now potent MCT inhibitors 
have been developed only for MCT1 and MCT2. The two non-steroidal anti-inflammatory drugs 
(NSAIDs) diclofenac and lumiracoxib, both known cyclooxygenase (COX) inhibitors, target 
MCT1 and MCT4. As they are the only identified inhibitors of MCT1 and simultaneously MCT4, 
they might be promising substances in the context of tumor therapy. Although an inhibition of 
glycolytic activity was observed, cytokine secretion was maintained in human naïve and effector 
memory CD8 T cell subsets and also in expanded CD8 T cell subsets. Only a reduction in 
proliferation was observed after six days. 
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These results were further supported by investigating a complete MCT1 and MCT4 inhibition 
in murine T cells. To mimic this pan-MCT inhibition, MCT4 deficient T cells were cultured in the 
presence of a MCT1/2 inhibitor. Although the glycolytic activity was almost completely blocked, 
murine T cells were still able to secret important effector cytokines such as IFNγ; however levels 
were moderately reduced. 
In this thesis, CD8 T cells showed subset specific differences in their metabolic activity. While 
glucose restriction did not harmed T cell function, glutamine deprivation had a strong impact on 
the T cell immune response. Therefore, targeting glucose metabolism is a promising strategy in 
cancer therapy, while drugs acting on the glutamine metabolism have to be considered carefully. 
Nevertheless, T cells were unaffected by glutaminase inhibitors. These findings suggest that 
anti-metabolic drugs are promising supplements in immunotherapeutic approaches as 
checkpoint blockade or adoptive T cell transfer therapy. 
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6. Zusammenfassung 
Immuntherapeutische Ansätze stellen heutzutage neuartige, erfolgsversprechende Strategien 
zur Krebsbehandlung dar. Diese neuen Vorgehensweisen gelten als Durchbruch des 
21. Jahrhunderts. So wurde kürzlich der Nobelpreis für Medizin für die Entdeckung verliehen, 
„die Bremsklötze“ des Immunsystems (sogenannte Checkpoints) zu lösen und dadurch 
Immunzellen zur Tumorbekämpfung zu befähigen. Allerdings wird eine andauernde 
Tumorregression durch eine solche Therapie nur in einer begrenzten Patientengruppe erreicht. 
Neben der Tatsache, dass Immunzellen aufgrund solcher Checkpoints und einer fehlenden 
Antigen-Präsentation den Tumor nur unzureichend erkennen, trägt das metabolische 
Tumormikromilieu zu einer verringerten anti-tumoralen Immunantwort bei. Das 
Tumormikromilieu ist nämlich durch einen Nährstoffmangel und gleichzeitig einer Anhäufung 
immunsuppressiver Metabolite gekennzeichnet, wie beispielsweise der Milchsäure, was die anti-
tumorale Immunantwort abschwächt. Daher könnte die Erfolgsquote einer Immuntherapie durch 
das Eingreifen in den Tumormetabolismus gesteigert werden. Der Link zwischen Metabolismus 
und humanen T-Zell-Effektor-Funktionen ist immer noch unzureichend geklärt, wobei es an 
Untersuchungen zum humanen System mangelt, vor allem in Bezug auf Daten für verschiedene 
CD8 T-Zell-Subpopulationen. Diesen Link zu verstehen ist essentiell für die Entwicklung neuer 
Therapieansätze, bei denen gezielt Tumorzellen bekämpft, gleichzeitig aber T-Zell-Funktionen 
erhalten bleiben.  
Deshalb wurden in dieser Arbeit die metabolischen Anforderungen charakterisiert, die für die 
Aufrechterhaltung von Funktionen, wie Proliferation oder Zytokinproduktion, in CD8 T-Zell-
Subpopulationen (naive Zellen, zentrale und Effektor-Gedächtniszellen) nötig sind. Mit Hilfe von 
Nährstoffentzugs-Experimenten wurde die metabolische Abhängigkeit von CD8 T-Zellen 
untersucht und zudem der Einfluss von anti-metabolischen Substanzen analysiert, die in der 
Krebsbehandlung Anwendung finden könnten. 
Im Vergleich zu murinen T-Zellen, schienen humane T-Zellen weniger auf den 
Glukosemetabolismus angewiesen zu sein, da das Zellwachstum und die Effektor-Funktionen, 
wie die Zytokinproduktion, nur leicht durch einen Glukoseentzug beeinträchtigt waren. Allerdings 
wurde die Proliferation in allen drei Subpopulationen inhibiert. Interessanterweise war vor allem 
in den naiven T-Zellen eine hohe Spendervarianz zu beobachten.  
Im Gegensatz dazu war der Glutaminstoffwechsel essentiell für die Funktionen der CD8       
T-Zellen, da ein Glutaminentzug zu einer unzureichenden Aktivierung in allen Subpopulationen 
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führte. Allerdings waren die Effektorfunktionen, in Form von IFNγ- und TNF-Sekretion, unter 
Glutaminentzug weniger stark in den Gedächtniszellen als in den naiven T-Zellen beeinflusst. 
Titrationsexperimente zeigten, dass Glutaminkonzentrationen von 0.1 mM die T-Zell-Aktivierung 
sowie die IFNγ- und TNF-Sekretion inhibierten, eine Konzentration, die schon in Tumoren 
nachgewiesen wurde. Die Proliferation war bereits bei einer Konzentration von 0.25 mM 
signifikant reduziert. Diese Ergebnisse demonstrieren, dass nicht nur Glukose sondern auch 
Glutamin einen Nährstoff darstellt, um den Tumorzellen und Immunzellen im Tumormikromilieu 
konkurrieren. 
Indem eine Kombination aus verschiedenen Metaboliten supplementiert wurde, die mit dem 
Glutaminstoffwechsel in Verbindung gebracht werden, wurde versucht ein Ersatzmetabolit für 
Glutamin zu finden. Das Scheitern dieser Experimente deutet darauf hin, dass Glutamin selbst 
einen essentiellen Nährstoff für T-Zellen darstellt. Vorläufige Ergebnisse suggerieren, dass die 
Glutaminabhängigkeit von T-Zellen in der Abwesenheit der Glutamin-Synthetase begründet sein 
könnte, einem Enzym, das die Reaktion von Glutamat zu Glutamin katalysiert. 
In einem nächsten Schritt wurde die Rolle der zellulären Atmung mit Hilfe von Oligomycin 
analysiert, ein Inhibitor der ATP-Synthase. T-Zell-Funktionen wie die Proliferation oder die IFNγ- 
und TNF-Sekretion waren stark gehemmt in naiven T-Zellen, aber nur leicht in den zentralen 
und den Effektor-Gedächtniszellen. 
Obwohl die Effektor-Gedächtniszellen als geschwächte Subpopulation gelten, zeigen unsere 
Ergebnisse, dass diese Zellen weniger stark von einem Nährstoffmangel als naive T-Zellen 
betroffen sind. Somit sollten auch Effektor-Gedächtniszellen bei immuntherapeutischen 
Ansätzen, wie dem adoptiven T-Zell-Transfer, berücksichtigt werden. 
Da aktivierte T-Zellen einen erhöhten Stoffwechsel aufweisen, ähnlich dem in Tumorzellen, 
wurde schließlich die Auswirkung von anti-metabolischen Substanzen auf frisch stimulierte CD8 
T-Zellen untersucht. Im Hinblick auf einen adoptiven T-Zell-Transfer, wurde zudem der Effekt 
von klinisch relevanten anti-metabolischen Substanzen auf expandierte T-Zell-Subpopulationen 
untersucht. 
Unter besonderer Berücksichtigung der Bedeutung des Glutamins für die T-Zell-Aktivierung, 
sollte die Applikation von Inhibitoren, die in den Glutaminstoffwechsel eingreifen, sorgfältig 
geprüft werden. Infolgedessen wurde in dieser Arbeit der Einfluss von Glutamin-Analoga (DON 
und Acivicin) sowie Glutaminase-Inhibitoren (BPTES und CB-839) untersucht. Die Inhibition der 
Glutaminase, die Glutamin zu Glutamat umwandelt, zeigte keinen Effekt auf die T-Zellfunktionen 
in CD8 T-Zellen, wohingegen die Glutamin-Analoga die T-Zell-Funktionen und die metabolische 
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Aktivität stark supprimierten. Überraschenderweise, zeigte DON keinen Effekt mehr auf 
expandierte CD8 Subpopulationen. 
Da der Glukose-Metabolismus eine übergeordnete Rolle für Tumorzellen spielt, wurde der 
Einfluss von Substanzen untersucht, die auf die Glykolyse wirken. Die Inhibition der 
Monocarboxylat-Transporter (MCTs) in Tumorzellen, durch welche die Laktatsekretion blockiert 
wird, würde Tumorzellen direkt beeinflussen und könnte zusätzlich die anti-tumorale 
Immunantwort unterstützen, indem eine Laktatakkumulation verhindert wird. Bislang wurden 
wirksame Inhibitoren lediglich für MCT1 und MCT2 entwickelt. Die beiden nichtsteroidalen 
Antirheumatika (NSARs, engl. NSAIDs) Diclofenac und Lumiracoxib, beide auch als 
Cyclooxygenase (COX)-Inhibitoren bekannt, hemmen MCT1 und zugleich MCT4. Da diese die 
einzigen bekannten Inhibitoren sind, die neben MCT1 auch MCT4 blockieren, könnten diese 
vielversprechende Substanzen im Kontext zur Tumortherapie darstellen. Obwohl eine Reduktion 
der glykolytischen Aktivität festgestellt wurde, war die Zytokinproduktion sowohl in naiven als 
auch in Effektor-Gedächtniszellen sowie in den expandierten Subpopulationen erhalten. 
Lediglich eine Hemmung der Proliferation war nach sechs Tagen zu beobachten. 
Diese Ergebnisse wurden zusätzlich durch eine vollständige Blockade von MCT1 und MCT4 
in murinen T-Zellen bestätigt. Um eine pan-Inhibition zu imitieren, wurden MCT4 defiziente T-
Zellen in Anwesenheit von einem MCT1/2 Inhibitor kultiviert. Obwohl die glykolytische Aktivität 
beinahe vollständig inhibiert war, waren die murinen T-Zellen immer noch in der Lage wichtige 
Effektorzytokine wie IFNγ zu produzieren, wobei die Werte zu einem gewissen Maß reduziert 
waren. 
Die in dieser Arbeit analysierten CD8 T-Zellen wiesen Gruppen-spezifische Unterschiede in 
ihrer metabolischen Aktivität auf. Während ein Glukoseentzug die T-Zell-Funktionen nicht 
schädigte, rief ein Glutaminentzug einen starken Effekt auf die T-Zell-Immunantwort hervor. 
Deshalb stellt der Glukosemetabolismus eine aussichtsreiche Zielstruktur in der Krebstherapie 
dar, während Medikamente, die auf den Glutaminstoffwechsel wirken, einer sorgfältigen Prüfung 
bedürfen. Dennoch blieben T-Zellen von den Glutaminase-Inhibitoren unbeeinträchtigt. Diese 
Ergebnisse zeigen, dass anti-metabolische Substanzen eine vielversprechende Ergänzung zu 
immuntherapeutischen Ansätzen darstellen, wie beispielsweise einer Checkpoint Blockade oder 
einem adaptiven T-Zell-Transfer. 
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